Membranes for the Life Sciences
Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes
Membranes for the Life Scie...
318 downloads
2296 Views
5MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Membranes for the Life Sciences
Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes
Membranes for the Life Sciences Volume 1
Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes
The Editors Dr. Klaus-Viktor Peinemann GKSS Research Center Institute of Polymer Research Max-Planck-Strasse 1 21502 Geesthacht Germany Dr. Suzana Pereira Nunez GKSS Research Center Institute of Polymer Research Max-Planck-Strasse 1 21502 Geesthacht Germany
All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate. Library of Congress Card No.: applied for British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library. Bibliographic information published by the Deutsche Nationalbibliothek The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at . # 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law. Typesetting Thomson Digital, India Printing Strauss GmbH, Mo¨rlenbach Binding Litges & Dopf GmbH, Heppenheim Cover Design Adam-Design Weinheim Wiley Bicentennial Logo Richard J. Pacifico Printed in the Federal Republic of Germany Printed on acid-free paper ISBN: 978-3-527-31480-5
V
Contents
Preface XI Contributors ((Peinemann Vol. 1))
1 1.1 1.2 1.3 1.3.1 1.3.1.1 1.3.1.2 1.3.1.3 1.3.1.4 1.3.1.5 1.3.1.6 1.3.2 1.3.2.1 1.3.2.2 1.3.2.3 1.3.2.4 1.4 1.4.1 1.4.2 1.4.3 1.4.4 1.5 1.6 1.6.1 1.6.2
XIII
Membranes in Hemodialysis 1 Jo¨rg Vienken Introduction 1 Historical Achievements 2 Membranes for Hemodialysis: Polymers and Nomenclature 7 Membranes from Regenerated Cellulose 8 Modified Cellulosic Membranes 9 Cellulose Acetates 9 DEAE-Modified Cellulose, Hemophan 10 Benzyl-Modified Cellulose (Synthetically Modified Cellulose, SMC) PEG-Grafted Cellulose 11 Vitamin E-Modified Cellulosic Membranes 12 Synthetic Membranes 12 Polyacrylonitrile (PAN) 13 Polymethylmethacrylate (PMMA) 14 Polysulfone (PSu) 15 Polyamide (PA) 17 Dialyzer Constructions 17 Hollow Fiber Dialyzers 17 Housing 18 Potting Material 18 Fiber Bundle 19 Dialysis Membranes and Performance: Principles of Membrane Transport 20 Dialysis Membranes and Biocompatibility 24 Some Basic Information on Membranes and Biocompatibility Parameters 24 Thrombogenicity of Different Types of Dialyzers and Filters 26
Membranes for the Life Sciences. Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes Copyright ß 2008 WILEY-VCH Verlag GmbH & Co. KGaA. All rights reserved ISBN: 978-3-527-31480-5
11
VI
Contents
1.6.3 1.6.4 1.6.4.1 1.6.5 1.6.5.1 1.6.6 1.6.6.1 1.6.7
1.6.8 1.6.9 1.7 2 2.1 2.2 2.2.1 2.3 2.4 2.4.1 2.4.2 2.5 2.6 2.6.1 2.6.2 2.7 2.7.1 2.7.2 3 3.1 3.2 3.3 3.4 3.4.1 3.4.2 3.5 3.6 3.7
Complement Activation by Different Dialyzers and Filters 29 Cell Activation by Different Types of Dialyzers and Hemofilters 31 Apoptosis 31 Oxygen Species Production – Induction of Oxidative Stress 32 Degranulation of Neutrophils 34 Stimulation of Cytokine Generation by Different Types of Dialyzers and Hemofilters 35 The Impact of Membrane Types on LPS-Stimulated IL-1b Secretion 36 The Impact of Large-Pore Dialysis Membranes on the Inflammatory Response in HD Patients by Cytokine Elimination 36 The Effect of Different Dialyzers on the Acute Phase Reaction 37 Activation of the Kinin System by Different Types of Dialyzers and Hemofilters 37 Conclusion 39 Membranes for Artificial Lungs 49 Frank Wiese Introduction 49 History of Blood Oxygenation 49 Membrane Oxygenators 50 Principle of Gas Transfer 53 Membranes and Membrane Properties 55 Microporous Membranes 55 Dense Membranes/‘‘Diffusion Membranes’’ 57 Membrane Production 59 Operational Modes and Membrane Makeup in Oxygenators Microporous Capillary Membranes, Blood Inside 62 Microporous Capillary Membranes, Blood Outside 62 Extracorporeal Circulation 65 Cardiodiapulmonary Bypass (CPB) 65 Lung Support Systems 65 Membranes for Blood Fractionation/Apheresis 69 Frank Wiese Introduction 69 History of Plasmapheresis 70 Principles of Plasmapheresis 73 Membranes and Membrane Properties 76 Plasma Separation Membranes 76 Plasma Fractionation Membranes 79 Membrane Production 81 Operational Modes in Plasmapheresis Procedures 83 Medical Indications for Blood Plasma Treatment 88
61
Contents
4
4.1 4.2 4.2.1 4.2.2 4.2.3 4.2.4 4.2.5 4.2.6 4.2.6.1 4.2.6.2 4.2.6.3 4.3 4.3.1 4.3.1.1 4.3.1.2 4.4 4.4.1 4.4.1.1 4.4.1.2 4.4.1.3 4.4.1.4 4.4.1.5 4.4.2 4.4.2.1 4.4.2.2 4.4.2.3 4.4.2.4 4.4.2.5 4.5 4.5.1 4.5.2 4.5.2.1 4.5.3 4.5.3.1 4.5.3.2 4.5.4 4.5.4.1 4.5.4.2
Membranes in the Biopharmaceutical Industry 91 Anthony Allegrezza, Todd Ireland, Willem Kools, Michael Phillips, Bala Raghunath, Randy Wilkins, Alex Xenopoulos Introduction 91 Microfiltration Membranes Used in the Biotech Industry 93 Introduction 93 Microfiltration Membranes: Development of Industrial Membranes 94 Effect of Membrane Structure on Properties 95 Aspects of Cartridge Design 97 Membrane Surface Modification 98 Sterilizing Filters 99 Retention 99 Permeability 101 Capacity 102 Practical Membrane Considerations for Sterile Filtration by Microporous Membranes 102 Sterile Filtration Process Considerations 103 Filter Selection 104 Device Selection 110 Ultrafiltration and Virus Filtration Membranes for Biopharmaceutical Applications 113 Ultrafiltration Membranes 113 Membrane Suppliers 114 Membrane Selection 114 Membrane Structures 115 Characterization 115 Devices 116 Virus Filtration Membranes 117 Membrane Suppliers 117 Membrane Structures 118 Devices 118 Membrane Selection 119 Characterization 120 Applications of Ultrafiltration Membranes in Biopharmaceutical Manufacturing 121 Ultrafiltration Theory 122 Typical Ultrafiltration Process 123 Process Development and Optimization 124 Processing Plan Optimization 128 Mode of Operation 128 Diafiltration Mode/Strategy 129 Scale-up Considerations 131 Process Implementation Considerations 132 Process Robustness 133
VII
VIII
Contents
4.5.5 4.5.5.1 4.5.5.2 4.6 4.6.1 4.6.2 4.6.3 4.6.4 4.6.5 4.6.6 4.6.7 4.7 4.7.1 4.7.2 4.7.2.1 4.7.2.2 4.7.2.3 4.7.3 5 5.1 5.2 5.2.1 5.2.2 5.2.3 5.2.4 5.3 5.3.1 5.3.1.1 5.3.1.2 5.3.2 5.3.2.1 5.3.2.2 5.3.3 5.3.4 5.3.5 5.3.6 5.3.7 5.3.8 5.4 5.5
System Considerations 134 Equipment Options 134 Process Control Options 134 Practical Aspects of Virus Filtration Process Design and Implementation 135 Membrane Selection 135 Process Development and Optimization 138 Capacity 140 Small-Scale Simulation 141 Pilot-Scale Studies 141 Virus Validation Studies 142 Implementation 143 Membrane Adsorbers 145 Membrane Chemistries 146 Current Applications 147 Flow-Through Polishing 147 Flow-Through Precapture 148 Large Molecule Bind–Elute Purification 149 Future Trends 149 Membrane Applications in Red and White Biotechnology 155 Stephan Lu¨tz, Nagaraj Rao Introduction 155 Types of Membrane Processes in Red and White Biotechnology 156 Bubble-Free Aeration 156 Filtration Processes 157 Dialysis and Electrodialysis 157 Adsorption of Microorganisms 158 Examples of Membrane Processes in Biotechnology 158 Bubble-Free Gassing 158 Hydrogen 158 Oxygen 159 Membranes for Cell Retention 161 Higher Cells/Red Biotechnology 161 Whole-Cell Biotransformation 162 Membranes for Enzyme Retention 162 Membranes for Cofactor Retention 166 Application of Dialysis and Electrodialysis in Biotransformations Application of Pervaporation and Stripping in Biotransformations 168 Nanofiltration and Ultrafiltration in Biotechnology 170 Bioelectrochemical Applications 170 Summary 172 Acknowledgment 172
167
Contents
6 6.1 6.2 6.2.1 6.2.2 6.3 6.3.1 6.3.2 6.3.2.1 6.3.2.2 6.4 7
7.1 7.2 7.2.1 7.2.2 7.2.3 7.2.3.1 7.2.3.2 7.2.3.3 7.2.3.4 7.3 7.3.1 7.3.1.1 7.3.1.2 7.3.1.3 7.3.1.4 7.3.2 7.3.2.1 7.3.2.2 7.3.2.3 7.4 8
8.1 8.1.1 8.1.2 8.2
Membranes in Controlled Release 175 Nicholas A. Peppas, Kristy M. Wood, J. Brock Thomas Introduction 175 Controlled Release Kinetics 176 Diffusion in Membrane-Controlled Release 176 Physical Parameters of Controlling Release 180 Membranes and Solute Transport 180 Characterization of Membranes 180 Solute Transport in Network Membranes 182 Structural Parameters of Membranes 182 Determination of Molecular Pore Sizes 183 Applications in Drug Delivery 184 Drug Delivery Through Skin: Overcoming the Ultimate Biological Membrane 191 Dimitrios F. Stamatialis Introduction 191 Human Skin – Fundamentals of Skin Permeation 192 Human Skin Structure 192 Stratum Corneum – Main Drug Barrier 193 Drug Transport Through the Skin 195 Passive Diffusion 195 Iontophoresis 198 Electroporation 204 Other Methods 207 Transdermal Drug Delivery System – Structure/Design 212 Passive TDD Systems 212 Types 212 Materials 213 Skin or Device-Controlled Delivery 214 Commercialization – Patents 215 Active TDD Systems 216 Types 216 Materials – Devices 216 Commercialization – Patents 218 Conclusions and Outlook 221 Application of Membranes in Tissue Engineering and Biohybrid Organ Technology 227 Thomas Groth, Zhen-Mei Liu Introduction 227 Application of Membranes in Blood Detoxification 227 Requirements to Support Adhesion and Function of Cells Application of Membranes in Tissue Engineering 231
228
IX
X
Contents
8.2.1 8.2.2 8.2.3 8.2.4 8.3 8.3.1 8.3.2 8.3.3 8.4 8.5 9
9.1 9.1.1 9.1.2 9.2 9.2.1 9.2.2 9.2.2.1 9.2.3 9.2.3.1 9.2.3.2 9.2.3.3 9.2.4 9.2.5 9.2.5.1 9.3 9.4
Introduction to Tissue Engineering and Membrane Applications 231 Tissue Engineering of Skin 232 Tissue Engineering of Bone 236 Further Tissue Engineering Applications of Membranes Membranes in Biohybrid Organ Technology 242 Organ Failure and Biohybrid Organ Technology 242 Biohybrid Liver 245 Biohybrid Kidney 249 Summary and Conclusions 253 Acknowledgments 254
240
Membranes in Bioartificial Pancreas – An Overview of the Development of a Bioartificial Pancreas, as a Treatment of Insulin-Dependent Diabetes Mellitus 263 Ana Isabel Silva, Anto´nio Norton de Matos, I. Gabrielle M. Brons, Marı´lia Clemente Velez Mateus Introduction 263 Diabetes and Its Treatment 263 The Bioartificial Organ Concept 265 Bioartificial Pancreas 266 Immunoprotection and Biocompatibility of Implanted Devices Vascular Devices 268 Biocompatible Materials in Vascular Devices 269 Extravascular Devices 272 Implantation Sites 272 Macrocapsules 273 Microcapsular Devices 280 Influence of Recipients Sensitization to Donor Antigens in Graft Survival 308 Islet Oxygenation Studies 308 Oxygenation of Ba-Alginate Microencapsulated Islets 311 Final Comments 312 Acknowledgment 313 Index
321
267
XI
Preface Life without membranes has never been possible. They are essential components of our body. But in the past 50 years the membrane scientists managed to incorporate artificial membranes in medical and engineering processes, which improved the life quality of a great part of the world population. Just to mention two examples, there are currently around 1.5 million hemodialysis patients worldwide, who decades ago would have been condemned to die at an early age. Two billion people are affected by water shortages in over 40 countries. Reverse osmosis desalination plants assure water supply to a large area of the planet, which barely has access to alternative sources. In the past decades the membrane technology established its place in the chemical industry. Rapidly growing applications are the nanofiltration of fine chemicals and the recovery of monomers in polymerization plants. The electronic industry depends on clean water obtained by membrane systems. The globalization of the food market requires active packaging ‘‘membrane’’ systems to allow the transport of fruits and vegetables for long distances and storage times. Membrane processes have been for a long time the integrated steps for the cheese and wine production, caring for the improvement of the product quality and for the introduction of new products. But this is just the start. Recently, the concern about global warming and the contribution of the greenhouse effect has increased dramatically. As a consequence, there is a growing demand for renewable energy carriers with low emission of CO2. Membranes are the core components of fuel cells and electrolysers. Apart from this, the implementation of the membrane processes in a modern society that is dependent on hydrogen technology and renewable energy is a long-term process, and in this transition period membranes are expected to play an important role. Fossil fuels are still the predominant source of hydrogen. Membranes can make the hydrogen production and processing in refineries much more effective. Processes such as steam reforming and water shift reaction can be significantly improved with the use of membranes. Membrane technology can also be involved in the CO2 emission reduction in refineries and coal plants. After publishing the book ‘‘Membrane Technology in the Chemical Industry,’’ we clearly saw a demand for more information on membranes and their Membranes for the Life Sciences. Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes Copyright ß 2008 WILEY-VCH Verlag GmbH & Co. KGaA. All rights reserved ISBN: 978-3-527-31480-5
XII
Preface
applications in different fields. A series of six books with the following topics was then initiated: Membranes in Life Science, Membranes for Energy, Membranes in the Food Industry, Membranes for Water Treatment, Membranes for Chemical Technology, and Membrane Preparation. Suzana Nunes, Klaus-V. Peinemann
XIII
Contributors ((Peinemann Vol. 1)) Anthony Allegrezza Millipore Corporation Bioprocess R & D 80 Ashby Road Bedford, MA 01730 USA
Willem Kools Millipore Corporation Bioprocess Applications Engineering 900 Middlesex Turnpike Billerica, MA 01821 USA
I. Gabrielle Brons University of Cambridge Department of Surgery Cambridge Institute of Medical Research CIMR Box 139 Addenbroke’s Sie Cambridge CB2 2XY UK
Zhen-Mei Liu Martin-Luther-Universita¨t HalleWittenberg Institute of Pharmacy Kurt-Mothes-Strasse 1 06120 Halle (Saale) Germany
Thomas Groth Martin-Luther-Universita¨t HalleWittenberg Institute of Pharmacy Kurt-Mothes-Strasse 1 06120 Halle (Saale) Germany Todd Ireland Millipore Corporation Bioprocess Sales Management 900 Middlesex Turnpike Billerica, MA 01821 USA
¨tz Stephan Lu Forschungszentrum Ju¨lich GmbH Institut fu¨r Biotechnologie 2 Leo-Brandt-Str. 52425 Ju¨lich Germany Marilia Mateus IBB-Institute for Biotechnology and Bioengineering Centre for Biological and Chemical Engineering Instituto Superior Te´cnico Av. Rovisco Pais 1049-001 Lisboa Portugal
Membranes for the Life Sciences. Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes Copyright ß 2008 WILEY-VCH Verlag GmbH & Co. KGaA. All rights reserved ISBN: 978-3-527-31480-5
XIV
Contributors ((Peinemann Vol. 1))
Anto´nio Norton de Matos University of Porto ICBAS and HGSA-Santo Anto´nio General hospital Division of Angiology and Vascular Surgery Largo Professor Abel Salazar 4099-001 Porto Portugal
Ana Isabel Silva IBB-Institute for Biotechnology and Bioengineering Centre for Biological and Chemical Engineering Institute Superior Te´cnico Av. Rovisco Pais 1049-001 Lisboa Portugal
Klaus-Viktor Peinemann GKSS Research Center Institute of Polymer Research Max-Planck-Strasse 1 21502 Geesthacht Germany
Dimitrios F. Stamatialis University of Twente Faculty of Science and Technology Biomedical Technology Institute Membrane Technology Group PO Box 217 7500 AE Enschede The Netherlands
Nicholas Peppas The University of Texas Departments of Chemical and Biological Engineering University Code C 0400 Austin TX, 78712 USA Michael Phillips Millipore Corporation Bioprocess R & D 80 Ashby Road Bedford, MA 01730 USA Bala Raghunath Millipore Corporation Bioprocess Applications Engineering 900 Middlesex Turnpike Billerica, MA 01821 USA Nagaraj Rao Rane Rao Reshamia Laboratories Pvt. Ltd. Plot 80, Sector 23, CIDCO Industrial Area 400705-Navi Mumbai India
J. Brock Thomas The University of Texas Departments of Chemical and Biological Engineering University Code C 0400 Austin TX, 78712 USA Jo¨rg Vienken BioSciences Department Fresenius Medical Care Else Kroenerstrasse 1 61346 Bad Homburg Germany Frank Wiese Consulting Membrane Technology/ Application Starenstrasse 100 42389 Wuppertal Germany
Contributors ((Peinemann Vol. 1))
Randy Wilkins Millipore Corporation Bioprocess Field Marketing 900 Middlesex Turnpike Billerica, MA 01821 USA
Kristy M. Wood The University of Texas Departments of Chemical and Biological Engineering University Code C 0400 Austin TX, 78712 USA
XV
1
1 Membranes in Hemodialysis Jo¨rg Vienken 1.1 Introduction
The treatment of kidney patients by hemodialysis with tubular sheet or capillary membranes represents a convincing success story in medical therapy. When John Abel in the United States and Georg Hass in Germany started to investigate the application of membranes at the onset of the twentieth century, they would never have dreamt that nearly a hundred years later, in 2005, about 1.9 million kidney patients would undergo treatment for end-stage renal disease and nearly 1.5 million patients would owe their lives to hemodialysis and related devices such as membranes, tubing systems, and so on [1] (Figure 1.1). One reason for this overwhelming success may be the successful miniaturization of dialyzers that facilitates the mass production of these devices. Further, and as of today, the exclusive use of capillary membranes considerably contributes to better performance properties of dialysis membranes. Therefore, the following figures may not be surprising: In total, in 2005, dialysis patients all over the world are currently in need of about 150 million dialyzers annually. Compared to 2002, this figure represents an increase of 15%. Taking into account that one dialyzer contains a length of about 3 km of capillary membranes, nearly 450 million km of these materials have to be manufactured annually. The figure reflects the unimaginable dimension of an annual capillary membrane production being equivalent to nearly three times the distance between the earth and the sun. The technical skill of manufacturing capillary membranes in such large quantities represents half a century of an effective research and development. A reproducible high capillary membrane quality in terms of constant geometry, adequate performance, and high-level blood compatibility guarantees the safety of patients. Further, membrane production at a large scale allows for a reasonable cost of production and consequently for a facilitated access to these devices all over the world. Membranes are the centerpiece of dialyzers and more than 650 different types of dialyzers are currently available on the market. How they are characterized and how they differ, will be the scope of this chapter.
Membranes for the Life Sciences. Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes Copyright ß 2008 WILEY-VCH Verlag GmbH & Co. KGaA. All rights reserved ISBN: 978-3-527-31480-5
2
1 Membranes in Hemodialysis
Fig. 1.1 The ESRD patient population is continuously increasing and adds up to 1 900 000 patients worldwide in 2005. A majority of 1 297 000 patients is treated by hemodialysis.Source: FMC database 2005.
1.2 Historical Achievements
Following Gekas [2], a membrane is both an intervening phase to separate two phases and a barrier to the transport of matter between phases adjacent to it. The separation of water and toxins from blood, as observed in the glomeruli of the kidney, is also a membrane process. Therefore, it is of no surprise that physicians searched for ways to treat renal failure through the application of artificial membranes [3] (Table 1.1). The first artificial membranes were handmade from collodium, a cellulose-nitrate derivative. These collodium membranes are considered to be the forerunners of today’s capillary hollow fiber membranes. They were used in the early experiments by Abel [4] on rabbits and dogs. Abel termed for the first time the devices containing collodium membranes as ‘‘artificial kidneys.’’ The membrane transport process applied in these experiments was dialysis, that is, transport of low-molecular-weight compounds such as urea and creatinine through a dense membrane driven by a concentration gradient (Figure 1.2)
Tab. 1.1
1748 1861 1913 1923 1932 1938 1943 1968 1969 1974 1983 1987 1997 2000 2001 2005
Chronicle of capillary membranes and persons/companies behind. Pig bladder as a membrane Definition of term ‘‘dialyzer’’ Collodium (cellulose nitrate) tubes in dog dialysis Collodium tubes for hemodialysis in humans Continuous production of tubular membranes Cellophane, Heparin Rotating drum with cellophane Capillary dialyzer with cellulose acetate Polyacrylonitrile (PAN, AN69) Cuprophan hollow fiber Polysulfone (PSu), high flux, biocompatible DEAE-modified cellulose Hemophan Vitamin E-bonded membrane Polyamide–PES membrane Helixone, PSu, nanocontrolled spinning Vitabran E, vitamin E-bonded PSu
Jean Antoine Nollet Thomas Graham John Abel George Haas Richard Weingand William Thalhimer Willem Kolff Richard Stewart Hospal Company Werner Bandel Ernst Streicher Enka Company Terumo Company Gambro Company Fresenius Medical Care ASAHI Medical Ltd
1.2 Historical Achievements
Fig. 1.2 The famous Chemist and Scotsman Thomas Graham (1805–1869) was the first to define the term ‘‘dialyzer’’ in 1861.
The credit for pioneering the first hemodialysis in humans, however, goes to the German physician Hans Georg Haas (1886–1971), who developed a system for hemodialysis in 1923 independent of Abel in Baltimore, USA. Like Abel, Georg Haas used collodium tubes [5–7]. Haas commented on his experimental efforts in membranes by saying, ‘‘I’d like to say, it was a way of the Cross, because once, one obstacle had been removed another followed.’’ and ‘‘Above all, it was necessary to find a suitable dialysis membrane. I have tried a series of different dialyzers from a variety of materials, animal, vegetable membranes and paper dialyzers. The best performances were obtained by dialyzers from Collodium with respect to fabrication, dialysis effects, safe sterilization and, because they can be obtained in any geometric shape’’ [7]. Haas could profit from the results published earlier in 1921 by Arnold Eggerth from the Hoagland Laboratories in New York. Eggerth had shown that it was possible to achieve a tailor-made membrane clearance by just choosing the appropriate dilution of the alcoholic solvent [8]. In 1932, Weingand [9] proposed an apparatus for a continuous manufacturing of membrane tubes from cellulose solutions. The cellulose solution issues from the annular nozzle and flows – guided by gravity – along a guide member. ‘‘The solidified tube is treated in a series of baths: wasting, bleaching, desulfurizing, and plasticizing baths.’’ The application of a desulfurizing bath in Weingand’s experiments leads us to the conclusion that the cellulose solution was a viscose solution (viscose – cellulose xanthate in NaOH). Progress in the development of dialysis membranes and dialyzers was not made until 1938, when William Thalhimer [10] discovered that a membrane used in the sausage industry could be employed in removing solutes from the blood. This manmade cellulose hydrate material called cellophane was manufactured either by the Visking Company in Chicago, USA, or the Kalle Company in Germany. Cellophane membranes turned out to be uniform in thickness and strength, and one that could be produced in large quantities. Thalhimer experimented with dog blood and used for the first time heparin as an anticoagulant in hemodialysis [11].
3
4
1 Membranes in Hemodialysis
Fig. 1.3 Dialysis became a reality when Kolff developed his ‘‘Rotating Drum.’’ Kolff’s concept of a rotating drum with wound tubular membranes from Cellophane/Cuprophan was the basis of dialysis therapy until the early sixties of the last century. The right-hand photo
shows Kolff (right, and 89 years old in 1999) ¨rg Vienken explaining his ‘‘Rotating Drum’’ to Jo (left) and Horst Klinkmann (center) during a visit in Bad Homburg in 1999. A modified Kolffdialysis machine in use in Glasgow until 1965 is shown on the left.
This was the first contribution to the long lasting success story of cellulosic membranes in hemodialysis that were later considered to be the golden standard. The next milestone in membrane application for hemodialysis was the development of the ‘‘Rotating Drum’’ by Willem Kolff. Supported by the local industry, Kolff [12–14] treated his first patient in a hospital in Kampen, Netherlands. His dialyzer contained a tubular membrane made from cellophane. By this means, Kolff was able to separate 40 g urea from blood in 6 h (Figure 1.3). The first dialyzer of Kolff [12] contained membrane tubes (Cellophane, later Cuprophan) with a sufficiently large membrane surface area and made an efficient clinical dialysis possible. Kolff commented at that time: ‘‘It had an additional advantage: one could repair a leak in the cellophane tubing.’’ Kolff reported later that ‘‘Once a nurse handed me a pair of scissors over the artificial kidney. Between of us, we dropped it and there were light holes in the cellophane. We then stopped the rotating drum, cut out the damaged spots of cellophane tubing, spliced the two ends over a glass tube coated with soft rubber, and went on with the dialysis’’ [14] (Figure 1.4). According to Klinkmann, Falkenhagen, and Courney [3], the Swede Niels Alwall can be considered to be the inventor of ultrafiltration. Ultrafiltration needs a pressure difference as a driving force and can separate molecules with molecular weights up to 1 million by convectional forces. Alwall [15] used a device that allowed to exert a negative pressure on the dialysis membrane by inserting the membrane into a pressure-stable housing. By this means, he could control ultrafiltration and consequently overhydration in uremic patients.
1.2 Historical Achievements
Fig. 1.4 The chemical formula of the major membrane polymers. Cellulosic membranes are mainly hydrophilic by means of their hydroxyl groups, whereas most synthetic membranes are basically hydrophobic and have to be rendered partially hydrophilic by adding hydrophilizing agents, such as polyvinylpyrrolidone.
The first artificial kidney with tiny capillary membranes was described by Richard Stewart in 1964 [16]. The membrane material used for the production of membranes at that time was cellulose acetate. Later, cellulose acetate hollow fiber membranes were accompanied by membranes from unmodified regenerated cellulose. Based on the traditional German Bemberg experience with the Cuprophan/Cuoxam process [17], the ENKA Company in Wuppertal, Germany (later Membrana GmbH, Wuppertal, Germany) developed the first cellulosic tubular membranes in cooperation with the American nephrologist L. Bluemle, followed by the development of capillary membranes. For both the membrane types, cuoxam was used as a solvent for the membrane polymer. Cuprophan hollow fiber membranes represent the classical dialysis membranes with a dense morphology. Its ultrastructure consists of cellulosic microfibrils, which
5
6
1 Membranes in Hemodialysis
leads to a high mechanical stability of the tiny capillaries, while maintaining its high flexibility. As a consequence, it was possible to produce capillary membranes with very small wall dimensions: thickness between 5 and 11 mm is the standard till date. These small dimensions allowed the manufacturing of compact and handy dialyzers with a small extracorporeal blood volume. In 1974, the ENKA Company started the routine production of Cuprophan hollow fiber membranes [18] in Europe followed by the first clinical studies in 1977. Since that time and as a standard, dialyzers contain about 11 000 capillaries representing a membrane surface area of >1 m2 [17]. In contrast to ENKA, CD Medical Inc. (USA), the inventor of capillary membranes for dialyzers, still continued to use cellulose acetate as a raw material for the following reason: by saponification of cellulose acetate the morphology of the cellulose membrane could be rendered more spongeous. As a result, membrane transport properties could be improved and resulted in the formation of a membrane with an increased ultrafiltration profile. This finally leads to the development of the so-called high-flux dialysis [19]. Today, standardly applied high-flux membranes are typically made by new synthetic materials such as polysulfone (PSu), polyethersulfone (PES), polyacrylonitrile (PAN), polyamide (PA), or polymethylmethacrylate (PMMA). In 1983, Fresenius [20] started to produce hollow fibers made of polysulfone for high-flux dialysis in parallel to the development of dialysis machines with ultrafiltration control. Ultrafiltration control is the prerequisite for high-flux dialysis; it allows to run membranes under high convective forces. In parallel to Fresenius, the Gambro Company [21] with its subsidiary in Germany started to manufacture polyamide capillary membranes for hemofiltration. In 1985, Henderson and Chenoweth published an article entitled ‘‘Cellulose membranes, time for a change?’’ [22]. Based on investigations on blood/membrane interaction, they challenged cellulosic membranes for their alleged lack of blood compatibility in terms of cell and complement activation. Previous experiments had shown that blood compatibility depends on the chemical composition of the membrane surface. An optimal surface modification would then improve blood membrane interaction. Investigations lead to the development of membranes from both modified cellulose and synthetic polymers, which showed domain-like surface structures with lipophilic/hydrophilic areas [23]. Membranes with this composition proved to show reduced direct interaction with blood and its components and thus a better biocompatibility. Modified cellulosic membranes such as cellulose acetate and cellulose-ether Hemophan, as well as the synthetic counterparts of cellulosic materials, polysulfone, polyamide, or polymethylmethacrylate are examples for such biocompatible membranes. During recent years, the performance of dialysis membranes has been further improved through the introduction of nanotechnology into the production process. With the nanocontrolled spinning technology [24] defined porosities in membranes could be achieved as found in the new Helixone membranes in the FX Series of dialyzers from Fresenius Medical Care. A further improvement for the Helixone membrane bases on a special Moire´-like ondulation structure of the fiber, facilitating
1.3 Membranes for Hemodialysis: Polymers and Nomenclature
the easy entry of dialysis fluid into the center of the membrane bundle and thus optimizes the concentration gradient of diffusible uremic toxins.
1.3 Membranes for Hemodialysis: Polymers and Nomenclature
A wide spectrum of hemodialyzers and filters combined with a multitude of different membranes are currently offered in the market. In 2004, more than 650 different dialyzer types with membranes made of 22 different polymers were commercially available [25]. Chemical and physical behaviors of a dialysis membrane are primarily determined by its polymer composition. The sterilization mode of the final dialyzer, resistivity against sterilizing agents possibly used for reprocessing of the dialyzer, and biocompatibility are influenced by the type of polymer. Polymers for dialysis membrane manufacturing typically originate from the textile industry due to its spinning expertise. The ideal polymer suitable for dialysis should easily be manufactured to a biocompatible membrane family whose members exhibit different hydraulic permeabilities and display a considerable physical strength and excellent diffusive properties, as well as the resistance to all chemicals and sterilizing agents used in hemodialysis procedures, including steam (temperature to stand: >121 8C). Additionally, some appreciate the ability of a hemodialysis membrane to adsorb endotoxins at the outer surface because it is of substantial benefit against microbial contamination of the dialysis fluid. However, only the polysulfone and the polyamide membrane families fulfill these demands completely at the moment. As can be concluded from historical details, hemodialysis membranes of today are high-tech products that are tailored to the scientific-based demands of hemodialysis therapy. Even ‘‘early’’ materials such as regenerated cellulose are subject to permanent improvement by their manufacturers, and actual types vary in several aspects from their counterparts made 10 years ago, although they may not reach the maximal demands formulated above. Two classes of materials are currently used for the production of dialysis membranes: cellulose and synthetics that can be divided into two and three subclasses, respectively. Some structural differences exist between these two classes beside their different polymers: cellulosic membranes have relatively thin walls (in the range of 6.5– 15 mm) and a uniform (symmetric) composition across their entire capillary wall in order to achieve a high diffusive solute transport. This thin membrane does not provide enough strength to withstand high ultrafiltration rates as are employed in convective therapies. Therefore, most cellulosic membranes are not suitable for convective dialysis treatments like hemodiafiltration or hemofiltration with the only exception of cellulose triacetate (CTA) membranes. In contrast to the classical cellulose membranes, synthetic membranes exhibit a membrane wall thickness of 20 mm and more, which may be symmetric (e.g., PMMA) or asymmetric (e.g., Fresenius Polysulfone) (Figures 1.5 and 1.6).
7
8
1 Membranes in Hemodialysis
Fig. 1.5 Cross section of a capillary membrane made from the regenerated cellulose (Cuprophan). The membrane wall exhibits a homogeneous structure with a tiny wall thickness of 8 mm and an inner diameter of 200 mm.
1.3.1 Membranes from Regenerated Cellulose
For the production of cellulosic membranes, purified cellulose (e.g., linters) is solved in an ammonia solution of cupric oxide (origin of the brand name Cuprophan). The
Fig. 1.6 Cross section of a capillary membrane made from Fresenius Polysulfone. The polsulfone membrane is represented by a small layer of about 1 mm thickness at the luminal side of the capillary. A heterogeneous spongeous wall of about 39 mm thickness guarantees mechanical stability.
1.3 Membranes for Hemodialysis: Polymers and Nomenclature
cellulosic polymer chains are newly arranged in the spinning process, therefore, the term ‘‘regenerated cellulose’’ is used. The result of both the spinning processes is a macroscopically homogenous structure that is extremely hydrophilic, sorbs water, and thus forms a hydrogel. Actually, diffusion of solutes takes place through water swollen amorphous regions. Regions of crystalline cellulose give the necessary mechanical strength. Therefore, cellulosic membranes can be made very thin and down to a thickness of 6.5 mm. It is considered as an advantage that the hydrophilic or water attracting properties of the membrane allow only little protein adsorption and thus avoid secondary layer formation. The Japanese manufacturer Asahi Medical terms its cellulosic membrane ‘‘cuprammonium rayon’’ and the German manufacturer Membrana GmbH sells its product under the brand name Cuprophan. Originally, cellulosic membranes have all been of low hydraulic permeability. Today, dialyzers with regenerated cellulose membranes and higher fluxes with ultrafiltration coefficients up to 50 mL/h mmHg (Bioflux, H 2000, IDEMSA, Spain) are available on the market. In RC-HP 400 the average diameter of pores is increased from 2.76 nm for the standard regenerated cellulose to 7.23 nm that was achieved in the production process by the following ways: (i) an alteration of the concentration in the polymer solution, (ii) the solvent content in the coagulation bath, and (iii) the velocity of membrane formation through the coagulation bath [26]. In order to maintain the physical strength, wall thickness also had to be elevated to 18.5 mm (RC-HP 400) and 20 mm (Xanthogenate), respectively. The sieving coefficient (SC) for b2-m, however, is only 0.3 for RC-HP 400, and elimination takes place solely by membrane transfer. However, these more permeable membranes are not suitable for convective treatments, like hemofiltration or even hemodiafiltration, because their mechanical strengths are not appropriate and their sieving coefficients for b2-m are too low. Membranes made of regenerated cellulose have – due to their low wall thickness – a good low-molecular-weight clearance that is comparable and in a good dialyzer even superior to low-flux synthetic membranes. The other advantage of unmodified regenerated cellulosic membranes is their resistance to all sterilization modes. A disadvantage, however, is the poor biocompatibility, and bacterial products are not retained by some synthetic low-flux membranes. 1.3.1.1 Modified Cellulosic Membranes As it became obvious that cellulosic materials and especially, the nucleophilic hydroxyl groups of the cellulose polymer interact with humoral systems of blood, for example, with complement proteins, modifications of the polymer were produced mostly in the direction of substitution of the hydroxyl groups [23] in the molecular backbone of the cellulose molecule. 1.3.1.2 Cellulose Acetates In cellulose acetate (CA) membranes, at least two of the three hydroxyl groups of the glucose monomer have been replaced by acetyl groups. In the presence of sulfuric acid, cellulose is treated with pure acetic acid and acetic anhydride to form a cellulose
9
10
1 Membranes in Hemodialysis
acetate ester. This ester bond is responsible for the thermolability – CA cannot be sterilized by steam – and the chemolability of the CA polymer at pH >7. Some reports exist about polymer degradation resulting in polymer fragments such as acetylated carbohydrate derivatives that may lead to adverse reactions in the patients within 24 h after cellulose acetate treatment, for example, anaphylactoid reactions, scleritis, iritis, tinnitus, conjunctivitis, red eye syndrome, visual loss, or hearing loss [27,28]. The acetate substitution makes the hydrophilic cellulosic backbone polymer more hydrophobic and allows some protein adsorption on the inner surface. Several types of CA membranes are currently on the market, differing in their degree of hydroxyl-group substitution, their hydraulic permeability, and their manufacturing process (meltspun or coextrusion). All these differences may lead to some small advantages of one CA over the other [29]. Altogether, CA membranes exhibit the good performance characteristics of their unmodified cellulosic counterparts but are improved in their biocompatibility, although not reaching the excellent profile of some synthetic membranes. Althin Medical AB, Sweden (acquisition by Baxter Healthcare Corporation, USA, in the late 1990s) took over the Cordis Dow meltspun process from 1963 and produced a symmetric cellulose diacetate membrane under the brand name Althane that used to be available in a high-flux as well as in a low-flux version. Dialyzers with this kind of membrane are held responsible for a number of deaths among dialysis patients in Spain, Croatia, and Texas, USA, in 2001. Intensive investigations [30–32] revealed that residual perfluorocarbon (PF5070), a processing fluid used for the repair of leaky dialyzers, is the reason for these fatal reactions. The production of this kind of Althane dialyzers had therefore been ceased in 2001, according to a press release of Baxter Healthcare in 2001. Cellulose triacetate with a thin uniform skin structure was first used only as highly porous membrane for high-flux dialysis or hemodiafiltration (Nissho/Nipro) and was the first and only cellulosic membrane capable for more convective therapies than hemodialysis. Today low-flux types are also available. The highly permeable CTA membrane is also suitable for continuous renal replacement therapy [33]. 1.3.1.3 DEAE-Modified Cellulose, Hemophan Assuming that cellulose acetate was the ‘‘oldest’’ polymer used for hemodialysis, N,N-dimethyl-aminoethyl (DEAE) modified cellulose was the first cellulosic membrane that was modified on purpose in order to increase biocompatibility (brand name Hemophan, Membrana Germany, was available during the years in dialyzers from Baxter, Bellco/Sorin, B. Braun, Gambro AB, Haidylena, Cobe, IDEMSA, JMS, Kawasumi, NephroSystems/Meditech, and Nikkiso). Only 1.5 % of all hydroxyl groups of the cellulose molecule is replaced in this polymer by tertiary amino groups through stable ether bonds [34]. These positively charged bulky groups first set hydrophobic spots on a hydrophilic surface and then led to a steric hindrance of the interaction between complement factors and the membrane. A marked improvement of the biocompatibility profile in comparison to unsubstituted regenerated cellulose with equal performance characteristics is observed. In respect to C5ageneration and activation of leukocytes no statistically significant difference could be
1.3 Membranes for Hemodialysis: Polymers and Nomenclature
observed during dialysis with DEAE-cellulose in comparison to ETO-sterilized polysulfone low-flux dialyzers. But the positively charged DEAE groups are under suspicion to lead to an increased platelet activation as well as to heparin consumption during treatment. Heparin adsorption could be demonstrated with DEAE cellulose from saline as well as from blood [35,36]. Advantageous effects are found in that the positively charged DEAE groups attract the negatively charged phosphate molecules from plasma, improving phosphate clearance along with that [37,38]. DEAE-cellulose exhibits the hydraulic properties of regenerated cellulose (Cuprophan) and is available as low-flux and high-flux types (Hemophan HP, UFcoeff 24 and 32 mL/h mmHg, respectively, g-wet Nikkiso [39]). Due to its stable ether modification of cellulose, the membrane is sterilizable by all current methods. In early 2006, Membrana GmbH, Wuppertal, Germany, announced the termination of the production of cellulosic membranes by the end of 2006. Thus, membrane polymers, which have influenced the development of kidney therapy to a high degree over decades, will disappear from the market and leave the forum to their synthetic counterparts. 1.3.1.4 Benzyl-Modified Cellulose (Synthetically Modified Cellulose, SMC) Another example for the creation of hydrophobic domains on a hydrophilic surface is synthetically modified cellulose) produced by Membrana GmbH Wuppertal [40]. It is available in different housings from different manufacturers (under the brand name Polysynthane from Baxter, as SMC from Bellco/Sorin, B. Braun and Kawasumi). In this polymer, less than 1 % of the hydrophilic hydroxyl groups (OH) of the cellulosic backbone have been replaced by hydrophobic benzyl groups through ether bonds. This modification leads to an improved biocompatibility in comparison to unmodified regenerated cellulose, although it does not reach that of low-flux polysulfone [41]. Furthermore, biocompatibility parameters such as elastase release, complement activation, and leukopenia are timely delayed during dialysis with benzylcellulose: the nadir of leukopenia is at 30 min rather than around 15 min as it is with other modified or unmodified cellulosic membranes. Maximum complement activation and elastase release are also observed after 30 min [42]. However, all the cellulosic properties are sustained in this low-flux membrane type, which is available as for sterilizability with all current methods, mechanical strength, and good low-molecular-weight clearances [43]. 1.3.1.5 PEG-Grafted Cellulose Improvement of biocompatibility with cellulosic membranes was also achieved by grafting the cellulosic backbone of cuprammonium rayon with a polyethyleneglycol (PEG) layer (AM-BIO membrane, Asahi Medical Co. Ltd, Tokyo, Japan). Alkylethercarboxylic acid (PEG acid) is esterified with its terminal carboxyl group to the hydroxyl group of the cellulose [44]. These PEG chains form a so-called hydrogel layer on the cellulosic surface (thickness 2.4 nm) that may act as a buffer zone between the cellulosic backbone and blood hindering the direct contact of plasma proteins with the membrane surface. This may lead to a reduction in platelet adhesion and
11
12
1 Membranes in Hemodialysis
complement activation. Lower platelet adhesion could be observed with this kind of membrane in vitro in comparison to unmodified and PEG-grafted cellulosic membranes [45]. 1.3.1.6 Vitamin E-Modified Cellulosic Membranes The first attempt to create a ‘‘bioreactive’’ dialysis membrane is the development of a vitamin E-coated (D-a-tocopherol) cellulosic membrane with the brand name ‘‘Excerbane’’ from the Terumo Company in Japan (today in 2006: ASAHI Medical [46]). Here, performance capabilities of a high porosic cellulosic membrane are combined with the biocompatibility features of a synthetic copolymer together with the therapeutic approach to reduce the oxidative stress during treatment by supporting the body’s own antioxidant defense mechanisms with the supplementation of vitamin E [47]. The surface modification is carried out during the fiber spinning process: the modifying solution consists of a hydrophilic acrylic polymer with reactive epoxy groups. This polymer, based on fluorescein, possesses an inhibitory effect on complement activation. A second polymer, an oleyl alcohol chain, shows inhibitory properties with platelet aggregation. Both are dissolved into the core solution. The original solved regenerated cellulose and the core solution, containing the modifier, are both coextruded through the spinerette into the coagulation bath, where two phases are formed. The outer circumference of the hollow fiber is composed of the cellulosic membrane, and the primary hydrophilic inside is covered by a hydrophobic layer of the modifier. This takes place by covalent bonding of the reactive epoxy group of the modifier with the hydroxyl groups of the cellulosic membrane. The amount of vitamin E immobilized via hydrophobic bonding to oleyl alcohol is around 150 mg/m2 [48]. Some clinical reports exist already with this kind of membrane showing an improved biocompatibility in comparison to regenerated cellulose. The long-term therapeutical effect of this kind of vitamin E supplementation has to be further elucidated. 1.3.2 Synthetic Membranes
The majority of synthetic membrane polymers currently on the market are basically hydrophobic and have to be made more hydrophilic by additives or copolymers during the production process. The polymer mixture is extruded through a spinerette followed by phase inversion and immersion. Partial evaporation of the solvent is responsible for skin formation. Phase separation determines the structure of the membrane as well as its crystallinity. The main purpose to develop synthetic membranes was to create membranes with higher porosity in order to mimic more the natural kidney filtration process [20] and remove middle molecules and higher molecular weight uremic toxins like b2-m. As an indication for a possible pore size dimension of high-flux dialysis membranes, the
1.3 Membranes for Hemodialysis: Polymers and Nomenclature
molecular radius (Stokes radius) of b2-m is described as being 1.6 or 2.2 nm. It was calculated that the pore radius of a b2-m removing membrane should be greater than the double radius of the molecule, which is approximately 5 nm for b2-m removal and lower than 8 nm to avoid albumin loss [49]. 1.3.2.1 Polyacrylonitrile (PAN) The company Rhone Poulenc in France has been the first manufacturer who brought a highly permeable, symmetric, synthetic membrane on the market, which is a blend of a copolymer of the hydrophobic polyacrylonitrile with the hydrophilic methallylNa-sulfonate. The medium-sized pores are distributed in high density over the homogenous polymer, and glycerol is used as a pore filler. This membrane produced and marketed under the brand name AN69 by Hospal (Gambro) till date has been of great success over the years. ASAHI Medical is the other PAN producer (PAN, PAN DX, ASAHI Medical, Japan). Their membrane consists of the hydrophobic monomers, acrylonitrile and methacrylate and is made hydrophilic by the addition of acrylic acid. Due to the special process, the membrane is asymmetric and exhibits a skin layer with pores in a wide range determining the sieving properties of the membrane. Until the early 1990s AN69 was held as one of the most biocompatible dialysis membranes, although it has one drawback: like all PAN membranes it is not sterilizable by heat. Moreover, since 1990, reports were published reporting anaphylactoid reactions with AN69 in combination with the consumption of angiotensinconverting enzyme (ACE) inhibitors [50–53]. Contact phase activation of the kallikrein–kinin system on the negatively charged surface of the AN69 membrane resulting in bradykinin formation was identified as the underlying mechanism. Surface electronegativity (zeta potential, see also Table 1.4) of the membrane, the pH of the rinsing solution [54,55], as well as the dilution factor of the plasma were found to be the influencing factors for the extent of reaction. These observations have also been found true for the second polyacrylonitrile membrane currently on the market, which also leads to bradykinin generation but to a lower extent: its zeta potential was found to be lower, which was 60 mV in comparison to 70 mV of AN69. Due to its microstructure and its surface electronegativity, AN69 exhibits through negative charges of the sulfonate groups, a high adsorption capacity for proteins, especially in positively charged proteins [58]. This was proven for complement factor D, b2-microglobulin, and low-molecular-weight proteins [56,57]. This feature is of advantage with respect to complement activation and b2-m elimination, but negative with respect to high-molecular-weight kininogen adsorption resulting in contact activation and higher residual blood volume in comparison to polysulfone membranes. Furthermore, therapeutic proteins like erythropoietin (EPO) are also adsorbed, probably diminishing their effectiveness. In cases where EPO is administered subcutaneously after hemodialysis treatment, this is of no clinical importance. But protein adsorption in substantial amounts may be a disadvantage, if dialyzers should be reused, because they have to be cleaned with aggressive chemicals like sodium hypochlorite that may damage their fibers in order to rebuild their performance.
13
14
1 Membranes in Hemodialysis
Both polyacrylonitrile membranes are available only with high hydraulic permeability suitable for high-flux dialysis, hemodiafiltration, and hemofiltration. AN69 is additionally available in flat sheet format incorporated into plate dialyzers for acute hemofiltration. In order to overcome problems with anaphylactic reactions, Hospal developed a new AN69 type by coating the polyacrylonitrile flat sheet membrane with polyethylenimine (PEI), a polycationic polymer [59]. During the manufacturing process PEI is sprayed onto the membrane surface until an optimized concentration of 9 mg/m2 is reached. In the resulting AN69ST (ST stands for surface treated [59]) the zeta potential is reduced to around 0 mV. Negatively charged sulfone groups of the AN69 polymer should be masked by the polycationic polymer and further provide a steric barrier via its thickness of the layer. First reports exist about clinical experiences with such a modified plate dialyzer (Crystal ST): No hypersensitivity reaction could be observed during 3 years and 10 630 dialysis sessions, among them 3400 with ACE inhibitor therapy. These data have to be confirmed by other centers to make sure that this new membrane is safe for the patients even in combination with ACE inhibitor therapy [60]. Coating the membrane with a positively charged polymer furthermore leads to another effect, the binding of negatively charged heparin. First clinical trials show that if heparin was brought onto the membrane during the priming procedure no further systemic heparinization was needed during treatment. Heparin release from the membrane was undetectable. This anticoagulation regimen was possible only with unfractionated heparin, whereas low-molecular-weight heparin desorbs quickly. It will be of great interest to know how the introduction of positive charges on the surface will alter biocompatibility in comparison to the ‘‘old’’ AN69 type. That biocompatibility will be different is quite sure because changes in electronegativity of the surface have a great impact on protein adsorption. 1.3.2.2 Polymethylmethacrylate (PMMA) PMMA membranes were introduced into the market in 1977 in Japan by Toray Industries and have been the first g-ray sterilized synthetic membranes [49]. They consist of a hydrophobic, nonpolar polymer produced from methylmethacrylate monomers, homo-PMMA, or are in some type also copolymerized with the addition of small amounts of p-styrene sodium sulfonate. The polymer forms a membrane that is symmetric, almost homogeneous, and isotropic. In current PMMA membranes the pore radius varies between 2 and 10 nm, having a volume fraction of pores (porosity ranging from 50 to 70 % [49]). A membrane family consisting of nine different members was created with lowflux types (B2, B3 series), high-flux types (B1 series), which are mostly used for HD today, and a version with increased b2-m removal (BK series U/P/F). The last was achieved by increasing the pore size, resulting also in increased adsorption properties for b2-m of the membrane [61]. The BK-F model is the most strongly b2-m adsorbing HD-membrane currently on the market, where convective b2-m removal is negligible [49,62]. The larger pores (10 nm) also allow the removal of
1.3 Membranes for Hemodialysis: Polymers and Nomenclature
larger uremic toxins. An erythopoiesis-inhibiting fraction, KR4-0 and its subfraction YS-1 (MW 40 000), has been isolated from dialyzate of a PMMA BK-F HD treatment [63]. A clinical benefit could be demonstrated through the fact that EPO doses could be diminished to half in patients receiving BK-F treatment after 2 years in comparison to HD with standard cellulosic membranes. Whether this is a unique property of the BK-F membrane or it can also be achieved with other highly permeable membranes has to be further elucidated. A multicenter, randomized, controlled trial with 84 patients for 12 weeks could not confirm any effect on anemia with highly porous membranes (BK-F PMMA) in comparison to low-flux cellulose hemodialysis [64]. The strong adsorbing property of PMMA has also some disadvantages: it also results in an undesired adsorption of platelets to the membrane with all its effects on fibrin formation. A higher residual blood volume was also reported for PMMA membranes. Due to the negative surface, anaphylactoid reactions occurred under ACE inhibitor therapy. Therefore, with respect to biocompatibility, the membrane is placed only at an upper level among the synthetic membranes. All dialyzers containing PMMA are sterilized by g-irradiation. The material is not steam sterilizable. 1.3.2.3 Polysulfone (PSu) Not less than 18 suppliers of polysulfone dialyzers are currently on the market underlining the great success of this membrane polymer. Polysulfone fits all demands of a modern polymer: It is sterilizable with all methods (g-ray, b-ray, ethylene-oxide, steam), biocompatible, has physical strength, and chemical resistance. The membrane material exhibits its good performance characteristics both in its low-flux as well as in its high-flux versions that remove considerable amounts of b2-m by filtration. Moreover, polysulfone is suitable as an endotoxin adsorber and thus an active protection system for contaminated dialysis fluids (Table 1.2). Because of all these advantages more and more membrane producers have developed their own polysulfone, although it is sometimes hidden among difficult nomenclature. Fresenius introduced the first high-flux polysulfone in 1983 [20], followed by the low-flux version in 1989. Table 1.2 provides an overview about the different manufacturers of polysulfones and some special features of the particular polymer. Due to patent protection, all polysulfones developed till date have to be different from the original Fresenius Polysulfone. They differ in their basic copolymer/polymer alloy, the addition of polyvinylpyrrolidone (PVP) (polysulfone alone is hydrophobic and has to be made more hydrophilic, which happens in most cases by blending the polymer with the hydrophilic PVP or not), and in their entire production processes, resulting in different morphologies. In chemistry, the terminus ‘‘polysulfone’’ comprises simply a group of polymers containing sulfone groups and alkyl or aryl (e.g., arylether) groups. However, according to chemical convention, all such polymers that additionally contain isopropyliden groups are termed as polysulfones (Fresenius Polysulfone, Asahi Polysulfone, Toraysulfone). Those dialysis membrane polysulfones that do not contain isopropyliden groups are termed as polyarylethersulfones or shortly as
15
16
1 Membranes in Hemodialysis Membranes of the polysulfone (PSu) and polyarylethersulfone (PES) family on the market and their characteristics.
Tab. 1.2
Manufacturer
Brand name
Sterilization
Flux
Fresenius Medical Care
Fresenius Polysulfone
InLine steam ETO e-beam
Low
Helixone ASAHI Medical Gambro AB Hospal/Cobe Kimal Membrana GmbH (Allmed, Baxter, Bellco, Helbio, Haidylena, IDEMSA, Kawasumi, Saxonia) Minntech Nikkiso Saxonia (B. Braun) Toray Industries
High Low High High
APS Vitabran E Polyamix (PES) PolyamideSa Arylane (PES) Polyethersulfone DIAPES
g-wet g-wet Heat g-dry g-dry b-dry
Low High High High Low
Purema (PES) Minntech PS Polyphen PEPA a-Polysulfone Toraysulfone
g-dry, steam ETO ETO g-wet g-dry g-wet
High High High High High High
a According to the manufacturer, PolyamideS is a copolymer of polyarylethersulfone and only a small amount of polyamide. Therefore, it is mentioned under polysulfones [65].
Source: data from Ref. [1].
polyethersulfones (DIAPES, Arylane). This is a little bit confusing because, as mentioned above, all dialysis membrane polysulfones include an arylether. PEPA and PolyamideS contain another polymer in addition to polyarylethersulfone: PEPA polyarylate and PolyamideS polyamide and PVP [66]. The polyamide in PolyamideS is a matter of debate at the moment because some investigators could not find any polyamide in PolyamideS [65]. PEPA is the only polysulfone membrane that does not contain PVP and therefore exhibits some special characteristics: it adsorbs larger quantities of b2-m, which is uncommon for all other membranes, but despite this adsorption removal rates for b2-m are even lower than that of the other polysulfone membranes. Recently an improved version of the original Fresenius Polysulfone, the Helixone membrane, was developed [24,67]. The polymer is unchanged, but the wall thickness (from 40 to 35 mm) and inner diameter of the fiber (from 200 to 185 mm) are reduced. By applying nanotechnology-based fabrication procedures [24,67] for the first time in hemodialysis, the nominal average pore size has been increased in Fresenius Polysulfone from 3.10 to 3.30 nm. With the advanced production process, it was possible to create an almost uniform pore distribution at the dense innermost layer and a homology in pore size that results in a sharper
1.4 Dialyzer Constructions
molecular weight cut-off. The sieving coefficient for b2-m was extended to 0.8, whereas the sieving coefficient for albumin was preserved in the range between 0.001 and 0.01. First clinical studies revealed no difference in biocompatibility in comparison to that of Fresenius Polysulfone, due to no changes in polymer composition [68]. A considerably better performance was found with helixone due to higher mass transfer coefficients, when compared with that of urea, creatinine, phosphate, and b2-m clearances, which is explained by a new geometric dialyzer, fiber design and pore size dimensions [69]. 1.3.2.4 Polyamide (PA) Polyamide membranes (in Polyflux dialyzers, Hemoflux hemofilters, and FH hemofilters, Gambro Hechingen, Germany) consist of a hydrophobic aromatic-aliphatic copolyamide that is blended with hydrophilic polyvinylpyrrolidone [70]. This mixture leads to a microdomain structure with alternating positively and negatively charged regions on the surface. This is held responsible for the good biocompatibility of the polymer. The membrane is asymmetric with three distinguishable regions: a thin skin of 0.1–0.5 mm on the blood side followed by a sponge structure of 5 mm that is supported by a finger structure of about 45 mm. Pore size increased dramatically from the blood side to the dialyzate side, being smallest at the skin layer with around 5 nm. Polyamide dialyzers and filters exhibit good b2-m removal with a SC of 0.6. This is due to their performance characteristics and not due to adsorption because protein adsorption is very low with this membrane. However, bacterial products are successfully rejected at the dialyzate side. Polyamide dialyzers and filters are available only in ETO-sterilized form. In order to overcome this disadvantage, polyarylethersulfone was added to the blend. The new membrane PolyamideS is heat sterilizable and described under polysulfone membranes.
1.4 Dialyzer Constructions
Biocompatibility, the size of removed particles, and the possibility of sterilization mode are mainly determined by the dialysis membrane, and all other aspects of effective dialysis are related to the design of a dialyzer. Current dialyzers are available only as hollow fiber devices. 1.4.1 Hollow Fiber Dialyzers
A current hollow fiber dialyzer consists of a housing that contains one membrane fiber bundle. This is fixed at its both ends in the housing by polyurethane (PUR). An advanced cutting process is necessary to form a smooth surface after embedding in order to minimize activation of humoral or cellular systems in the blood. This surface
17
18
1 Membranes in Hemodialysis
is covered by caps that contain the ports for the inlet and outlet of blood respectively, and in recent developments also for dialysis fluid. Normally the dialyzer housing contains two ports for the inlet and outlet of the blood and the dialysis fluid, respectively. Behind this relatively simple construction stand the 60 years of knowledge and development. The trend to minimize devices is evident, if Kolff’s artificial kidney from 1943 [12] is compared to the latest dialyzer of today. Current dialyzers are optimized with respect to nearly each component. 1.4.2 Housing
The size of each dialyzer housing is tailored to the performance characteristics of the included fiber bundle. The blood compartment volume and resistance to blood flow have to be as low as possible, and each fiber has to be equally washed round with dialysis fluid. The number of fibers and the filling degree of the dialyzer housing increase with surface area until an increase in surface is inefficient for a rise in performance. Then the housing has to be increased. The comparison of dialyzers from various manufacturers that contain the same membrane clearly demonstrates the differences and what an advanced technology stands behind the creation of a good housing design. Current trends in device technology are the introduction of materials that can be disposed in an environmentally friendly manner. Polypropylene is such a material that is used in the newest housings instead of polycarbonate [69]. Furthermore comparing dialyzer performances, housings are getting smaller and smaller since the development of the first disposable hollow-fiber dialyzer. This is possible because membranes with higher performance characteristics are available due to reduction of wall thickness, reduction of inner surfaces of fibers, and a special bundle design. Smaller dialyzers avoid waste, have a sparing effect on transport costs, and are beneficial for the patient because blood contact surface area as well as blood volume in the extracorporeal circuit is reduced. An advantage for the clinic is the saving of storage space. 1.4.3 Potting Material
Composition of the potting compound changed over years in order to minimize risks of toxic substances that may evolve after sterilization of the polyurethane. Especially, the irradiation with b- or g-beams may lead to the fission product 4,40 methylene dianiline, a proven carcinogenic substance [71]. The amount of PUR was considerably reduced over time, as it was obvious that it functions as a reservoir for ETO leading to allergic reactions in the patients [72]. Furthermore, effective surface area is increased with less potting area. Some manufacturers treat the reduced surface of the potting area in a special manner in order to avoid blood activation (e.g., Hospal Arylane series, FMC FX class series). Also, polycarbonate and/or
1.4 Dialyzer Constructions
silicon rings were introduced that allowed the PUR content of the hollow fiber dialyzers to be reduced. 1.4.4 Fiber Bundle
Of considerable importance for the performance of a dialyzer is the fiber bundle construction that has been dramatically improved till date. In early dialyzers, kinked fibers resulting from insufficient potting technology were a big problem leading to considerable thrombus formation. In modern high quality dialyzers, this problem has been overcome due to sophisticated embedding and cutting procedures. Even fiber distribution is nearly uniform in high quality products. In order to improve dialysis fluid flow around the fibers, several bundle configurations have been developed and tested. The dialysis fluid flowed across the fibers rather than along them. Multiple bundles, with the use of a solid central core with fibers wound in a spiral manner, or warp knitted hollow-fiber mats have been introduced into dialyzer technology. Today, the newest fiber developments use an undulation of the fiber itself in order to provide space for a continuous uniform flow of the dialysis fluid. Besides this, fibers with fins and bundles with spacer yarns are also on the market [73–76] (Figures 1.7 and 1.8). Fiber bundle size and swelling of the membrane determine the priming blood volume, which is an important parameter in the choice of the dialyzer for patients with low blood volume, especially children. Today, the blood volume in most dialyzers is smaller than that of the blood tubing sets.
Fig. 1.7 Dialyzer performance considerably depends on the arrangement of capillaries in the membrane bundle. In order to allow for an easy access and flow of dialysis fluid to the center of the bundle, capillary membranes have to be either separated through the insertion of spacer yarns (b in left-hand panel) or have to be
ondulated (a in left-hand panel). An ondulation ´ structure, as following the geometry of a Moire realized in FX-dialyzers with helixone membranes (c) guarantees optimal clearance characteristics through a homogeneous flow of dialysis fluid. Source: modified from Ref. [73].
19
20
1 Membranes in Hemodialysis
Fig. 1.8 The new FX-class of dialyzers exhibits improved clearance characteristics due to a modified PSu membrane and a special ondulation configuration of the capillaries. As a consequence, urea clearance is increased as compared to traditional dialyzer configurations. This allows for reducing dialysis fluid consumption at comparable blood flows.
1.5 Dialysis Membranes and Performance: Principles of Membrane Transport
Dialysis is a membrane separation process in which one or more dissolved species flow across a selective barrier in response to a difference in concentration and a difference in pressure. Concentration differences refer to the mode of transport of diffusion, where separation occurs because small molecules diffuse more rapidly than larger ones. In the absence of difference of pressure and temperature across the membrane, A. Fick’s phenomenological description of diffusion, published in 1855 [77], states that solutes will move from regions of greater to regions of lesser concentration [DC] and at a rate proportional to the differences (Figure 1.9). J ¼ DADC=Dd;
ð1Þ
with J representing solute flow, D the diffusion coefficient, A the area, and d the distance between the two separated compartments, that is, the membrane thickness in the dialysis situation. The minus sign for the diffusion coefficient accounts for the
1.5 Dialysis Membranes and Performance: Principles of Membrane Transport
Fig. 1.9 Annual growth rates for dialyzer sales show that high-flux and synthetic membranes have become the dominating products in dialysis therapy. Source: re. FMC market survey 2003.
convention that flux is considered positive in the direction of decreasing concentration. According to Albert Einstein, diffusion concentration decreases roughly in proportion to the square root of molecular weight. In order to increase solute flow, membrane manufacturers have tried for years to have a membrane thickness as small as possible. Complications may arise from the observation that blood in contact with artificial surfaces, like a hemodialysis membrane, leads to the formation of a secondary layer of proteins. This boundary layer affects diffusional transport across a membrane. A further effect for reduced diffusional clearance can be attributed to drug administration to the patient, such as human recombinant erythropoietin (rhEPO). Because the removal of solutes by the process of hemodialysis is dependent on the flow of the solute and water from the blood compartment to the dialyzate compartment, it is comprehensible that the fraction of water in the blood is reduced by raising the hematocrit (Hct). Indeed, increasing Hct from 20 to 40 %, leads to a reduction of creatinine and phosphate clearances of 8 and 13 %, respectively. Urea removal, however, is less affected [78]. Based on these observations, it appears prudent to increase hemodialysis prescription, that is, treatment time, by 10–15 %, when Hct is raised to near 40. Dialysis membranes are primarily categorized according to their permeability for water and solutes. The ultrafiltration factor (UF) and sieving coefficients are the appropriate parameters. Ultrafiltration factors refer to the amount of filtered water in mL/h in relation to the applied transmembrane pressure (TMP) in mmHg, which is exerted through the blood pump of the dialysis machine. The sieving coefficient is equivalent to the amount of a given solute removed (Figure 1.10): SC ¼
2CF þ CBo ; CBi
ð2Þ
21
22
1 Membranes in Hemodialysis
Fig. 1.10 The weekly performance of the human kidney overrides by far the performance of classical dialysis therapies, such as low- and high-flux dialysis. A closer bridging the gap between the performance of conventional therapy and the human kidney will certainly be based on convective therapies such as hemodiafiltration.
whereby CF refers to the concentration of solute in filtrate and CBi and CBo to the solute concentrations in blood inlet and blood outlet, respectively. Consequently, the maximum value for a sieving coefficient is ‘‘1’’ representing a 100 % sieving. Following Table 1.3 and a general agreement, low-flux membranes are characterized by an UF factor of less than 10 mL/h mmHg, whereas high-flux membranes have an UF factor greater than 10 mL/h mmHg. In addition to their UF factors, hemofilters and high-flux dialysis membranes are characterized by their sieving coefficient for b2-microglobulin (b2-m). b2-m is a small protein of a molecular weight of 11.818. High serum levels of b2-m are considered to be causative for dialysis-related amyloidosis. The molecular weight cutoff of high-flux membranes, which refers to the molecular weight of molecules that cannot pass through the dialysis membrane, is typically around 60 000. It implies that albumin is retained in the patient’s blood.
Tab. 1.3
Categories for hemodialysis membranes.
Category Low flux High efficiency High flux Hemofilter
UF factor (mL/h mmHg)
Cut-off molecular weight
Sieving coefficient (for b2-m)
Surface area (m2)
<10 >10 >10 >20
–— –— <60 000 >60 000
–— –— >0.6 >0.6
<1.5 >1.5 –— –—
Low- and high-flux refer only to the hydraulic permeability.
1.5 Dialysis Membranes and Performance: Principles of Membrane Transport
By increasing the transmembrane pressure (e.g., by means of the peristaltic pump), filtration flow will increase. This increase is almost linear as long as aqueous solutions are used. With whole blood, the increase of filtration flow tends to become nonlinear because of the formation of a secondary layer protein coat by protein adsorption, which is a fast process. Albumin, one of the proteins with the highest blood concentration, is already deposited in 50 ms after the contact with the dialysis membrane [79]. These observations have to be taken into account when fixing ultrafiltration rate and dialysis time. The amount of ultrafiltered water, for example, in the treatment of acute renal failure, may determine the mortality of patients as shown by Storck et al. [80], who compared pump-driven and spontaneous continuous hemofiltration in postoperative renal failure. Increasing the ultrafiltration volume per day improved mortality by about 20%. Recent investigations in the treatment of kidney patients have focused on the removal of large molecular weight solutes such as cytokines, complement proteins, and proteins modified either by glucose (advanced glycation end products [AGEs]) or by oxidative stress pathways. Transport of large solutes across a dialysis membrane is improved if convectional transport mechanisms are applied. Convective clearance is defined by CConvection ¼ SC QF;
ð3Þ
and thus determined by the membrane’s sieving coefficient (SC) and the filtrate flow (QF). It is possible to increase the sieving coefficient for a given solute by switching from a low-flux to a high-flux membrane. Filtrate flow depends on internal filtration, which is defined as the total water flux across the membrane within the closed blood and dialyzate compartment of a dialysis filter. Internal filtration depends on the pressure gradient characteristics (Dp) along the length of dialyzer and may be given by a simplified approach through the application of Hagen–Poiseulle’s law: Dp ¼
8hLQB ; NpR4
ð4Þ
where h is the blood viscosity, L is the length of dialyzer membrane, QB is the blood flow, N is the number of capillaries in the dialyzer, and R is the internal radius of a capillary membrane. Consequently, a better convective clearance (higher Dp) directly depends on blood viscosity to be adapted through the administration of erythropoietin, the length of the dialyzer, and the blood flow. Applying higher blood flows, that is, >300 mL/min is therefore mandatory in high-flux dialysis or in hemodiafiltration. Convective clearance depends indirectly on the number of capillary membranes in a dialyzer and on the membrane’s luminal radius to the power of four. Thus, reducing the inner diameter of a capillary membrane would considerably increase the convective clearance [73,81].
23
24
1 Membranes in Hemodialysis
Fig. 1.11 Data sheets of dialysis membranes refer to ultrafiltration in relation to the applied transmembrane pressure. However, the amount of ultrafiltrate (QF) depends on the exclusive presence of water/saline or blood. Due to a secondary layer formation by blood proteins, QF is leveling off at higher TMPs.
Modern capillary membranes, for example, Helixone polysulfone membranes (Fresenius Medical Care, Germany, inner diameter: 185 mm) have a reduced inner diameter as compared to the classical diameter dimension of 200 mm for typical dialysis membranes. Decreasing the inner diameter from 250 mm over 200 mm down to 175 mm has no impact on small solute clearances such as urea, but shows considerable consequences for the removal of larger solutes such as b2-microglobulin, for which convective clearance increases threefold [81] (Figures 1.11–1.13).
1.6 Dialysis Membranes and Biocompatibility 1.6.1 Some Basic Information on Membranes and Biocompatibility Parameters
The biocompatibility of a dialyzer, particularly that of its membrane, is one of the main criteria that influences dialyzer choice. During the ‘‘Consensus Conference on Biocompatibility held in 1993, biocompatibility was defined as ‘‘the ability of a material, or device, or system to perform without a significant host response in a specific application’’ [82]. The definition was weakened by adding ‘‘significant’’ in comparison to first explanations because it was realized over the years that any foreign material would lead to some kind of reaction in the host. In hemodialysis treatment, blood/artificial surface interactions (as special aspect of biocompatibility also termed as hemocompatibility) are of special importance because of its chronic treatment character.
1.6 Dialysis Membranes and Biocompatibility
Fig. 1.12 Reducing the inner diameter of a capillary membrane leads to a high pressure drop along the length of the dialyzer and thus favors convective forces for the removal of larger solutes. Here, a reduction
of the inner diameter of a polysulfone capillary membrane from 200 to 175 mm leads to a nearly 80 % increase of inulin- and vitamin B12-clearance. Source: modified from Ref. [73].
Fig. 1.13 Improved clearances can be obtained for small proteins, such as b2-microglobulin (b2-m), if the inner diameter of a capillary membrane is reduced. b2-m clearance is found to be up to threefold higher, when the inner
diameter is reduced from 250 mm over 200 mm down to 175 mm. With this simple change in fiber geometry convective therapies, such as hemofiltration or hemodiafiltration, gain an even better performance.
25
26
1 Membranes in Hemodialysis
Parameters of biocompatibility are manifold and their number increases continuously with scientific knowledge. In the beginning of chronic hemodialysis (CRF) treatment, thrombogenicity and hemolysis were the main matters of concern for physicians [83]. Manufacturers focused on the development of less thrombogenic surfaces and on the toxicity of the material that should not liberate plasticizers and chemical additives. In the late 1970s, hypersensitivity reactions in response to ethyleneoxide (ETO) sterilization of the dialyzer were reported [84]. At the same time, complement gained attention and was linked to the transient leukopenia and sequestration of neutrophils in the lung during dialysis with cellulosic membranes [85,86]. The influence of chronic hemodialysis treatment on the immune system was recognized in more detail over the years with the formulation of the ‘‘Interleukin Hypothesis’’ in 1983 being a milestone in this kind of research [87]. Stimulation of immune cells during dialysis, the release of mediators such as cytokines, and the pathological consequences thereof have from then on been topics of intensive research. In the early 1990s, the possible interaction between extracorporeal treatment and pharmacological action of some drugs became clinically evident: Anaphylactoid reactions had been observed in ACE inhibitor patients in combination with the use of certain negatively charged dialysis membrane, which until then had been considered ‘‘biocompatible’’ [88]. Investigations revealed that the kallikrein–kinin system was involved in this sort of side effects leading the attention to the new biocompatibility parameter bradykinin (Figure 1.14). What are the biocompatibility parameters of today? Some parameters can be measured relatively easily in the clinical setting, such as the differential cell count, whereas factors of the complement and clotting cascade need specialized laboratories. On a more in-depth scientific level, an assessment of gene expression in relation to cytokine or b2-microglobulin generation, and the stimulation of immune cells and their reactions (receptor expression, generation of reactive oxygen species [ROS], etc.) have become state of the art.
1.6.2 Thrombogenicity of Different Types of Dialyzers and Filters
The thrombogenic potential of a dialyzer or filter is strongly dependent on the type of membrane polymer, its permeability, the design of the device influencing flow conditions, and its manufacturing quality. Surface free energy, charge, roughness, and chemical composition of a dialyzer membrane have been identified as being responsible for the variable thrombogenic potential of dialysis membranes [89]. As the extrinsic system of the clotting cascade is activated by negatively charged surfaces, membrane polymers that exhibit an anionic surface, such as polyacrylonitrile membranes (PAN DX, PAN; AN69) could be considered more thrombogenic than more neutral polymers such as polysulfone.
1.6 Dialysis Membranes and Biocompatibility
Fig. 1.14 Contact of blood with negatively charged biomaterial surfaces leads to the activation of the contact phase and subsequently to the formation of the nonapeptide bradykinin via the kallikrein pathway. If degradation of bradykinin by angiotensin-converting enzyme is blocked
through the administration of ACE-inhibitors, blood pressure is downregulated by prostaglandin generation. Generally speaking, synergistic effects between biomaterial or membrane properties and the administration of pharmaceutical drugs may not be neglected in the future.
In fact, the highest factor XII adsorption and autoactivation to factor XIIa can be observed with AN69 membranes in vitro [90]. However, the activation of the coagulation cascade also depends on other plasma constituents, for example, highmolecular-weight kininogen, prekallikrein, plasma inhibitors of XIIa, and the action of heparin [90]. High-molecular-weight kininogen (HMWK), another constituent of the trimolecular complex initiating contact activation, could be eluated in its intact form from the used cellulose acetate (Cordis Dow) and regenerated cellulose (Cuprophan), whereas it was cleaved at PMMA and polyacrylonitrile (PAN; AN69) surfaces suggesting activation [91]. Moreover, low-molecular-weight fragments of plasminogen were detected in eluates from polyacrylonitrile (AN69) dialyzers indicating that the fibrinolytic system was activated in response to clotting activation. Intact plasminogen was adsorbed also with all other materials [91] (Figure 1.15). Clinical studies investigating coagulation activation with different types of membranes using the ex vivo formation of the thrombin–antithrombin III complex (TAT) as clotting parameter showed a higher TAT formation with polyacrylonitrile membranes (Asahi PAN and Hospal AN69) than with polysulfone (Fresenius Polysulfone) and regenerated cellulose (Cuprophan) [92]. In another study higher levels with PMMA than with EVAL or polysulfone [93] were shown. These findings were confirmed in controlled ex vivo studies, which found higher TAT generation, platelet factor 4 release, and platelet consumption with AN69 (Nephral 300,
27
28
1 Membranes in Hemodialysis
Fig. 1.15 Bradykinin formation after in vivo contact of patient blood with the surfaces of different dialysis membranes. Bradykinin levels in the venous line of negatively charged PAN (AN69) dialyzers is far above normal and
explains adverse events in these patients. Note that the concentration of bradykinin in these cases is found to be in the femtomolar (fmol) range. Source: adapted from Ref. [157].
Hospal) in comparison to regenerated cellulose (Cuprophan, Renak RA-15U, Kawasumi) and polysulfone (Fresenius Polysulfone, Hemoflow F6HPS) [94]. A low TAT generation with regenerated cellulose is in agreement with the findings that hydroxyl-bearing surfaces are relatively inert with respect to activation of the intrinsic coagulation pathway; such membranes inhibit the development of the trimolecular complex (HMWK, PK Factor XII) that is necessary for contact activation [95]. DEAE-modified cellulose (Hemophan), a membrane that is a low level platelet activator, led to more TAT generations than high-flux polyamide [96]. This is not the result of a higher contact system activation by DEAE cellulose, but it is rather due to the positive DEAE groups adsorbing negatively charged heparin from whole blood. This adsorption inactivates heparin and, consequently, sufficient amounts of heparin are not available for anticoagulation. This is normally reflected in an increased heparin consumption for Hemophan during treatment [97,98]. However, another in vivo investigation failed to find such an increased heparin requirement and also did not observe any increase in TAT formation with Hemophan in comparison to low-flux polysulfone [99]. Another, albeit less reliable, parameter for the assessment of thrombogenicity is the residual blood volume (RBV) in the dialyzer postdialysis. This subjective parameter has a number of pitfalls that mostly concern the reproducibility of the method. Although TAT measurements are preferable, RBV values have been reported in the literature. Under conditions of low heparin dosage, residual blood volume was found to be higher with Hemophan than with CA, PMMA and low with Fresenius Polysulfone [100]. In contrast to coagulation factors, platelets adhere more to cationic charges and hydrophobic materials [95]. Therefore, it is not surprising that a significant decrease
1.6 Dialysis Membranes and Biocompatibility
in the platelet count after 15 min of dialysis of about 9 % could be found with hydrophobic cellulose acetate dialyzers (Cordis Dow), whereas only insignificant decreases were observed with cuprammonium rayon (AM50-Bio, Asahi), DEAEcellulose (Hemophan, GFS, Gambro), polyacrylonitrile (AN69 Hospal), and high-flux polysulfone dialyzers (Fresenius Polysulfone F60, FMC) [101]. In another study, a similar ranking in platelet drop was observed with the same polymers but different manufacturers: cellulose diacetate (CA 150 Baxter), Hemophan (Bio-Allegro, Cobe), cellulose diacetate (Acepal 1500, Hospal), and low-flux polysulfone dialyzers (F6, FMC) [38]. One reliable parameter for platelet activation is the expression of the glycoprotein GMP-140 at the platelet membrane surface. The highest GMP-140 expression was found for Cuprophan dialyzers, less expression was observed with cellulose acetate and PMMA, and the lowest expression with polysulfone and polyacrylonitrile dialyzers [102]. This ranking for platelet activation was also found for another parameter, the expression of P-selectin on the platelet surface: Expression was highest with Cuprophan, followed by cellulose diactetate and cellulose triacetate, and was lowest with Hemophan and Fresenius Polysulfone [103]. Although platelets are obviously activated by regenerated cellulose, this activation does not result in or involve activation of the blood-clotting cascade, as is obvious from previously mentioned investigations into the formation of the TAT complex. A number of publications have dealt with theoretical considerations about artificial surfaces and their thrombogenic potential, but biological processes are too complex to easily predict the thrombogenic behavior from charges, functional groups, or other characteristics of current dialysis membranes. Differences between membranes, and even between dialyzers of different manufacturers containing the same membrane exist. This has been shown in controlled ex vivo or in vivo studies using the same blood for all membranes compared. However, the numbers of reports about membranes correlate with their frequency of use in the market and not necessarily with their thrombogenic behavior. Therefore, although no published data are available for some membranes this should not be interpreted as absence of thrombogenic potential per se.
1.6.3 Complement Activation by Different Dialyzers and Filters
It is accepted today that membranes made of regenerated, unmodified cellulose are the strongest complement activators among all dialysis membranes. This can be partly explained by the binding of complement factor C3b to the hydroxyl groups on the membrane surface. In fact, either partial substitution of these hydroxyl groups with acetyl groups (cellulose diacetate or cellulose triacetate), DEAE groups (Hemophan), and benzyl groups (SMC), or coating with polyethylene glycol (PEG-grafted regenerated cellulose) resulted in considerable reduction of complement activation compared to unmodified regenerated cellulose. Surprisingly, the
29
30
1 Membranes in Hemodialysis
degree of substitution does not necessarily correlate with the degree of complement activation, demonstrating involvement of other factors. For example, in Hemophan, less than 1 % of all hydroxyl groups are modified, but complement activation is at least equal to or even better than that of cellulose acetate membranes where about 60 (cellulose diacetate) to 90–100 % (cellulose triacetate) of all hydroxyl groups are substituted [23]. Binding of regulatory proteins that downregulate the alternative pathway such as ‘‘factor H’’ by Hemophan [104] or ‘‘factor D,’’ a rate-limiting enzyme of the alternative pathway by AN69 [105] and PMMA [106], also plays a role in the extent of complement generation. Factors H and B bind onto cellulose acetate membranes resulting in an accelerated degradation of surface-bound C3b; neither of these factors bind to regenerated cellulose [107]. However, all measures taken to prevent the interaction of C3 molecules with nucleophilic groups, for example, hydroxyl or amino groups, on a polymeric surface reduce activation of the alternative pathway. This can be achieved either by avoidance of such groups as in synthetic membranes or by masking of such groups with acetyl, DEAE, or benzyl groups (as in cellulose acetates, Hemophan, or SMC) or by coating the whole surface with, for example, PEG groups. In order to avoid activation of the classical pathway, none of the IgG, IgM, C1, C2, or C4 complement components should be adsorbed to the polymeric surface [108]. Parameters mostly used for the assessment of complement activation by hemodialysis membranes are the complement factors C3a and C5a. The amount of detectable C3a or C5a in the effluent of a dialyzer depends on the capability of the membrane to adsorb or to filtrate these factors besides its grade of generation: The polyacrylonitrile membrane AN69 generates more C3a than regenerated cellulose, but adsorbs C3a and C5a almost completely [109]. Furthermore, these anaphylatoxins are eliminated during dialysis by high-flux membranes due to their middle molecular weight (MW C3a: 8900; C5a: 11 000) [110,111]. This is also the fact for the regulatory factor D (MW 23 000). This upregulator of the alternative complement pathway is eliminated by glomerular filtration in the healthy individuals and its concentration is, therefore, markedly elevated in ESRD patients. Factor D removal is negligible in low-flux dialysis but can be significant in hemofiltration [112]. Hence, detectable complement generation may differ between the low-flux and high-flux versions of a particular membrane [113]. Furthermore, binding to receptors of circulating blood cells may lower the concentrations of C3a and C5a in blood. What are the long-term consequences of complement activation in the long-term perspective? Because complement generation peaks 15–30 min after the start of treatment and returns to nearly normal levels until the end of treatment, it is of interest whether this effect is important or detectable in the long-term perspective. Unfortunately, little data exist on this aspect of complement activation. Predialysis C3a levels were reported to increase slowly over a time period of 1 year with the low complement activating membranes, Hemophan and polyamide [114]. In long-term HD patients (around 8 years on dialysis), the C3 activity is altered in such a way that both the alternate and the classical pathways are suppressed after stimulation. This effect lasts more than 4 h after the end of a dialysis session and is more pronounced
1.6 Dialysis Membranes and Biocompatibility
in sera of patients treated with regenerated cellulose membranes (AM-SD18M, Asahi Medical, Japan), than in the sera of those treated with polyacrylonitrile membranes (PAN17DX, Asahi Medical). Therefore, it appears that due to the chronic high stimulation three times a week, membranes made of regenerated cellulose may induce a suppression of complement activation in the long term. The mechanism has not been fully elucidated, but a contribution of increased levels of the regulatory complement proteins, factor H and SP-40,40, has been discussed [115].
1.6.4 Cell Activation by Different Types of Dialyzers and Hemofilters
Essential functions of polymorphonuclear leukocytes are disturbed in ESRD patients and are additionally influenced by the dialysis procedure, for example, phagocytosis, oxygen species production, upregulation of specific cell surface receptor proteins, and apoptosis. With the exception of polymorphonuclear leukocyte degranulation, complement and consequently, complement generating dialysis membranes have the greatest impact on functional alterations of these cells. Leukopenia, the most widespread used parameter to assess leukocyte activation, is the assessment of the disappearance of leukocytes from the blood 15–30 min after the start of hemodialysis. This dialysis-induced leukopenia is mainly induced by the overexpression of receptors (CD11b/CD18, CD15s), leading to an increased adhesiveness and aggregation with subsequent sequestration in the lung. Because these activation processes are mostly complement mediated, complement activation and leukopenia directly correlate with each other [116]. Therefore, regenerated cellulose membranes cause the strongest leukopenia, modified cellulosic membranes cause an intermediate-to-low drop in leukocyte numbers, depending on the type of modification, and synthetic membranes also induce a moderate-to-very low drop depending on the polymer. Leukocyte drop is found to be similar to that of polyamide (Polyflux 130, Gambro) and polysulfone (Fresenius Polysulfone F60, FMC) after 15 min at approximately 12 %. Increasing the permeability of regenerated cellulose should, theoretically, result in an increased removal rate of complement factors and, consequently, an improved biocompatibility with respect to measurable complement generation and leukocyte drop. Surprisingly, this was not the case with RC-HP 400 – a high performance version of Cuprophan – which induces the same leukocyte drop as low-flux Cuprophan [117].
1.6.4.1 Apoptosis Dialysis membranes promote neutrophil apoptosis both directly and through interaction with monocytes. Reactive oxygen species seem to be strong mediators of this process [118]. In in vitro experiments, low-flux cellulose diacetate induced significantly greater apoptosis than low-flux polysulfone [118]. An effect of HD membranes
31
32
1 Membranes in Hemodialysis
Fig. 1.16 The effect of different dialysis membranes on apoptosis of mononuclear cells. During the in vivo study period, bacterial and endotoxin contamination was below detection limit. Cell apoptosis was measured in circulating MNCs isolated from heparinized blood. Source: adapted from Ref. [119].
on apoptosis was also found in vivo. The percentage of mononuclear cell (MNC) apoptosis was high with Hemophan and Cuprophan dialyzers, was moderate with cellulose diacetate, and was relatively low with both high-flux polyacrylonitrile and polysulfone membranes. When seven of these patients were switched from Hemophan to Fresenius Polysulfone, apoptosis decreased markedly only after 8 weeks of treatment [119]. This in vivo study was repeated in vitro with mini dialyzers of the membranes used and with blood from healthy donors in order to eliminate the influence of uremia. Interestingly, the results were quite similar implicating a role of the type of dialysis membrane in inducing apoptosis beside uremia [119] (Figure 1.16). 1.6.5 Oxygen Species Production – Induction of Oxidative Stress
Dialysis treatment enhances oxidative stress in chronic renal patients who additionally suffer from a chronic deficiency in the major antioxidant systems [120,121]. Detectable manifestations of this physiological condition are the increased plasma levels of protein oxidation products (oxidation of plasma protein-associated thiol groups) in HD patients [122]. Oxidative stress may contribute to atherosclerosis, cardiovascular disease, dialysis-related amyloidosis, and anemia [123,124]. Four main factors are held responsible: uremia and the comorbid status of the ESRD patient, antioxidant and trace element losses during treatment, the bioincompatibility of the system, especially of the dialysis membrane, and contamination of blood with trace amounts of endotoxins introduced by microbial contaminated dialysis fluid [125,126] (Figure 1.17).
1.6 Dialysis Membranes and Biocompatibility
Fig. 1.17 Relative amount of IL-1b gene expression in peripheral blood mononuclear cells from healthy volunteers, nondialyzed uremics and chronic hemodialysis patients treated with different dialyzers. Maximal accumulation of IL-1b mRNA was observed in
blood samples taken from the venous line after 5 min of dialysis. IL-1b gene expression could be detected in cells from all HD-patients, but not in healthy volunteers and nondialyzed uremics. Source: adapted from Ref. [144].
The highest increase in reactive oxygen species production during dialysis was reported in complement activating membranes [126,127]: Cuprophan induced a significant production of reactive oxygen species 15 and 30 min after the start of dialysis. A lower production was observed with Hemophan, cellulose diacetate and low-flux Fresenius Polysulfone, whereas increases with SMC were not even statistically significant [127]. Another clinical study reported low ROS production with polyacrylonitrile (AN69) and EVAL [128]. However, ROS production in response to stimulation by endotoxins is suppressed in patients treated with Cuprophan membranes and normal with low-flux polysulfone or PMMA membranes [126,129]. Apart from measures regarding the improvement of treatment such as the use of more biocompatible membranes and pyrogen-free dialysis fluid, another approach to reducing the possible deleterious consequences of the prooxidant status has been followed: supplementation with antioxidant vitamins such as vitamin E [130]. In addition to oral prescriptions, some clinical experience has been made in the vitamin E-coated membrane Excebrane: a 10 % predialysis increase of plasma vitamin E concentrations (exclusively in HDLs not in LDLs) was observed after a 3-month treatment period with this membrane, whereas plasma levels did not change when conventional biocompatible membranes, AN69, Fresenius Polysulfone, or PMMA membranes were used. This effect is believed to be due to the vitamin E sparing effect by the Excebrane membrane [130]. The b-carotene content of plasma and the LDL and HDL levels were about 26 % higher than when other biocompatible membranes were used, a finding which can be explained by the secondary protective effect of vitamin E toward b-carotene [131]. However, no improvement in the blood oxidative stress status could be found in this study, which used determinations of thiobarbituric acid-reactive substances and
33
34
1 Membranes in Hemodialysis
antioxidant defenses, like erythrocyte-Cu, Zn-superoxide dismutase and plasma, and erythrocyte glutathione peroxidase [130]. In contrast, another investigation detected an improvement in oxidative stress in the form of a threefold increase in plasma glutathione concentration and a slight increase in erythrocyte numbers after three months of treatment [132]. In this study, the improved antioxidant status (increased vitamin E and glutathione peroxidase concentration in plasma) resulted in a 10-fold increase in plasma levels of arachidonic acid, one of the most abundant polyunsaturated lipids and a useful marker for lipoperoxidation. Leukocyte function (responsiveness to chemical stimuli) was significantly improved after one month of treatment with Excebrane, and the number of apoptotic cells was reduced in comparison to dialysis with regenerated cellulose [132]. An increase in oxidative markers, like malondialdehyde, advanced glycation end products, and 8-hydroxydeoxyguanosine was prevented with Excebrane but not during dialysis with Terumo polysulfone [133]. Another study used plasma vitamin C levels and constant ascorbyl free radical (AFR)/vitamin C ratio postdialysis as an index of oxidative stress. After AN69-dialysis, basal vitamin C levels were decreased and the AVR/vitamin C ratio was increased compared to predialysis levels and to dialysis with Excebrane. Both of these oxidative stress parameters remained nearly unchanged compared to predialysis values when the Excebrane membrane was used [134]. Reviewing the available literature, the antioxidant characteristics of Excebrane compared to other membranes from regenerated cellulose or polysulfone are controversial. It seems an interesting new approach to offer a specific and timely protection against oxygen free radicals at their site of generation. However, the efficiency of membrane-associated effects must be compared with other treatment forms, such as oral prescription of vitamin E or other antioxidant therapy, for example, vitamin C supplementation. A comparison of vitamin E-coated membranes with regenerated cellulose plus additional vitamin C infusion revealed that both approaches had equal positive effects on thiobarbituric acid reacting substances [135]. It is further argued that vitamin E deficiency is rare in uremic patients because the vitamin is not removed during dialysis. Lower vitamin E levels may be induced via vitamin C loss, due to its low molecular weight (MW 176 Da). Vitamin C loss may be considerably high during dialysis and result in less regeneration of vitamin E after dialysis [135]. In 2005, Asahi Medical further introduced a vitamin E-bonded polysulfone membrane into the dialysis market, and thus proved that it is possible to bind biologically active compounds also to synthetic dialysis membranes and sterilize them without loss of performance. 1.6.5.1 Degranulation of Neutrophils During hemodialysis neutrophil degranulation occurs, which is independent of complement activation but influenced by intracellular calcium and two neutrophil degranulation-inhibiting proteins: angiogenin (MW 14 000) [136] and complement factor D (MW 23 000) [137]. Both inhibitors are found to be up to 15-fold elevated in end-stage renal disease patients protecting against degranulation and consequently
1.6 Dialysis Membranes and Biocompatibility
degranulation products like lactoferrin [137]. Both molecules are removed only in small amounts by highly convective treatments, but some protein adsorbing membranes like PMMA and AN69 adsorb angiogenin [116] and factor D onto their surfaces [105,106]. AN69 reduced plasma angiogenin levels by 66 % and factor D level by 37 % during HD treatment, whereas Fresenius Polysulfone reduced plasma angiogenin concentration by 36 % and had no influence on factor D [116]. The removal of inhibitors during AN69 dialysis resulted in a more neutrophil degranulation and lactoferrin release than did treatment with polysulfone [116]. PMMA and regenerated cellulose induced more neutrophil degranulation than Hemophan, high-flux Fresenius Polysulfone, and polyamide [113].
1.6.6 Stimulation of Cytokine Generation by Different Types of Dialyzers and Hemofilters
Predialysis intracellular interleukin-1 (IL-1) and TNFa levels are higher in HD patients than in healthy individuals. Furthermore, both cytokines may be transiently generated during dialysis treatment with nonultrapure dialysis fluid [138–140]. The same has been described for the soluble receptors, IL-1RA and TNFsRp55 [138]. Predialysis IL-1b and TNFa in zymosan-stimulated PBMCs were found to be higher in patients treated with regenerated cellulose than in patients treated with PMMA and in healthy volunteers [141]. As complement is involved in the activation process, cytokine mRNA production and complement activation normally correlate [141,142]. However, a second stimulus is necessary for cytokine protein production and release. In hemodialysis, this is mainly provided by microbial contamination products [143] and, if used, by acetate from the dialysis fluid. Therefore, neither higher IL-1 nor TNFa plasma levels could be observed with membranes from regenerated cellulose [144] when pure, acetate-free dialysis fluid was used. In studies using pure dialysis fluid, increased plasma levels of IL-1 were observed to differ only insignificantly between normal subjects, nondialyzed chronic renal failure patients, and hemodialyzed patients [143]. Therefore, comparison of results from different clinical studies is only meaningful if the purity of the dialysis fluid is similar. In cases of contaminated dialysis fluid, the permeability of a membrane as well as its ability to adsorb microbial products at its outer surface is key factor for cytokine release [145]. The level of circulating cytokines that can be determined with modern methods may also be affected by patient-specific factors such as residual renal function, different renal and comorbid diseases, drugs, and different cellular productions. Dialyzer-related influencing factors are permeability/clearance, ultrafiltration rate, adsorption of cytokines, and stimulation of generation by different materials [140,146]. A comparison of plasma cytokine levels of circulating IL-1b, IL-6, and IL-10 measured using hemodialysis over a period of 4 months with high-flux polyamide and low-flux Hemophan revealed no differences between the membranes [147].
35
36
1 Membranes in Hemodialysis
In contrast, in vitro experiments with isolated monocytes from these patients reveal a higher state of preactivation of these cells with Hemophan. Preactivated monocytes secrete high amounts of proinflammatory cytokines when exposed to a second stimulus such as endotoxin [147]. A second study compared gene expression of IL-1b with different membranes using pure dialysis fluid: No differences in plasma levels among dialysis patients using different membranes, healthy subjects, and nondialyzed ESRD patients were found, but gene expression of IL-1b was threefold higher with regenerated cellulose in comparison to PMMA and polysulfone [144]. These data clearly demonstrate that gene expression of cytokines, but not necessarily their release from cells, is triggered with regenerated cellulose membranes. Therefore, plasma levels of circulating cytokines may remain stable during treatment. 1.6.6.1 The Impact of Membrane Types on LPS-Stimulated IL-1b Secretion Intracellular cytokine levels, such as IL-1b, are increased in hemodialysis patients, especially during dialysis with regenerated cellulose [139]. This chronic stimulation obviously leads to a suppression of the response to biological stimulants such as bacterial products. Lipopolysaccaraides (LPS)-induced IL-1b secretion is reduced in patients treated with membranes made of regenerated cellulose compared to that of healthy controls, nondialyzed chronic renal failure patients, and patients dialyzed with polyacrylonitrile membranes [148]. This functional change in PBMC response is specific for IL-1b, and it does not happen with TNF-a, is hemodialysis membrane is dependent and reversible. As possible mechanism may refer to increased prostaglandine E2 (PGE2) levels that suppress IL-1b secretion due to the following observed effects: when patients dialyzed with regenerated cellulose were switched to PAN membranes, total cell-associated and secreted IL-1b concentrations remained nearly constant, but the secreted amount after LPS stimulation increased. In parallel, PGE2 synthesis decreased with PAN compared to regenerated cellulose. Evidence for the role of PGE2 is further provided by the fact that with the addition of a PGE2 inhibitor, IL-1b secretion after LPS stimulation improved in PBMCs from HD-patients treated with regenerative cellulose.
1.6.7 The Impact of Large-Pore Dialysis Membranes on the Inflammatory Response in HD Patients by Cytokine Elimination
Due to the presence of large pores and their ability to adsorb proteins, high-flux dialyzers or hemofilters may eliminate some cytokines. Here some limitations of extracorporeal removal have to be kept in mind: cytokines are molecules of molecular size ranging from 15 000–30 000, which have a short half-life (in the range of minutes) and may be bound to carrier proteins such as a2-macroglobulin [149]. Therefore, a detectable amount may only be efficiently removed when convective treatments like hemofiltration with high ultrafiltration volumes and highly permeable membranes are performed. The adsorption capacity of the membrane for
1.6 Dialysis Membranes and Biocompatibility
cytokines is probably of more importance. In contrast to membranes from regenerated cellulose, membranes made from PAN (AN69) are able to adsorb considerable amounts of IL-1 in vitro [146].
1.6.8 The Effect of Different Dialyzers on the Acute Phase Reaction
IL-6 is the major regulator of the hepatic acute phase response in inflammation: it stimulates hepatic synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) up to several 100-fold [150]. Cultured PBMCs from patients dialyzed with Cuprophan spontaneously released more IL-6 than PBMCs from healthy individuals or from patients dialyzed with PMMA membranes [151], SMC, or cellulose diacetate [152]. The same effect was observed with the soluble IL-6 receptor, which probably reflects more the biological activity of IL-6 [153]. IL-6 release correlates positively with levels of circulating CRP [150], and hemodialysis patients exhibit elevated levels of IL-6, C reactive protein and serum amyloid A [150]. The reason for this is yet not clear, but the role of dialysis membranes and contaminated dialysis fluid is implicated: IL-6 levels were found to be elevated after the third hour of treatment with cuprammonium rayon membranes (Asahi AM-UP-75) and correlated with the release of acute phase proteins, albeit with different time schedules [150]. Increased concentrations of CRP and secretory phospholipase A2 (sPLA2) were found 24 hafter the start of hemodialysis with this membrane. In contrast, dialysis with polysulfone (F60S, FMC) showed no marked variation at these time points neither for IL-6, CRP nor sPLA2 levels [150].
1.6.9 Activation of the Kinin System by Different Types of Dialyzers and Hemofilters
The main factor determining activation of the kinin system with subsequent generation of bradykinin is the electronegativity of the dialysis membrane [154]. Table 1.4 provides an overview of the zeta potentials –as parameter for membrane electronegativity – of seven frequently used membranes. As is obvious from these in vitro experiments, AN69 and PAN DX membranes are the most electronegative membranes and generate the highest amounts of bradykinin, a mediator for anaphylactoid reactions [154]. When the electronegativity of the polyacrylonitrile polymer is reduced to near zero, as found for the PAN modification AN 69ST, in vitro bradykinin generation is reduced 200-fold. This was achieved by coating of the membrane with the polycationic polymer, polyethyleneimine [154]. Bradykinin generation with PAN membranes could be detected in vivo, especially in patients under ACE inhibitor therapy. Bradykinin is normally rapidly degraded in the body by the serine protease kininase II and therefore most patients are symptomfree under AN69 and PAN DX dialyzes. However, if this enzyme is blocked by ACE,
37
38
1 Membranes in Hemodialysis Zeta potential (surface electronegativity) plasma kallikrein activity and bradykinin generation with different membranes in vitro.
Tab. 1.4
Membrane Polyacrylonitrile AN69 Polyacrylonitrile PAN DX Polymethylmethacrylate Cellulose triacetate Cuprophan Fresenius Polysulfone Polyacrylonitrile AN69ST
Zeta potential (mV)
Plasma kallikrein (U/mL)
Bradykinin generation (fmol/mL)
70 5
60 15
32 100 (26 500–41 200)
60 4
80 20
28 983 (22 600–36 150)
25 2 20 2 10 1 5 1 3 1
10 5 <5 <5 <5 <5
130 65 78 62 150
(50–130) (25–100) (25–150) (25–120) (30–450)
Source: adapted from Ref. [154]
inhibitors plasma levels may increase by more than 100-fold and patients will suffer from severe anaphylactoid reactions [50–55,155]. The highest bradykinin generation reported was measured in vivo in sheep under ACE inhibitor therapy and treated with poylacrylonitrile membranes (AN69). Lower
Fig. 1.18 What is the possible future strategy for the treatment of kidney patients by means of extracorporeal blood circuits? Recent investigations have shown that a variety of uremic toxins is found in the larger molecular weight range. Conventional dialysis membranes such as the F60S PSu-membrane are determined by their molecular weight cutoff, that is, the sieving coefficient distribution.
Based on the experience with liver failure therapy, recent observations have shown that adsorber cartridges placed in a secondary circuit may support the removal of largemolecular-weight toxins, given that a filter with a higher cut-off (e.g., an Albuflow filter with a highly permeable polysulfone membrane) allows for the separation of plasma in the primary circuit.
References
generation was observed when a PAN membrane with lower surface electronegativity (SPAN-Membrana, not available any more on the market) was used [156]. In another study, even symptom-free patients without ACE medication exhibited an approximately 10-fold higher bradykinin generation with PAN (AN69) plate dialyzers than with Cuprophan, Hemophan, and high-flux Fresenius Polysulfone [157]. A very low bradykinin generation by high-flux Fresenius Polysulfone and low-flux Hemophan membranes was confirmed also for patients under ACE inhibitor therapy [158].
1.7 Conclusion
During the last 20 years of hemodialysis therapy, an intense research on membranerelated factors and properties has been performed. Understanding of membrane properties and performance in the clinical setting has considerably improved such that adverse events related to the membrane material have become rare. A general trend can be seen in that cellulosic membranes have lost their dominating role and synthetic membranes have taken the lead. Furthermore, membranes with high-flux properties gain increasing importance due to new concepts of therapy, such as online hemodiafiltration. Dialysis membranes of today have become bulk products and are available without any restriction. Future therapies will possibly involve highly permeable membranes combined in series with adsorber cartridges in order to cope with newly identified uremic toxins of large molecular weights and under hemodiafiltration treatments (Figure 1.18).
References 1 Grassmann, A., Gioberge, S.,
Moeller, S., Brown, G. (2006) Endstage renal disease: global demographics in 2005 and observed trends. Artificial Organs, 30, 895–897. 2 Gekas, V. (1988) Terminology for pressure-driven membrane operations. Desalination, 68, 77–92. 3 Klinkmann, H., Falkenhagen, D., Courney, J. (1987) Biomaterials and biocompatibility in hemodialysis. Contributions to Nephrology, 55, 231–239. 4 Abel, J., Rowntree, L., Turner, B. (1914) On the removal of diffusible substances from the circulating blood of living animals. Journal of Pharmacology and Experimental Therapeutics, 5, 275–316.
5 Haas, G. (1923) Dialysieren des
6
7 8
9
10
stro¨menden Bluts am Lebenden. Klinische Wochenschrift, 2, 1888. Haas, G. (1925) Versuche der Blutauswaschung am Lebenden mit Hilfe der Dialyse. Klinische Wochenschrift, 4, 13–14. ¨ ber Blutwaschung. Haas, G. (1928) U Klinische Wochenschrift, 7, 1356–1362. Eggerth, A. (1921) The preparation and standardisation of collodion membranes. Journal of Biological Chemistry, 18, 203–221. Weingand, R. (1932) Apparatus for manufacturing seamless flexible tubes from cellulose solution. US-Patent: 1 864 006 21.06. Thalhimer, W. (1938) Experimental exchange transfusions for reducing
39
40
1 Membranes in Hemodialysis
11
12
13
14
15
16
17
18 19
20
21
22
23
azotemia. Use of the artificial kidney for this purpose. Proceedings of the Society for Experimental Biology and Medicine, 37, 641–643. Thalhimer, W., Solandt, D., Best, C. (1938) Experimental exchange transfusions using purified heparin. The Lancet, ii, 554–556. Kolff, W. J. and Berk, H. T. (1943) De kunstmaatige Nier: een dialysator met groot oppervlak. Ned Tijdschr Geneeskunde, 87 (46/47), 1684. Kolff, W. J. (1993) The beginning of the artificial kidney. Artificial Organs, 17, 293–299. Kolff, W. J. and Watchinger, B. (1956) Further development of a coil kidney: disposable artificial kidney. Journal of Laboratory and Clinical Medicine, 47, 969–977. Alwall, N. (1947) Apparatus for dialysis of the blood in vivo. Acta Medica Scandinavica, 128, 317–325. Stewart, R. D., Gerny, J., Mahoni, H. (1964) The capillary ‘‘kidney’’: preliminary report. Medical Bulletin (Ann Arbor), 30, 116–118. Vienken, J., Baurmeister, U. (1992) Dialysemembranen aus Cellulose fu¨r die ku¨nstlicheNiere. Festschrift for the 200. Anniversary of the BembergCompany, 36–45, Akzo Fibres Wuppertal. Bandel, W. and Mitt, A. G. (1975) Klinische Nephrologie, 4, 29. Wetzel, E. (1986) Ha¨modialyse, Peritonealdialyse, Membranplasmapherese, Springer-Verlag, Berlin-Heidelberg. Streicher, E. and Schneider, H. (1983) Polysulphone membrane mimicking human glomerular basement membrane. The Lancet, ii, 1136. Go¨hl, H., Konstantin, P., Gullberg, C. (1982) Hemofiltration membranes. Contributions to Nephrology, 32, 20–30. Henderson, L. and Chenoweth, D. (1985) Cellulosic membranes, time for a change. Contributions to Nephrology, 44, 112–118. Vienken, J., Diamantoglou, M., Hahn, C., Kamusewitz, H., Paul, D. (1995) Considerations on
24
25
26
27
28
29
30
31
developmental aspects of biocompatible dialysis membranes. Artificial Organs, 19, 398–406. Bowry, S. and Ronco, C. (2001) Surface topography and surface elemental composition analysis of Helixone: a new high-flux polysulfone dialysis membrane. International Journal of Artificial Organs, 24, 757–764. Ronco, C., Ghezzi, P. M., Hoenich, N. A., Delfino, P. (2004) Membranes and filters for hemodialysis. Database. CD-ROM, Karger Basel. Hoenich, N. A. and Stamp, S. (2000) Clinical investigation of the role of membrane structure on blood contact and solute transport characteristics of a cellulose membrane. Biomaterials, 21, 317–324. Averbukh, Z., Modai, D., Sandbank, J., Berman, S., Cohn, M., Galperin, E., Cohen, N., Dishi, V., Weissgarten, J. (2001) Red Eye Syndrome: clinical and experimental experience in a new aspect of diffuse eosinophilic infiltration?Artificial Organs, 25, 437–440. Hutter, J., Kuehnert, M., Wallis, R., Lucas, A., Sen, S., Jarvis, W. (2000) Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialyzers. Journal of American Medical Association, 283, 2128–2134. Hoenich, N. A., Woffindin, C., Cox, P., Goldfinch, M., Roberts, S. (1997) Clinical characterization of Dicea, a new cellulose membrane for haemodialysis. Clinical Nephrology, 48, 253–259. Gasparovic, V., Ostojic, R., GnejeroMargan, I., Kes, P. (2001) Sudden death of Croatian dialysis patients in 2001. Croatian Medical Journal, 42, 606–610. Canaud, B., European Expert Panel (2002) Performance liquid test as a cause for sudden death of dialysis patients: perfluorocarbon, a previously unrecognized hazard for dialysis patients. Nephrology Dialysis Transplantation, 17, 545–548.
References 32 Canaud, B., Aljama, P., Tielemanns,
33
34
35
36
37
38
39
40
C., Gasparovic, V., Gutierrez, A., Locatelli, F. (2005) Pathochemical toxicity of perfluorocarbon-5070, a liquid test performance fluid previously used in dialyser manufacturing confirmed in animal experiment. Journal of the American Society of Nephrology, 16, 1819–1823. Ronco, C., Brendolan, A., Everard, P., Irone, M., Ballestri, M., Cappelli, G., Inguaggiato, P., Bellomo, R. (1999) Cellulose triacetate: another membrane for continuous renal replacement therapy. Journal of Nephrology, 12, 241–247. Akzo Faser, A. G., Wuppertal, Germany Hemophan, a DEAE modified cellulose for dialysis. USPatent No. 4 668 396. European Patent No. 172 497. Holland, F., Gidden, H., Mason, R., Klein, E. (1978) Thrombogenicity of heparin-bound DEAE cellulose hemodialysis membranes. ASAIO Journal, 1, 24–36. Nakagawa, K., Inagaki, O., Saian, Y., Fujita, Y. (1992) A study on heparin adsorption in Hemophan membrane dialyzer. Kidney, 15, 71. Kerr, P., Lo, A., Chin, M., Atkins, R. (1999) Dialyzer performance in the clinic: comparison of six low-flux membranes. Artificial Organs, 23, 817–821. Oosterhuis, W. P., deMetz, M., Wadham, A., Daha, M. R., Go, R. H. (1995) In vivo evaluation of four hemodialysis membranes: biocompatibility and clearances. Dialysis and Transplantation, 24, 450–458. Ward, R., Schaefer, R., Falkenhagen, D., Joshua, M., Heidland, A., Klinkmann, H., Gurland, H. (1993) Biocompatibility of a new highpermeability modified cellulose membrane for haemodialysis. Nephrology Dialysis Transplantation, 8, 47–53. Bowry, S. and Rintelen, T. (1998) Synthetically modified cellulose [SMC]: a cellulosic hemodialysis membrane with minimized
41
42
43
44
45
46
47
48
49
complement activation. ASAIO Journal, 44, 579–583. Hoenich, N., Woffindin, C., Stamp, S., Roberts, S., Turnbull, J. (1997) Synthetically modified cellulose: an alternative to synthetic membranes for use in haemodialysis?Biomaterials, 18, 1299–1303. Mandolfo, S., Tetta, C., David, S., Gervasio, R., Ognibene, D., Wratten, M., Tessore, E., Imbasciati, E. (1997) In vitro and in vivo biocompatibility of substituted cellulose and synthetic membranes. Artificial Organs, 20, 603–609. Clark, W. and Shinaberger, J. (2000) Clinical evaluation of a new high efficiency hemodialyzer: polysynthane. ASAIO Journal, 46, 288–292. Kishida, A., Mishima, K., Corretge, E., Konishi, H., Ikada, Y. (1992) Interaction of poly[ethylene glycol]grafted cellulosic membranes with proteins and platelets. Biomaterials, 13, 113–118. Fushimi, F., Nakayama, M., Nishimura, K., Hiyoshi, T. (1998) Platelet adhesion, contact phase coagulation activation, and C5a generation of polyethylene glycol acid-grafted high flux cellulosic membranes with varieties of grafting amounts. Artificial Organs, 22, 821– 826. Sasaki, M., Hosoya, N., Saruhashi, M. (2000) Vitamin E modified cellulose membrane. Artificial Organs, 24, 779–789. Saruhashi, M. and Sasaki, M. (2000) Antioxidant function of Vitamin E-modified dialyzer CL-EE. Japanese Journal of Artificial Organs, 29, 161– 165. Sasaki, M.,Hosoya, N.,Saruhashi, M.(1999)Development of vitamin E-modified membrane, in Vitamin EBonded Membrane: A Further Step in Dialysis Optimization (Karger AG, Basel, CH, eds C. Ronco and G. La Greca) (Contributions to Nephrology, 127, 49–70). Takeyama, T., Sakai, Y. (1998) Polymethylmethacrylate: one
41
42
1 Membranes in Hemodialysis
50
51
52
53
54
55
56
biomaterial for a series of membrane, in Polymethylmethacrylate. A Flexible Membrane for a Tailored Dialysis (Karger AG, Basel, CH, ed. C. Ronco) (Contributions to Nephrology, 125, 9–24). Verresen, L., Waer, M., Vanrenterghem, Y., Michielsen, P. (1990) Angiotensin-convertingenzyme-inhibitors and anaphylactic reactions to high-flux membrane dialysis. The Lancet, 336, 1360–1362. Tielemans, C., Madhoun, P., Lenaers, M., Schandene, L., Goldman, M., Vanherweghem, J. (1990) Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney International, 38, 982–984. Parnes, E. and Shapiro, W. (1991) Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney International, 40, 1148–1152. Brunet, P., Jaber, K., Berland, Y., Baz, M. (1992) Anaphylactoid reactions during hemodialysis and hemofiltration: role of associating A69 membrane and angiotensin I converting enzyme inhibitors. American Journal of Kidney Diseases, 9, 444–447. Brophy, P., Mottes, T., Kudelka, T., McBryde, K., Gradner, J., Maxvold, N., Bunchman, T. (2001) AN-69 membrane reactions are pHdependent and preventable. American Journal of Kidney Diseases, 38, 173–178. Krieter, D., Grude, M., Lemke, H., Finke, E., Bo¨nner, G., Scho¨lkens, B., Schulz, E., Mu¨ller, G. (1998) Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin. Kidney International, 53, 1026–1035. Valette, P., Thomas, M., De´jardin, P. (1999) Adsorption of low molecular weight proteins to hemodialysis membranes: experimental results and simulations. Biomaterials, 20, 1621–1634.
57 Moachon, N., Boullanger, C., Fraud,
58
59
60
61
62
63
64
S., Vial, E., Thomas, M., Quash, G. (2002) Influence of the charge of low molecular weight proteins on their efficacy of filtration and/or adsorption on dialysis membranes with different intrinsic properties. Biomaterials, 23, 651–658. Renaux, J., Thomas, M., Crost, T., Loughraieb, N., Vantard, G. (1999) Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. Kidney International, 55, 1097–1103. Renaux, J. L. and Atti, M. (2001) The AN69ST dialysis membrane. Contributions to Nephrology, 137, 111–119. Maheut, H. and Lacour, F. (2001) Using AN69ST membrane: a dialysis center experience. Nephrology Dialysis Transplantation, 16, 1519–1520. Ono, T., Iwamoto, N., Kataoka, H., Yamada, S., Sakai, Y., Kunitomo, T. (1988) Clinical significance of a dialysis membrane that can remove b-microglobulin. Transactions of American Society for Artificial Internal Organs, 34, 342–345. Klinke, B., Ro¨ckel, A., Abdelhamid, S., Fiegel, P., Walb, D. (1989) Transmembranous transport and adsorption of b2-m during hemodialysis using polysulfone, polyacrylonitrile, polymethylmethacrylate and cuprammonium rayon membranes. International Journal of Artificial Organs, 12, 697–702. Yamada, S., Kataoka, H., Kobayashi, H., Ono, T., Minakuchi, J., Kawano, Y. (1998) Identification of an erythropoietic inhibitor from the dialysate collected in the hemodialysis with PMMA membrane [BKF] and its clinical effects, in Polymethylmethacrylate. A Flexible Membrane for a Tailored Dialysis (Karger AG, Basel, CH, ed C. Ronco), (Contributions to Nephrology, 125, 159–172). Locatelli, F., Andrulli, S., Pecchini, F., Pedrini, L., Agliata, S., Lucchi, L., Farina, M., La Milia, V., Grassi, C.,
References
65
66
67
68
69
70
71
72
Borghi, M. (2000) Effect of high-flux dialysis on the anemia of haemodialysis patients. Nephrology Dialysis Transplantation, 15, 1399–1409. Gores, F., Montag, P., Schall, C., Vienken, J., Bowry, S. K. (2002) Verification of the chemical composition and specifications of haemodialysis membranes by NMR and GPC-FITIR-coupled spectroscopy. Biomaterials, 23, 3131–3140. Hoenich, N. A. and Stamp, S. (2000) Clinical performance of a new highflux synthetic membrane. American Journal of Kidney Diseases, 35, 345–352. Ronco, C. and Bowry, S. (2001) Nanoscale modulation of the pore dimensions, size distribution and structure of a new polysulfone-based high-flux dialysis membrane. International Journal of Artificial Organs, 24, 726–735. Stefoni, S., Coli, L., Cianciolo, G., Donati, G., Ruggeri, G., Ramazzotti, E., Pohlmeier, R., Lang, D. (2003) Inflammatory response of a new synthetic dialyser membrane. A randomized cross-over comparison between polysulfone and helixone. International Journal of Artificial Organs, 26, 26–32. Mandolfo, S., Malbertio, F., Imbasciati, E., Cogliatii, P., Gauly, A. (2003) Impact of blood and dialysate flow and surface on performance of a new polysulfone hemodialysis diaysers. International Journal of Artificial Organs, 26, 113–120. Deppisch, R., Betz, M., Ha¨nsch, G. M., Rauterberg, E. W.Ritz, E. (1992) Biocompatibility of the polyamide membrane, in Polyamide – The Evolution of a Synthetic Membrane for Renal Therapy (eds G. Berlyne and S. Giovannetti), (Contributions to Nephrology, 96, 26–46). Wilski, H.(1987) The radiation induced degradation of polymers. Radiat. Phys. and Chem., 29, 1–14. Ansorge, W., Pelger, M., Dietrich, W., Baurmeister, U. (1987) Ethylene oxide in dialyser rinsing fluid: effect
73
74
75
76
77 78
79
80
81
of rinsing technique, dialyser storage time, and potting compound. Artificial Organs, 11, 118–122. Vienken, J. and Ronco, C. (2001) New developments in hemodialysers. Contributions to Nephrology, 133, 105–118. Ronco, C., Brendolan, A., Crepaldi, C., Rodighiero, M., Scabardi, M. (2002) Blood and dialysate flow distributions in hollow-fiber hemodialyzers analyzed by computerized helical scanning technique. Journal of the American Society of Nephrology, 13 (Suppl. 1), S53–S61. Ronco, C., Brendolan, A., Crepaldi, C., Rodighiero, M., Everard, P., Ballestri, M., Capelli, G., Spittle, M., La Greca, G. (2000) Dialysate flow distribution in hollow fiber hemodialysers with different dialysate pathway configurations. International Journal of Artificial Organs, 23, 601– 609. Ronco, C., Scabardi, M., Goldoni, M., Brendolan, A., Crepaldi, C., La Greca, G. (1997) Impact of spacing filaments external to hollow fibers on dialysate flow distribution and dialyser performance. International Journal of Artificial Organs, 20, 261– 266. ¨ ber Diffusion. Annals Fick, A. (1855) U of Physics and Chemistry, 94, 59–86. Ward, R. and Schmidt, B. (1989) The impact of erythropoietin on hemodialyzer design and performance. Artificial Organs, 13, 35–42. Basmadijan, D., Sefton, M., Baldwin, S. (1997) Coagulation on biomaterials in flowing blood: some theoretical considerations. Biomaterials, 18, 1511–1522. Storck, M., Hartl, W. H., Zimmerer, E., Inthorn, D. (1991) Comparison of pump-driven and spontaneous continuous hemofiltration in postoperative acute renal failure. The Lancet, 337, 452–455. Delanna, F., Wu¨pper, A., Baldamus, C. A. (1996) Internal filtration – advantage in hemodialysis?Nephrology
43
44
1 Membranes in Hemodialysis
82
83
84
85
86
87
88
89
90
Dialysis Transplantation, 11 (Suppl. 2), 83–86. Gurland, H., Davison, A., Bonomini, V., Falkenhagen, D., Hansen, S., Kishimoto, T., Lysaght, M., Moran, J., Valek, A. (1994) Definitions and terminology in biocompatibility. Nephrology Dialysis Transplantation, 9 (Suppl. 2), 4–10. Salzmann, E. (1971) Thrombosis in artificial organs. Transplantation Proceedings, 3, 1491–1496. Dolovich, J. and Bell, B. (1978) Allergy to a product of ethylene oxide gas: demonstration of IgE and IgG antibodies. Journal of Allergy and Clinical Immunology, 62, 30–32. Craddock, P., Fehr, J., Brigham, K., Kronenberg, R., Jacob, H. (1977) Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. New England Journal of Medicine, 296, 769–774. Craddock, P., Fehr, J., Dalmasso, A., Brigham, K., Jacob, H. (1977) Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from complement activation by dialyser cellophane membranes. Journal of Clinical Investigation, 59, 879–888. Henderson, L., Koch, K., Dinarello, C., Shaldon, S. (1983) Hemodialysis hypotension: the interleukin hypothesis. Blood Purification, 1, 3–8. Tielemanns, C., Madhoun, P., Lenaers, M., Schandene, L., Goldman, M., Vanherweghem, J. (1990) Anaphylactoid reactions during hemodialysis with AN69 membranes in patients receiving ACE-inhibitors. Kidney International, 38, 982–984. Tsunoda, N., Kobuko, K., Sakai, K., Fukuda, M., Miyazaki, M., Hiroshi, T. (1999) Surface roughness of cellulose hollow fiber dialysis membranes and platelet adhesion. ASAIO Journal, 45, 418–423. Matata, B., Courtney, J., Sundaram, S., Wark, S., Bowry, S., Vienken, J., Lowe, G. (1996) Determination of contact phase activation by the measurement of the activity of
91
92
93
94
95
96
97
98
supernatant and membrane surfaceadsorbed factor XII: its relevance as a useful parameter for the in vitro assessment of hemodialysis membranes. Journal of Biomedical Materials Research, 31, 63–70. Cornelius, R. and Brash, J. (1993) Identification of proteins adsorbed to hemodialysis membranes from heparinzed plasma. Journal of Biomaterials Science Polymer Edition, 4, 291–304. Mulvihill, J., Crost, T., Renaux, J., Cazenave, J. (1997) Evaluation of hemodialysis membrane biocompatibility by parallel assessment in an ex vivo model in healthy volunteers. Nephrology Dialysis Transplantation, 12, 1968–1973. Ishii, Y., Yano, S., Kanai, H., Maezawa, A., Tsuchida, A., Wakamatsu, R., Naruse, T. (1996) Evaluation of blood coagulationfibrinolysis system in patients receiving chronic hemodialysis. Nephron, 73, 407–412. Frank, R., Weber, J., Dresbach, H., Thelen, H., weiss, C., Floege, J. (2001) Role of contact system activation in hemodialyser-induced thrombogenicity. Kidney International, 60, 1972–1981. Matsuda, T. (1989) Biological responses at non-physiological interphases and molecular design of biocompatible surfaces. Nephrology Dialysis Transplantation, 4 (Suppl.), 60–66. Schultze, G., Go¨hl, H., Hollmann, S., Sinah, P. (1991) Formation of thrombin-antithrombin complex using polyamide and cellulosic dialysers (Abstract). International Journal of Artificial Organs, 14, 543. Holland, F., Gidden, H., Mason, R., Klein, E. (1978) Thrombogenicity of heparin-bound DEAE cellulose hemodialysis membranes. ASAIO Journal, 1, 24–36. Nakagawa, K., Inagaki, O., Saian, Y., Fujita, Y. (1992) A study on heparin adsorption in Hemophan membrane dialyser. Kidney, 15, 71–75.
References 99 Ward, R., Schmidt, B., Gurland, H.
100
101
102
103
104
105
106
107
(1993) Prevention of blood loss in dialysers with DEAE cellulose membranes does not require increased doses of heparin. Nephrology Dialysis Transplantation, 8, 1140–1145. Debrand-Passard, A., Lajous-Petter, A., Schmidt, R., Herbst, R., vonBaeyer, H., Krause, A., Schiffl, H. (1989) Thrombogenicity of dialyser membranes as assessed by residual blood volume and surface morphology at different heparin dosages. Contributions to Nephrology, 74, 2–9. Verbeelen, D., Jochmanns, K., Herman, A., Vander Niepen, P., Sennesael, J., DeWaele, M. (1991) Evaluation of platelets and hemostasis during hemodialysis with six different membranes. Nephron, 59, 567–572. Cases, A., Reverter, J., Escolar, G., Sanz, C., Lopez-Pedret, J., Revert, L., Ordinas, A. (1993) Platelet activation on hemodialysis: influence of dialysis membranes. Kidney International, 43 (Suppl. 41), S217–S220. Cases, A., Reverter, J., Escolar, G., Sanz, C., Sorribes, J., Ordinas, A. (1997) In vivo evaluation of platelet activation by different cellulosic membranes. Artificial Organs, 21, 330–334. Rauterberg, E., Ritz, E., Schulze, H., Rother, K. (1987) Limited derivatisation of Cuprophan increases factor H binding and diminishes complement activation (Abstract). Kidney International, 31, 243. Pascual, M. and Schifferli, J. (1993) Adsorption of complement factor D by polyacrylonitrile membranes. Kidney International, 43, 903–911. Pascual, M., Schifferli, J., Pannatier, J., Wauters, J. (1993) Removal of complement factor D by adsorption of polymethacrylate dialysis membranes. Nephrology Dialysis Transplantation, 8, 1305–1306. Cheung, A., Parker, C., Wilcox, L., Janatova, J. (1989) Activation of the
108
109
110
111
112
113
114
alternative pathway of complement by cellulosic hemodialysis membranes. Kidney International, 36, 257–265. Deppisch, R., Goehl, H., Smeby, L. (1998) Microdomain structure of polymeric surfaces – potential for improving blood treatment procedures. Nephrology Dialysis Transplantation, 13, 1354–1359. Cheung, A., Parker, C., Wilcox, L., Janatova, J. (1990) Activation of complement by hemodialysis membranes: polyacrylonitrile binds more C3a than Cuprophan. Kidney International, 37, 1055–1059. Jorstadt, S., Smeby, L., Balstad, T., Wideroe, T. (1988) Generation and removal of anaphylatoxins during hemofiltration with five different membranes. Blood Purification, 6, 325–335. Falkenhagen, D., Brown, G., Boetcher, M., Falkenhagen, U., Schmidt, B., Gurland, H., Klinkmann, H. (1987) Permeation of complement factors through highflux dialysers and plasma separation membranes. In Bambauer, R. Malchesky, P. Falkenhagen, D. (eds) Therapeutic plasma exchange and selective plasma separation, Schattauer Verlag, Stuttgart, 215–222. Kaiser, J., Oppermann, M., Gotze, O., Deppisch, R., Goehl, H., Asmus, G., Rohricht, B., vonHerrath, D., Schaefer, K. (1995) Significant reduction of factor D and immunosuppressive complement fragment Ba by haemofiltration. Blood Purification, 13, 314–321. Deppisch, R., Ritz, E., Ha¨nsch, G., Scho¨ls, M., Rauterberg, E. (1994) Biocompatibility perspectives. Kidney International, 45 (Suppl. 44), S77– S84. Meier, P., von Fliedner, V., Markert, M., VanMelle, G., Deppisch, R., Wauters, J. (2000) One year immunological evaluation of chronic hemodialysis in end stage renal
45
46
1 Membranes in Hemodialysis
115
116
117
118
119
120
121
122
disease patients. Blood Purification, 18, 128–137. Ohi, H., Tamano, M., Sudo, S. (2001) Cellulose membranes suppress complement activation in patients after hemodialysis. American Journal of Kidney Diseases, 38, 384–389. Hoerl, W. (1998) Hemodialysis membranes: interleukins, biocompatibility and middle molecules. Journal of the American Society of Nephrology, 22, 585–590. Hoenich, N. and Stamp, S. (2000) Clinical investigation of the role of membrane structure on blood contact and solute transport characteristics of a cellulose membrane. Biomaterials, 21, 317–324. Nahar, N., Shah, H., Sui, J., Colvin, R., Baskaran, M., Ranjan, R., Wagner, J., Singhal, P. (2001) Dialysis membrane induced neutrophil apoptosis is mediated through free radicals. Clinical Nephrology, 56, 52–59. Martı´n-Malo, A., Carracedo, J., Ramirez, R., Rodriguez-Benot, A., Soriano, S., Rodriguez, M., Aljama, P. (2000) Effect of uremia and dialysis modality on mononuclear cell apoptosis. Journal of the American Society of Nephrology, 11, 936–942. Nguyen-Khoa, T., Massy, Z., DeBandt, J., Kebede, M., Salama, L., Lambrey, G., Witko-sarsat, V., Drueke, T., Lacour, B., The´venin, M. (2001) Oxidative stress and hemodialysis: role of inflammation and duration of dialysis treatment. Nephrology Dialysis Transplantation, 16, 335–340. Weinstein, T., Chagnac, A., Korzets, A., Boaz, M., Ori, Y., Herman, M., Malachi, T., Gafter, U. (2000) Hemolysis in hemodialysis patients: evidence for impaired defense mechanisms against oxidative stress. Nephrology Dialysis Transplantation, 15, 883–887. Himmelfarb, J. and McMonagle, E. (2001) Manifestations of oxidative stress in uremia. Blood Purification, 19, 200–205.
123 Nourooz-Zadeh, J. (1999) Effect of
124
125
126
127
128
129
130
131
dialysis on oxidative stress in uremia. Redox Report, 4, 17–22. Morena, M., Cristol, J., Canaud, B. (2000) Why hemodialysis patients are in a pro-oxidant state? What could be done to correct the pro/antioxidant imbalance?. Blood Purification, 18, 191–199. Canaud, B., Cristol, J., Morena, M., Leray-Moragues, H., Bosc, J., Vaussenat, F. (1999) Imbalance of oxidants and antioxidants in hemodialysis patients. Blood Purification, 17, 99–106. Himmelfarb, J., Ault, K., Holbrook, D., Leeber, D., Hakim, R. (1993) Intradialytic granulocyte reactive oxygen species production: a prospective cross-over trial. Journal of the American Society of Nephrology, 4, 178–186. Bonomini, M., Sirolli, V., Settefrati, N., Stuard, S., Tropea, F., DiLiberato, L., Tetta, C., Albertazzi, A. (1999) Surface antigen expression and platelet neutrophil interactions in hemodialysis. Blood Purification, 17, 107–117. Sirolli, V., Ballone, E., Amoroso, L., DiLiberato, L., Di Mascio, R., Capelli, P., Albertazzi, A., Bonomini, M. (1999) Leukocyte adhesion molecules and leukocyteplatelet interactions during hemodialysis: effects of different synthetic membranes. International Journal of Artificial Organs, 22, 536–542. Vanholder, R., Ringoir, S., Dhondt, A., Hakim, R., Waterloos, M., VanLantschoot, N., Gung, A. (1991) Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney International, 39, 320–327. Galli, F., Canestrari, F., Buoncristiani, U. (1999) Biological effects of oxidant stress in hemodialysis: the possible role of vitamin E. Blood Purification, 17, 79–94. Bonnefont-Rousselot, D., Lehmann, E., Jaudon, M., Delattre, J., Perrone,
References
132
133
134
135
136
137
138
B., Reschke, J. (2000) Blood oxidative stress and lipoprotein oxidizability in hemodialysis patients: effects of the use of a vitamin E coated dialysis membrane. Nephrology Dialysis Transplantation, 15, 2020–2028. Galli, F., Rovidati, S., Chiarantini, L., Campus, G., Canestrari, F., Buoncristiani, U. (1998) Bioreactivity and biocompatibility of a vitamin Emodified multilayer hemodialysis filter. Kidney International, 54, 580–589. Satoh, M., Yamasaki, Y., Nagake, Y., Kasahara, J., Hashimoto, M., Nakanishi, N., Makino, H. (2001) Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney International, 59, 1943–1950. Clemont, G., Lecour, S., Cabanne, J., Motte, G., Guilland, J., Hevet, D., Rochette, L. (2001) Vitamin E-coated dialyser reduces oxidative stress in hemodialysis patients. Free Radical Biology and Medicine, 31, 233–241. Eiselt, J., Racek, J., Trefil, L., Opatrny, K. (2001) Effects of vitamin Emodified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artificial Organs, 26, 430–436. Fett, J., Strydom, D., Lobb, R., Alderman, E., Bethune, J., Riordan, J., Vallee, B. (1985) Isolation and characterisation of angiogenin, an angiogenin protein from human carcinoma cells. Biochemistry, 24, 5480–5486. Schmaldienst, S. and Hoerl, W. (2000) Degranulation of polymorphonuclear leukocytes by dialysis membranes. Nephrology Dialysis Transplantation, 15, 1909– 1910. Pereira, B., Shapiro, L., King, A., Falagas, M., Strom, J., Dinarello, C. (1994) Plasma levels of Il-1b, TNF and their specific inhibitors in undialysed chronic renal failure. CAPD and hemodialysis patients. Kidney International, 45, 890–896.
139 Haeffner-Cavaillon, N., Cavaillon, J.,
140
141
142
143
144
145
146
147
Ciancioni, C., Bacle, F., Delons, S., Kazatchkine, M. (1989) In vivo induction of interleukin-1 during hemodialysis. Kidney International, 35, 1212–1218. Bingel, M., Lonnemann, G., Koch, K., Dinarello, C., Shaldon, S. (1988) Plasma interleukin-1 activity during hemodialysis: the influence of hemodialysis membranes. Nephron, 50, 273–276. Schindler, R., Gelfand, J., Dinarello, C. (1990) Recombinant C5a stimulates transcription rather translation of Il-1 and TNF: translational signal provided by LPS or IL-1 itself. Blood, 76, 1631–1638. Varela, M., Kimmel, P., Philips, T., Mishkin, G., Lew, S., Bosch, J. (2001) Biocompatibility of hemodialysis membranes: interrelations between plasma complement and cytokine levels. Blood Purification, 19, 370–379. Okusawa, S., Dinarello, C., Yancey, K., Endres, S., Lawley, T., Frank, M., Burke, J., Gelfand, J. (1987) C5a induction of human interleukin 1: synergistic effect with endotoxin or interferon. Journal of Immunology, 139, 2635–2640. Qian, J., Yu, Z., Dai, H., Zhang, Q., Chen, S. (1995) Influence of hemodialysis membranes on gene expression and plasma levels of interleukin-1. Artificial Organs, 19, 842–846. Lonnemann, G., Behme, T., Lenzner, B., Floege, J., Schulze, M., Colton, C., Koch, K., Shaldon, S. (1992) Permeability of dialyser membranes to TNF-inducing substances derived from bacteria. Kidney International, 42, 61–68. Lonnemann, G., Koch, K., Shaldon, S., Dinarello, C. (1988) Studies on the abilities of dialysis membranes to induce, bind, and clear human interleukin-1. Journal of Laboratory and Clinical Medicine, 112, 76–86. Girndt, M., Heisel, O., Ko¨hler, H. (1999) Influence of dialysis with polyamide vs.haemophan dialysers on monkines and complement
47
48
1 Membranes in Hemodialysis
148
149
150
151
152
activation during a 4-month longterm study. Nephrology Dialysis Transplantation, 14, 676–682. Lonnemann, G., Barndt, I., Kaever, V., Haubitz, M., Schindler, R., Shaldon, S., Koch, K. (1995) Impaired endotoxin-induced interleukin-1 secretion, not total production of mononuclear cells from ESRD patients. Kidney International, 47, 1158–1167. Schindler, R., Senf, R., Frei, U. (2002) Influencing the inflammatory response of hemodialysis patients by cytokine elimination using large-pore membranes. Nephrology Dialysis Transplantation, 17, 17–19. Schouten, W., Grootemann, M., VanHoute, A., Schoorl, M., VanLimbeck, J., Nube, M. (2000) Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrology Dialysis Transplantation, 15, 379–384. Memoli, B., Libetta, C., Rampino, T., DalCanton, A., Conte, G., Scala, O., Ruocco, M., Andreucci, M. (1992) Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney International, 42, 320–326. Memoli, B., Minutulo, R., Bisesti, V., Postiglione, L., Conti, A., Marzano, L., Capuano, A., Andreucci, M., Balletta, M., Guida, B., Tetta, C. (2002) Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. American Journal of Kidney Diseases, 39, 266–273.
153 Memoli, B., Postiglione, L.,
154
155
156
157
158
Cianciaruzo, B., Bisesti, V., Cimmaruta, C., Marzano, L., Minutulo, R., Cuomo, V., Guida, B., Andreucci, M., Rossi, G. (2000) Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients. Kidney International, 58, 417–424. Renaux, J., Thomas, M., Crost, T., Loughraieb, N., Vantard, G. (1999) Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution and pH. Kidney International, 55, 1097–1103. Schaefer, R., Schaefer, L., Hoerl, W. (1994) Anaphylactoid reactions during hemodialysis. Clinical Nephrology, 42 (Suppl. 1), S44–S47. Krieter, D., Grude, M., Lemke, H., Fink, E., Bo¨nner, G., Scho¨lkens, B., Schulz, E., Mu¨ller, G. (1998) Anaphylactoid reactions during hemodialysis in sheep are ACEinhibitor dose-dependent and mediated by bradykinin. Kidney International, 53, 1026–1035. Verresen, L., Fink, E., Lemke, H., Vanrenterghem, Y. (1994) Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney International, 45, 1497–1503. Mannstadt, M., Touam, M., Fink, E., Urena, P., Hruby, M., Zingraff, J., Uhlenbusch-Ko¨rwer, I., Grassmann, A., Lemke, H., Drueke, T. (1995) No generation of bradykinin with a new polyacrylonitrile membrane [SPAN] in hemodialysis patients treated with ACE-inhibitors. Nephrology Dialysis Transplantation, 10, 1696–1700.
49
2 Membranes for Artificial Lungs Frank Wiese 2.1 Introduction
Membrane oxygenators are used inside heart–lung machines during open-heart surgery or for lung support systems. In the natural lung, oxygen and carbon dioxide are exchanged between the blood and the body environment. The oxygen is needed in the body tissues to sustain life. The carbon dioxide produced during the metabolism has to be removed. Worldwide, oxygenators are used in surgical interventions during which the heart– lung function is interrupted, for example, for cardiovascular bypass, heart valve replacement, or when repairing congestive heart failure [30–32]. Furthermore, extracorporeal membrane oxygenation (ECMO) is used in several configurations for long-term lung support, for example, in cases of multiorgan failure (MOF) and in different pulmonary diseases [7,33–35]. Implantable membrane devices for longterm lung support are under development [5]. Special newly developed membranes were required for these long-term applications. In general, at the very core of these devices are membranes that separate the patient’s blood from gases and that allow oxygen to enter and carbon dioxide to leave the blood. In 2005, around 1.2 million open-heart operations were carried out, corresponding to a consumption of 3 million km of oxygenation membranes. Membranes for gas exchange are also an important component in membrane bioreactors for biotechnology applications and in hybrid bioartificial organs (see Chapters 5 and 8).
2.2 History of Blood Oxygenation
Some milestones in the history of the development of blood membrane oxygenators [6,30,37] are listed below: 1812: Le Gallois’ suggestion for the first extracorporeal circulation
Membranes for the Life Sciences. Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes Copyright ß 2008 WILEY-VCH Verlag GmbH & Co. KGaA. All rights reserved ISBN: 978-3-527-31480-5
50
2 Membranes for Artificial Lungs
1876: an isolated kidney was perfused with oxygenated blood for the first time 1918: discovery of heparin 1944: Kolff had the idea of constructing an oxygenator (beginning of membrane oxygenation) 1955: development of the first membrane oxygenator by Kolff and Balzer 1956: first clinical application 1959: first heart surgery using a membrane oxygenator 1969: membrane oxygenators became commercially available.
The start of the historical development of extracorporeal circulation is strongly related to Ce´sar Julian Jean Le Gallois (1770–1814). He suggested that a part of the body might be preserved by a mechanical heart replacement and some kind of external perfusion devices. The important monograph ‘‘Experiences sur le principe de la vie’’ was published in 1812 [1] and 1 year later in the United States [2] (see Figure 2.1). Alexander Schmidt for the first time perfused an isolated dog kidney with oxygenated blood in 1876 [3]. Many different types of disks, films, and bubble oxygenators were developed for extracorporeal circulation experiments. All these early oxygenators exposed blood directly to gas mixtures or oxygen to provide oxygenation and remove CO2. The developments, started in the 1930s, resulted in disposable single-use bubble oxygenators and opened the area of cardiac surgery in the early 1950s. John Gibbon was a pioneer in this development [4,8,30]. In 1955, the DeWall–Lillehei bubble oxygenator was a major breakthrough [36,23]. The simplicity of the basic concept was linked to simple construction and disposability. The principle is: Venous blood is pumped into an oxygenation chamber where oxygen bubbles are dispersed. The gas exchange occurs on the bubble surface. The mixture of blood and gas that emerges from the bubble chamber has to be defoamed in a defoaming compartment. The main disadvantage of bubble oxygenators is that they are basically not biocompatible. The blood–gas interface represents a nonphysiological state resulting, for example, in hemolysis, coagulopathy, and so on. Nevertheless, bubble oxygenators were used until 10 years ago in around 2–3 % of open heart surgery worldwide. 2.2.1 Membrane Oxygenators
In 1944, Kolff and Berk found that venous blood was oxygenated while flowing through a cellophane dialyzer and being in contact with oxygen containing dialyzate. Oxygenation was carried out across the artificial membrane [24]. This discovery stimulated the development of the use of gas permeable membranes in order to separate the blood phase from the gas phase in an artificial lung. The first membrane oxygenator was reported by Kolff in 1955 [45,46] (Figure 2.2). At this time the available membrane materials were relatively impermeable to the respiratory gases.
2.2 History of Blood Oxygenation
Fig. 2.1 Front page of paper of Le Gallois, describing the basic idea of extracorporeal circulation and oxygenation of blood for the first time (1812).
The first membrane oxygenator built and used clinically was reported by Clowes and Hopkins in 1956 [8]. It was constructed of ethylcellulose multilayer flatsheet membranes and had a membrane area of 25 m2. These factors limited the clinical applications until the 1970s and early 1980s, although the very first thin sheet membranes of polyethylene and polytetraflourethylene were available. The development of polydimethylsiloxane with high permeability for oxygen and carbon
51
52
2 Membranes for Artificial Lungs
Fig. 2.2 Professor Kolf in 2004 – ‘‘The father of artificial organs,’’ also invented artificial coil kidney and the coil oxygenator 50 years ago [47].
dioxide brought a major advance in establishing the technical feasibility of membrane oxygenators in the 1960s and 1970s. The required membrane area could be optimized at less than 6 m2. The real breakthrough came with the development of hydrophobic microporous flat sheet membranes with pore sizes <0.1 mm in the 1980s [26]. Later in the 1980s microporous hollow fiber membranes [27] became commercially available. With the introduction of extraluminal flow oxygenators [28,29] membranes, areas of less than 2 m2 were required to treat an adult patient.
2.3 Principle of Gas Transfer
2.3 Principle of Gas Transfer
The transport of gas into the blood is a process of convection and diffusion via the membrane and the blood combined with O2 and CO2 reaction with the erythrocyte hemoglobin. The hemoglobin in the erythrocytes has a specific chemical gas-binding capacity for O2 and CO2 and assures the adequate transport of both these gases inside the body. The driving force for the gas exchange is the partial pressure difference of these gases between the blood side and the gas side (O2) of the membrane. According to the pressure differences, gas diffuses through the membrane wall from the side of high partial pressure to the side of low partial pressure (Figure 2.3). The maximum concentration of chemically bound O2, called the oxygen capacity, is calculated from the hemoglobin content of the blood and the binding capacity of hemoglobin for oxygen. For a mean hemoglobin content of Hb ¼ 0.12 kg/L and a binding capacity of Ha ¼ 1.34 L/kg, the oxygen capacity will be 0.1608 L O2/L blood. This value will be reached at an O2 partial pressure of approximately 20 kPa ¼ 150 mmHg, which is the ambient partial pressure of oxygen. An additional increase in the O2 content is possible but nonphysiological. The oxyhemoglobin dissociation curve is usually calculated according to the mathematical model of Hill [9] (Figure 2.4). Nowadays the active area of membrane oxygenators is between 0.5 and 2.5 m2. This is around 10 % of that of the natural lung of young children or adults. In order to reach a sufficient gas exchange, the contact time has to be increased and/or the partial pressure differences have to be increased or other suitable conditions have to be adjusted. According to Fick’s law (1) the gas exchange efficiency can be increased [30,37]. VO 2 ¼
P1 P2 KF: L
ð1Þ
In Equation (1), VO2 is the amount of oxygen exchanged in a certain time, P1 P2 is the partial pressure difference, K is the diffusion factor (adsorption coefficient, turbulence), F is the surface, and L is the diffusion layer thickness.
Fig. 2.3 Partial pressure difference of oxygen and carbon dioxide across an oxygenation membrane.
53
54
2 Membranes for Artificial Lungs
Fig. 2.4 Blood saturation according to Hill.
The transfer of oxygen into the blood is hindered by three main resistances: Rtotal ¼ RB þ RM þ RG :
ð2Þ
In Equation (2), the total resistance to gas transport Rtotal is the sum of the resistance on the blood side RB, the resistance across the membrane RM, and the resistance on the gas side RG (Figure 2.5). For a usual oxygenator type, containing microporous capillary membranes, as described in Section 2.4, the blood boundary layer lies outside the capillaries. The diffusion resistances that opposes the gas exchange consists of the resistance of the gas boundary layer, the membrane, and the blood boundary layer. Here the resistance of the gas boundary layer is infinitely small and approaches zero, and accordingly, can be neglected. The resistance of the membrane is about 1.25 104 cm2 s cmHg/cm3. The resistance in the blood boundary layer is approximately 100 times larger and should be optimized in such a way that this layer becomes very small (see Section 2.6). The mass transfer in relation to the geometry flow pattern and the hydrodynamics of an artificial lung has been investigated in hundreds of papers [6,10–13].
Fig. 2.5 Mass transfer model for an extraluminal flow oxygenator.
2.4 Membranes and Membrane Properties
2.4 Membranes and Membrane Properties
Nowadays membranes for oxygenators used in open-heart surgery are mostly microporous hydrophobic capillary membranes with pore sizes <0.1 mm and outer diameters between 300 and 500 mm. For special applications, for example, in lung support systems, dense skinned membranes are used because of better long-term blood plasma resistance. The main membrane polymers used are polyolefins such as polypropylene (PP), polyethylene (PE), and poly-4-methylpentene (PMP). Further, the polymers used on a small scale are polyvinylidenfluoride (PVDF) and silicon rubber. In flat sheet membrane oxygenators, the blood is separated from the gas by spiral wound membranes or stapled membranes. Baffles placed in the area between the membranes, in order to reduce the boundary layer and increase efficiency, require a lot of effort. Therefore, only one type of microporous flat sheet membrane oxygenator is available but without any market relevance. Around 80 % of oxygenation membranes used worldwide are produced by Membrana GmbH in Wuppertal. Other producers of oxygenation membranes are Dainippon Inc. and Terumo. 2.4.1 Microporous Membranes
Gas exchange between the blood side and the gas side in microporous membranes is performed by diffusion and convection of the respiratory gases via the open pores. Thus, the resistance of the membrane is very low for these gas exchanges, as explained in Section 2.3. Most microporous oxygenator membranes are made from polypropylene by temperature-induced phase separation (TIPS) process (see Section 2.5). The sponge-like structure of this membrane is homogeneous and isotropic with open surfaces on both wall sides (Figure 2.6). These membranes achieve reliable, adequate performance (Figure 2.10), and the mechanical stability in terms of tensile strength and elongation at break is combined with high reliability and handling safety during the manufacturing process (see Section 2.6). Today, it is the most widely used oxygenation membrane. The second type of microporous membranes is produced by the ‘‘melt spin stretch process’’ (see Section 2.5), resulting in fibrillar polymer structures (see Figure 2.7). Polyolefins are again suitable for these processes because only polymers with a certain crystallinity are suitable for creating such membrane structures. Performance wise the membranes can reach a comparable level to that of TIPS membranes. Long-term plasma breakthrough characteristics are a little more critical because of the structure. Due to the hydrophobicity of the membrane and the pore size (<0.1 mm), gas molecules can pass through the membrane wall, whereas liquids and corpuscular components are retained. The polar part of the surface energy [15] has to be very small so that no wetting of the pores with aqueous solutions, for example, blood, is possible,
55
56
2 Membranes for Artificial Lungs
Fig. 2.6 REM photograph of a microporous PP membrane (OXYPHAN, Membrana, Wuppertal).
and a water droplet on this surface has to create a high-contact angle 908 (see Figure 2.8). For the duration of an open-heart operation and for several days, these open membranes work very reliably and are safe. However, during the treatment, plasma proteins adsorb first at the membrane surface and then this protein layer also grows
Fig. 2.7 REM photograph of a microporous PP membrane produced by a melt spin stretch process.
2.4 Membranes and Membrane Properties
Fig. 2.8 Contact angle of hydrophilic and hydrophobic surfaces.
through the membrane pores. This results in an increase in the surface energy of the pore ‘‘skin.’’ Moreover, due to this surfactant impact the pores become wet and plasma breakthrough from the blood side to the gas side occurs [41,42]. 2.4.2 Dense Membranes/‘‘Diffusion Membranes’’
Dense membranes, also called ‘‘diffusion’’ membranes, have no open pores in the membrane wall or the outer skin of the wall [38,44,53]. In long-term ‘‘extracorporeal membrane oxygenation’’ applications such membranes are used to prevent plasma breakthrough. The respiratory gases have to have a good solubility in the membrane polymer. Driven by the concentration difference of the gases on both sides of the membrane, the gases are transported by diffusion through the polymer matrix to the lower concentration. In the past, silicon rubber or silicon-skinned microporous membranes were used because of the high specific permeability of this polymer. The disadvantage of these membranes was their relatively high wall thicknesses due to mechanical requirements. According to Fick’s law (Section 2.3), the diffusive gas transport is reciprocally proportional to the thickness of the polymer layer. Thus, high membrane areas were required to achieve sufficient gas exchange. To overcome this problem, membranes made of poly-4-methylpentene were developed. The membrane with the best performance is produced by a thermally induced phase separation process (ACCUREL) (Figure 2.9). The membrane is integrally asymmetric, as it has a sponge-like microporous wall with a thin dense outer skin (Figure 2.9). Due to the high specific permeabilities of PMP to oxygen and carbon dioxide (Table 2.1) and the dense outer skin, which is kept very thin (0.1 mm), OXYPLUS has gas transfer capabilities comparable to common microporous membranes. Figure 2.10 shows a comparison of the gas transfer of the same oxygenator types equipped with either PMP or PP membranes. The plasma breakthrough times for OXYPLUS are very much longer than those of common microporous membranes: in the clinical experience of different working groups the membrane has worked properly in ECMO for up to 42 days without exchanging the device [18,19]. Additionally, the dense outer skin largely prevents entry of gas into the blood and avoids direct blood–gas contact. As a trade off, the transfer of volatile anesthetics is impaired [20] and the anesthetic protocol may have to be amended. The permeability of PMP is higher for oxygen than for nitrogen. This membrane is thus also suitable for gas separation or enrichment. Table 2.2 shows the fluxes of
57
58
2 Membranes for Artificial Lungs
Fig. 2.9 Gas transfer rates of two commercially available oxygenators, equipped either with a microporous PP membrane or with a PMP membrane with dense outer skin [16,17].
Gas permeability coefficients of polypropylene and poly-4-methylpentene for oxygen and carbon dioxide [14].
Tab. 2.1
Gas
PP
PMP
Oxygen Carbon dioxide
2.2 9.2
32.3 92.6
Permeability (1 Barrer ¼ 1010 cm3 cm/(s cm2 cmHg).
2.5 Membrane Production
Fig. 2.10 REM photograph of a microporous PMP membrane with dense outer skin (OXYPLUS, Membrana, Wuppertal).
Gas permeabilities of OXYPLUS for different gases and the resulting separation coefficients.
Tab. 2.2
Gas Nitrogen Oxygen Carbon dioxide
Flux (L/m2 min bar) 1.68 5.90 16.90
Separation coefficient related to nitrogen –— 3.53 10.13
different gases through OXYPLUS and the resulting gas separation coefficients. With this membrane, the enrichment of oxygen in air to a concentration of, for example, 25 %, is possible and effective in a single-step process.
2.5 Membrane Production
Oxygenation membranes are mainly produced by two different processes: Temperature-induced phase separation process Melt spin stretch process. Seventy percent of oxygenation membranes worldwide are produced by a special TIPS process, the so-called ‘‘ACCUREL’’ process [48–50] (Figure 2.11). A suitable polymer and a solvent or solvent mixture such as natural seed oils (e.g., soybean and castor) are heated together in an extruder to produce a homogeneously mixed polymer solution. This solution is pumped through a spinneret together with a gas as bore medium to create the right geometry of the hollow fiber. The preformed hollow fiber geometry is then cooled in an air gap and in a cold spinning oil, initiating phase separation of the solvent and the porous polymer matrix with pores still filled
59
60
2 Membranes for Artificial Lungs
Fig. 2.11 Scheme of the ACCUREL process for manufacturing of membranes by thermally induced phase separation.
with oil. After a washing step, for example, with hot alcohol, to remove the solvent, the membrane is wound onto bobbins. The following makeup steps will be explained in Section 2.6. The membrane structure is adjustable by varying the composition of the polymer solution, the cooling speed, and the process temperatures during spinning and cooling. A homogenous sponge-like structure is formed, as shown schematically in Figure 2.12. In the melt spin stretch process, the membrane pores are produced in a completely different way. First a suitable crystalline or semicrystalline polymer is molten in an
Fig. 2.12 Schematic picture of ACCUREL membrane wall.
2.6 Operational Modes and Membrane Makeup in Oxygenators
Fig. 2.13 Scheme of the stretching process to produce microporous membranes.
Fig. 2.14 Scheme of microporous membrane produced by melt spin stretch process.
extruder. The molten polymer is pressed through a spinneret and on cooling a dense compact capillary a flat sheet is created. By annealing, stretching, and cooling steps with a special temperature and tension profile in several repeated steps (see Figure 2.13), microporous membranes with completely different structures are created. This process has advantages in that no solvent and extraction are required but also disadvantages due to the lower porosity, the limited range of pore size, and the elongated pores (lower selectivity) of the product. The schematic structure of the membrane wall is shown in Figure 2.14.
2.6 Operational Modes and Membrane Makeup in Oxygenators The oxygenator construction and the arrangement of the membranes inside the oxygenator are as important as the performance of the oxygenation membrane itself.
61
62
2 Membranes for Artificial Lungs
2.6.1 Microporous Capillary Membranes, Blood Inside
In the 1980s, the blood was pumped inside the capillary membrane (luminal flow) whereas the membrane was flushed with gas from the outside. The disadvantages of these oxygenators, which are no longer in use today, are a large membrane quantity is required, as the gas exchange surface is the smaller inner capillary surface poor biocompatibility large priming volume high production costs high pressure drop. 2.6.2 Microporous Capillary Membranes, Blood Outside
Because of the disadvantages of intraluminal blood flow described above, oxygenators with blood flowing outside the capillaries (extraluminal flow) were developed in the mid-1980s [28,29,37,43]. The structure of these oxygenators with wound capillary membranes or with knitted mats provides good mixing of the blood and thus an improvement in the oxygen transfer rates, especially in the blood boundary layer (see Section 2.3). The membrane surface used can be minimized. More than 95 % of the membrane oxygenators used in hospitals today are oxygenators with blood flow outside the capillaries. The most effective construction uses cross-laid knitted mats (Figure 2.15). With this capillary arrangement, the following features are achieved: ‘‘enhanced mass transfer efficiency’’ with ‘‘local laminar mixing’’ (static mixer effect) repeated renewal of the concentration in the boundary layers; therefore, highest efficiency (see Section 2.3) uniform distribution of capillaries
Fig. 2.15 Cross-laid knitted membrane mat.
2.6 Operational Modes and Membrane Makeup in Oxygenators
capillaries fixed by warp threads (no movement) suitable for various oxygenator designs (axial, tangential, crossflow, etc.) blood film thickness (pressure drop) can be adjusted easily easy handling during manufacture high production yield closed capillary ends for safe potting.
The process steps for the production of cross-laid knitted mats are shown in Figure 2.16. Several capillaries are continuously laid down in parallel to a knitting machine and connected with a warp thread at defined distances. During this step multiple mats are cut, the membrane ends are closed, and the mat spools are wound up in parallel. In the next step, two mats are pulled at each defined angle and wound up together.
Fig. 2.16 Scheme of production of cross-laid knitted hollow fiber mats.
63
64
2 Membranes for Artificial Lungs
Fig. 2.17 Mass transfer coefficient versus membrane angle in a cross-wound mat device.
For each oxygenator setup, a special distance between the membranes, and a special warp thread distance and angle between the cross wound mats are possible and can be optimized (Figure 2.18). In this way one can always create an optimal blood stream. In the case of membrane contactors in technical applications, such constructions are also an advantage. The effects of design and operating variables on module performance have been investigated with respect to oxygen transfer into water. It was found that the membrane angle with respect to the main direction of the liquid flow had a significant influence on oxygenator performance [37]. The mass transfer coefficient increased proportionally to the membrane angle up to about 108 and started leveling off at about 20–258 (Figure 2.17).
Fig. 2.18 Scheme of cross-laid hollow fibers.
2.7 Extracorporeal Circulation
2.7 Extracorporeal Circulation 2.7.1 Cardiodiapulmonary Bypass (CPB)
In Figure 2.19, an extracorporeal circuit called a cardiopulmonary bypass, as used during open-heart surgery, is schematically demonstrated. Venous blood is sucked out by several cannulas from the patient. The blood is pumped, directly or via a venous reservoir, through the oxygenator. If applied, it is mixed with a part of sucked cardiotomic wound blood. The blood flow through the oxygenator is between 3 and 6 L/min. Here the CO2 is removed from the blood and the oxygen is transported into the blood. All the blood from the wound is also brought back to the circuit (Figure 2.19). 2.7.2 Lung Support Systems
If the native lung is diseased, for example, by asthma, emphysema, or acute respiratory distress syndrome (ARDS), or is injured and thus no longer able to supply the body with sufficient amounts of oxygen, two treatment options exist, depending on the severity and comorbidities: lung support with oxygen-enriched air or blood oxygenation (ECMO). For the first treatment option, there is a need for a mobile oxygen-enriching device, and for the second option, there is a need for an oxygenation membrane suitable for long-term application (several days to weeks). Some membranes described in Section 2.4.2 are suitable for both tasks (Figure 2.21). In intensive care, artificial lungs with long-term oxygenation membranes, as described in Section 2.4.2 become a treatment option for acute lung failure (e.g.,
Fig. 2.19 Scheme of an oxygenator in a heart lung machine setup.
65
66
2 Membranes for Artificial Lungs
Fig. 2.20 Example of an oxygenator setup with heat exchanger, venous reservoir, and oxygenator and photo of the oxygenator with cross-laid knitted mats inside.
Fig. 2.21 Nova lung oxygenator for an ECMO application.
from virus pneumonia, after blunt trauma [21], following pancreatitis, or in conjunction with sepsis or multiorgan failure) or for lung failure, for example, posttransplant, postoperative, or pediatric cases. An excellent example for a pumpless ECMO device is the Novalung ‘‘membrane ventilator.’’ Two cannulas are connected to large vessels of the patient and by the force of the patients’ heart the blood is
Fig. 2.22 Implantable lung support setup.
References
pumped through the oxygenator to remove carbon dioxide and/or provide oxygen to the body [39] (Figure 2.21). The membrane can also be suitable for use in long-term paracorporeal or implantable artificial lungs, for example, inside the vena cava [22,25]. In Figure 2.22, an intravascular membrane oxygenator (IVOX) shows the first vena caval device with membranes [5,40]. Comparable devices and oxygenation membrane setups, as described in Sections 2.6 and 2.7, are also used in biotechnology (see Chapter 5) and bioartificial organs (see Chapter 8) [51,52].
References 1 Le Gallois, J.J.C. (1812) Expe´riences sur
2
3
4
5
6
le principe de la vie, nottament sur celui des mouvements du Coeur, et sur le sie´ge de ce principe; Suievies du Rapport fait a` la premie`re classe d l’I´nstitut sur celles relatives aux mouvemens du coeur, D’Hautel, Paris, 134–135. Le Gallois, J.J.C. (1813) Experiments on the Principle of Life, and Particularly on the Principle on the Motions of the Heart and on the Seat of this Principle: Including the Report Made the First Class of the Institute, upon the Experiments Relative to the Motion of the Heart, M. Thomas, Philadelphia, PA, 130–131. Schmidt, A. (1867) Die Atmung innerhalb des Blutes. Zweite Abhandlung. Aus dem physiologischen Institut zu Leipzig. Berichte u¨ber die Verhandlungen der ko¨niglich sa¨chsischen Gesellschaft der Wissenschaften zu Leipzig. Mathematisch–physische Classe, 19, 99–130. Gibbon, J. H. (1937) Artificial maintenance of circulation during experimental occlusion of pulmonary artery. Archives of Surgery, 34, 1105– 1131. Mallabiabarrena Ormeaetxea, I. (2003) Experimental set up and numerical simulations of intravenous gas transfer devices, Doctoral thesis no. 2873. E´cole Polyteechnique Fe´de´rale de Lausanne, Switzerland. Dierickx, P. (2001) Blood flow and gas transport in artificial lungs: in numero
7 8
9 10
11 12 13
14
15
16 17 18 19
and in vitro analysis, Doctoral thesis. University of Gent. Zwischenberger, J. B. and Alpard, S. K. (2002) Perfusion, 17, 253–268. Clowes, J. J. and Hopkins, A. L. (1956) An artificial lung depended upon diffusion of oxygen and carbon dioxide through plastic membranes. Journal of Thoracic and Cardiovascular Surgery, 32, 630–637. Sewringhaus, J. W. (1979) Journal of Applied Physiology, 46, 599–602. Diericks, P. W., De Somer, F., De Wachter, D. S., Van Nooten, G., Verdonck, P. R. (2000) ASAIO Journal, 46, 532–535. Mockros, L. F. and Leonard, R. (1985) ASAIO Transactions, 31, 628–633. Vaslef, S. N. and Mockros, L. F. (1994) ASAIO Transactions, 40, 990–996. Wicksramasinghe, S. R., Semmens, M. J., Cussler, E. L. (1992) Journal of Membrane Science, 69, 235–250. Allen, S. M., Fujii, M., Stannett, V., Hopfenberg, H. B., Williams, J. L. (1977) Journal of Membrane Science, 2, 153–163. Wiese, F., Paul, D., Possart, W., Malsch, G., Bossin, E. (1990) Acta Polymerica, 41, 95–98. Prospectus ‘‘Jostra QuadroxD’’, Jostra AG, Hechingen, Germany, 2003. Prospectus ‘‘Medos Hilite7000 LT’’, Medos AG, Stolberg, Germany, 2002. Philipp, A. (2003) Kardiotechnik, 1, 7–13. Horton, S., Thuys, C., Bennet, M. (2004) Perfusion, 19, 17–23.
67
68
2 Membranes for Artificial Lungs 20 Philipp, A., Wiesenade, C., Behr, R. 21
22 23
24 25 26
27
28
29
30
31
32
33
34
35
36 37
(2002) Perfusion, 17, 175–178. Schmidt, F. X., Philip, A., Link, J. (2002) Annals of Thoracic Surgery, 73, 1618–1620. Zwischenberger, J. P. (2001) ASAIO Journal, 47, 316–320. DeWall, R. A. and Lillehei, C. W. (1957) Surgery of Gynecology and Obstetrics, 104, 699. Kolff, W. J. and Berk, H. T. (1944) Acta Medica Scandinavica, 117, 121–134. Zwischenberger, J. P. and Alpard, S. K. (2002) Perfusion, 17, 253–268. Product information (1982) The Journal of Extracorporeal Technology, 14, 18. Sienkewich, M. and Maserko, J. J. (1982) Proceedings of the American Academy on Clinical Perfusion, 3, 13–16. Gassmann, C. J., Balbraith, G. D., Smith, R. G. (1987) The Journal of Extracorporeal Technology, 19, 297–304. Alpha, D., King, E., Bicknell, D. A. (1986) Proceedings of the American Academy on Clinical Perfusion, 7, 32–34. Lauterbach, G. (2002) Handbuch der Kardiotechnik, Urban & Fischer, Mu¨nchen. Tschaud, R. J. (1999) Extrakorporale Zirkulation in der Theorie und Praxis, Papst Science Publischers, Lengerich. Taylor, K. M. (1986) Cardiopulmonary Bypass, Lippincott Williams & Wilkins, Philadelphia, PA. Philipp, A., Foltan, M., Gietl, M., Reng, M., Liebold, A., Kobuch, R., Keyl, C., Bein, T., Mu¨ller, T., Schmid, F.-X., Birnbaum, D. E. (2003) Kardiotechnik, 1, 7–13. Schmid, F.-X., Philipp, A., Link, J., Zimmermann, M., Birnbaum, D. E. (2002) Annals of Thoracic Surgery, 73, 1618–1620. Zwischenberger, J. B., Anderson, C. M., Cook, K. E., Lick, S. D., Mockros, L. F., Bartlett, R. H. (2001) ASAIO Journal, 47, 316–320. Lillehei, C. W. (1955) Postgraduate Medicine, 17, 388–396. Wodetzki, A., Breiter, S., Scheuren, J., Wiese, F. (2000) Maku (Membrane),
38
39
40 41
42
43
44
45 46
47
48 49
50
51
52
53
Japanese Membrane Journal, 25, 102– 106. Breiter, S. M., Wiese, F., Wodetzki, A., Schuster, O. (2004) ASAIO Journal, 50, 153. Jegger, D., Revelly, J.-P., Horisberger, J., Boone, Y., Seigneul, I., Jachertz, M., von Segesser, L. K. (2004) ESAO, Aachen. Ex vivo evaluation of a new extracorporal lung assist device. Novalung, ESAO, Wausau. Mortensen, J. D. (1992) Artificial Organs, 16, 75–82. Steffen, S., Oedekoven, S. B., Henseler, A., Mottaghy, K. (1997) Kardiotechnik, 3, 68–71. Montoya, J. P., Shanely, C. J., Scott, I. M., Bartlett, R. H. (1992) ASAIO Journal, 38, 399–405. Catapano, G., Hornscheidt, R., Wodetzki, A., Baurmeister, U. (2004) Journal of Membrane Science, 230, 131–139. Baker, R. W. (2000) Membrane Technology and Applications, McGrawHill, New York. Kolff, W. J. and Balzer, B. R. (1955) ASAIO Transactions, 1, 39–42. Kolff, W. J. and Effler, D. B. (1956) Cleveland Clinic Quarterly, 23, 69–97. Prospectus Museum ICMT (2006) International Center for Medical Technologies. Castro, A. J. (1981) US Patent 4 247 498. Henne, W., Pelger, M., Gerlach, K., Tretzel, J. (1983) Lysagth M. J. and Gurland H. J. Plasmaseparation and Plasmafractionation, Karger AG, Basel. Hiatt, W., Vitzthum, G. H., Wagner, K. B., Gerlach, K. (1985) Materials Science of Synthetic Membranes, American Chemical Society, Washington, DC. Gerlach, J., Kloppel, K., Stoll, P., Vienken, J., Mulle, C. (1990) Artificial Organs, 14, 328–333. Gerlach, J. C. (1996) International Journal of Artificial Organs, 19, 645–654. Krause, B., Go¨hl, H., Wiese, F. (2006) Ohlrogge K. and Ebert K. Membranen, Wiley-VCH, Weinheim.
69
3 Membranes for Blood Fractionation/Apheresis Frank Wiese 3.1 Introduction
The use of membranes in extracorporeal systems connected to the human body started in the 1940s with Kolff’s first use of an artificial kidney. Since that time, the application of membranes has been established in different areas (Figure 3.1). Nowadays, the expression, apheresis or plasmapheresis, is used for the removal of blood plasma from cells as well as for the removal of protein components or fractions
Fig. 3.1 Membranes in extracorporeal systems.
Fig. 3.2 Therapeutic hemapheresis classified according to technologies. Membranes for the Life Sciences. Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes Copyright ß 2008 WILEY-VCH Verlag GmbH & Co. KGaA. All rights reserved ISBN: 978-3-527-31480-5
70
3 Membranes for Blood Fractionation/Apheresis
from this plasma. The origin is the Greek word aphairesis – ‘‘to separate, to remove, and to take away.’’ In comparison to 120 million artificial kidney treatments and 1.2 million open-heart operations using artificial lungs, there are only around 600 000 membrane apheresis treatments carried out per year. Nevertheless, these treatments are an important therapeutic tool for special medical indications for autoimmune diseases or diseases related to blood rheology. Membrane procedures have significance for plasma separation and plasma fractionation processes – also called cascade filtration or double filtration – as well as for specific adsorption processes because of the requirement for cell-free plasma for these procedures. For the functionality and the life-time of these modern adsorption processes, cell-free plasma is a strict requirement (Figure 3.2). Blood plasma donation for medical and pharmaceutical applications is dominated by centrifugal procedures. Procedures such as cytapheresis or cell separation are not discussed in this chapter because of the negligible use of membranes in these procedures.
3.2 History of Plasmapheresis
In the ancient world, the role of blood in health and illness was already known. The name of Hippocrates (460–377 B.C.), the ‘‘Father of Medicine,’’ is linked to the
Fig. 3.3 Hippocrates Hiraclidae (460–377 B.C.) – The ‘‘Father of Medicine.’’
Fig. 3.4 Bloodletting depicted by Peytel.
Fig. 3.5 ‘‘Plasmapheresis’’ described by Abel, Rowntree, and Turner [3].
72
3 Membranes for Blood Fractionation/Apheresis
Fig. 3.6 John Jacob Abel 1857–1938.
Fig. 3.7 Monsanto hollow fiber device as experimental plasma separator 1972 [4].
3.3 Principles of Plasmapheresis
Fig. 3.8 Principle of double filtration first described by Agishi [5].
introduction of bloodletting as a preventative method as well as a remedy [1,2]. Although bloodletting should not be confused with plasmapheresis, it is its therapeutic precursor (Figures 3.3 and 3.4). The term plasmapheresis was first used by Abel, Rowntree, and Turner in 1914. In their paper ‘‘Plasma Removal with Return of Corpuscles (Plasmapheresis)’’ [3], they investigated the effect of plasma removal from dog blood and reinjected the cells together with replacement solution (Figures 3.5 and 3.6). This was the early beginning of therapeutic plasmapheresis. The first hollow fiber membrane device for plasma separation was introduced by Monsanto in 1972 [4]. This was the start of therapeutic plasma separation by membranes (Figure 3.7). The first double filtration in place of two membrane filters with different pore sizes was described by Agishi [5]. High molecular weight proteins such as low-density lipoproteins (LDL) and triglycerides were removed and lower molecular weight proteins such as albumin and high-density lipoprotein (HDL) were returned to the body (Figure 3.8).
3.3 Principles of Plasmapheresis
The schematic setup of a plasma separation treatment is shown in Figure 3.9. The blood is removed from the body and filtered in a plasma filter device. Then the filtered plasma is removed and cells are returned to the body as concentrate, together with a substitution fluid such as an isotonic electrolyte solution, an albumin-isotonic electrolyte solution, or donor plasma [6–9]. Blood is a special streaming medium, and this special characteristic has to be considered by selecting the right process conditions. In capillary modules, the transmembrane pressure (TMP) is usually not higher than 150 mmHg, and the adjusted filtrate flow is between 20 and 35% of the blood flow rate of 50–250 mL/min. In most classical plasma exchange procedures (TPE – therapeutic plasma exchange), plasma is removed and replaced by donor plasma (FFP – fresh frozen plasma). It is used not only for the treatment of several immunological diseases but
73
74
3 Membranes for Blood Fractionation/Apheresis
Fig. 3.9 Membrane plasma separation set up.
also for the removal of metabolism products and exogenic and endogenic toxins [6,8]. In several countries, this unspecific exchange is carried out even now (mostly by the use of centrifuges), but the frequency is decreasing because of the availability of more specific adsorption methods and the many clinical disadvantages of this method. To save mostly patients’ own specific proteins such as albumin and IgG and to remove only the poisoning components, for example, LDL from, for example, hypercholesteremic patients, membrane plasma separation is used in combination with secondary membrane filtration called ‘‘plasma fractionation,’’ ‘‘membrane double filtration,’’ ‘‘rheopheresis,’’ or ‘‘cascade filtration’’ (Figure 3.10) [29]. The blood is divided into a cell-concentrated part and a cell-free plasma part in the first filtration step. In the second step, the blood plasma is divided into high and low molecular
Fig. 3.10 Membrane double filtration set up (cascade filtration, plasma fractionation).
3.3 Principles of Plasmapheresis Tab. 3.1
Blood as a streaming medium – specific features during application.
Primary filtration
Secondary filtration
Blood viscosity depends on Type of cells Concentration of cells (hematocrit) ‘‘Cross-flow operation’’: plasma-rich layer Hemolysis
Plasma viscosity depends on Type of macromolecules/proteins Concentration of macromolecules/proteins ‘‘Dead-end operation’’: secondary membrane layer Blocking
weight fractions of plasma. The low molecular weight fraction and nearly the complete plasma fluid volume are then recombined with the cell concentrate and returned to the patient. The sieving characteristics of these membranes are described in Section 3.4. The primary filtration step (plasma separation) is done as a ‘‘cross-flow operation,’’ and the secondary filtration as a ‘‘dead-end operation.’’ This has to be considered by selecting the right process conditions to prevent blood damage and to keep the process running. The right shearing profile in the primary filter prevents hemolysis, and the right pressure in the secondary filer prevents blocking (see Table 3.1 and Section 3.6). The setup of plasma fractionation in combination with adsorbers is shown in Figure 3.11. Again the plasma is separated with a plasma filter. In the second step, the separated plasma is pumped through protein-specific adsorbers to remove special proteins such as immunoglobulins or toxins according to the therapeutic objectives. Finally, the treated plasma together with the blood cells is returned to the patient. Different kinds of single-use adsorbers or regenerable double adsorbers for different medical indications are on the market. In Figure 3.11, an example of a double-column setup is shown. While one column is recirculated with plasma and loaded with
Fig. 3.11 Membrane plasma separation combined with plasma fractionation by adsorbers.
75
76
3 Membranes for Blood Fractionation/Apheresis
proteins to be removed, the second column is regenerated. The columns are switched from time to time and are applicable for multiple patient treatments.
3.4 Membranes and Membrane Properties
The general profile of the requirements of plasma treatment membranes is summarized as follows [6,7,10,28]: permeable for all plasma proteins/special sieving characteristics high surface porosity and volume porosity to reach high fluxes hydrophilic, spontaneous, and wettable low fouling behavior low protein adsorption smooth blood contact surfaces low hemolytic potential consistency in sieving behavior and filtration performance during treatment good blood compatibility [17–19,22,24] suitable mechanical stability stability against chemicals and all common sterilization procedures (ETO, g-radiation, steam). The plasma fractionation membranes have to have special sieving characteristics for the removal of different protein fractions, depending on the medical indications. Different producers of filters use different polymers such as cellulose acetate (CA), polypropylene (PP), polyethylene (PE), polysulfone (PSU), polyethersulfone (PES), and polymethylmethacrylate (PMMA) to fulfill these requirements as far as possible. Hydrophobic polymers such as PP are hydrophilized during module manufacture or PE is coated with polyethylvinylalcohol (EVAL), and PES is blended with polyvinylpyrolidone (PVP) [31–34]. 3.4.1 Plasma Separation Membranes
Plasma separation capillary membrane filters from different suppliers are listed in Table 3.2 [14]. All the used membranes have nominal pore sizes around 0.2–0.3 mm (microfiltration membranes). The module suppliers often do not explain whether the pore size in their data sheets is theoretically calculated from the bubble point or measured by a sieving curve, thus creating some confusion. The size exclusion pore size of 0.2 mm guarantees that all plasma proteins can pass through the membrane whereas all cells including the small thrombocytes with 2 mm diameter are rejected.
3.4 Membranes and Membrane Properties Capillary membrane plasma separation filters from different producers.
Tab. 3.2
Supplier
Filter
Asahi
Plasmaflo OP-02
B. Braun Bellco
Gambro Fresenius Kaneka
Kuraray Toray Edwards Dideco
Plasmaflo OP-05 Plasmaflo OP-08 Hemoselect MPS 02 MPS 05 MPS 07 PF 1000 PF 2000 Plasmaflux P1S Plasmaflux P2S Sulflux FS-03 Sulflux FS-05 Sulflux FS-07 Plasmacure Plasmax PS-02 Plasmax PS-05 Microplas MPS 05 Hemaplex BT 900
Membrane material
Membrane area (m2)
ID/wall (mm)
Sterilization mode
Polyethylene/ EVAL coating
0.20
330/50
ETO
330/150 300/100
Steam ETO
330/150
ETO
330/150
Steam
340/50
g-radiation
320/65 330/90
g-radiation g-radiation
300/100 330/150
ETO, g-radiation ETO
Polypropylene Polyethersulfone
Polypropylene Polypropylene Polysulfone
Polysulfone PMMA Polyethersulfone Polypropylene
0.50 0.80 0.20 0.28 0.45 0.68 0.16 0.35 0.25 0.50 0.30 0.50 0.70 0.60 0.15 0.50 0.45 0.50
The sieving coefficient (SC) for a special protein in a filtration experiment is calculated according to Equation (1): CF is the concentration of the protein in the filtrate, CBi the filter input concentration, and CBo the filter output concentration of the protein in the blood or blood plasma. SC ¼
2CF : CBi þ CBo
ð1Þ
The sieving characteristics of a typical plasma separation membrane are shown in Figure 3.12(a). Nearly 100 % of all plasma proteins pass through the membrane including the lipoproteins with molecular weights >2 000 000 Da. Fibrinogen is slightly reduced. This can be related to the special shape (see Figure 3.13) [11] of this molecule and adsorption effects. The same membrane was also investigated with latex beads of defined different sizes. The rampant sieving curve shows that it has a nominal pore size of 0.2 mm and a narrow pore size distribution (Figure 3.12(b)). These capillary membranes also meet the requirements of the HIMA test, which means that the membrane can also be used for sterile filtration, for example, intravenous filtration, because it is fully bacteria retentive against pseudomonas diminuta. Depending on the membrane polymer used, the composition of the spinning solution and the production process, and the structure and wall thickness of the
77
78
3 Membranes for Blood Fractionation/Apheresis
Fig. 3.12 Sieving coefficients of plasma separation membrane tested with blood and latex beads (MicroPES TF10, Membrana GmbH).
Fig. 3.13 Size comparison of noncellular blood components [11].
3.4 Membranes and Membrane Properties
Fig. 3.14 SEM picture of cross sections (a, b) and blood contacting inner surfaces (c, d) of two different plasma separation membranes [25] (a, c) Plasmaphan (Membrana GmbH) and (b, d) Plasmaflo (Asahi)).
membranes are different. The SEM pictures in Figure 3.14 illustrate this with examples of two different plasma separation membranes produced from polyolefins PP and PE. The PP membrane has a significantly higher wall thickness than the PE membrane and different pore structure of the inside skin, whereas in vivo performance is comparable. 3.4.2 Plasma Fractionation Membranes
Plasma fractionation capillary membrane filters from different suppliers are listed in Table 3.3. The membranes used in the filters have different sieving characteristics, depending on the medical indications. For example, the different Evaflux membrane filter types are used for the removal of different protein fractions. Evaflux 2A is used for the removal of immunoglobulins IgG and IgA, Evaflux 3A for the removal of cytokines, Evaflux 4A for the removal of IgM and LDL, and Evaflux 5A for the removal of LDL-C (cholesterin) [26]. The sieving coefficient for a special protein in a filtration experiment is calculated according to Equation (1). In Figure 3.15, the sieving characteristics of a plasma fractionation membrane are shown to exemplify the behavior of such a membrane.
79
80
3 Membranes for Blood Fractionation/Apheresis Tab. 3.3
Capillary membrane plasma fractionation filters from different producers.
Supplier
Filter
Membrane material
Membrane area (m2)
ID/wall (mm)
Sterilization mode
Asahi
Rheofilter Cascadeflo EC-20 Cascadeflo EC-30 Cascadeflo EC-40 Cascadeflo EC-50 Evaflux 2A Evaflux 3A Evaflux 4A Evaflux 5A Albuafe FP 2
Cellulose diacetate EVAL EVAL EVAL EVAL EVAL EVAL EVAL EVAL Polyethersulfone
2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 1.7
220/80 175/40 175/40 175/40 175/40 175/40 175/40 175/40 175/40 200/35
g-radiation
Kuraray
Dideco
g-radiation
g-radiation, steam
The sieving coefficient for albumin is around 0.88. This is important because the albumin has to pass through the membrane so that as much as possible of this protein is given back to the patient. Most molecules with molecular weights up to around 400 kDa, for instance HDL, pass through the membrane with the exception of fibrinogen. Fibrinogen is a stretched long molecule and for this geometric reason is partly rejected (see Figure 3.13). Larger molecules such as alpha-2-macroglobulin or IGM are mostly rejected – the sieving coefficient of IGM is 0.2. The main goal of the treatment is to remove these lipoprotein molecules. In conclusion, this membrane can be used for hypercholesteremic as well as for rheological indications in the clinical applications (see Section 3.7). The SEM picture of the cross section of this membrane (see Figure 3.16) shows an isotropic and homogeneous pore structure and a smooth inner surface. The inner diameter is 200 mm, and the wall thickness is 35 mm.
Fig. 3.15 Sieving coefficients of a plasma fractionation membrane for different blood plasma proteins – FractioPES (Membrana GmbH).
3.5 Membrane Production
Fig. 3.16 SEM picture of the membrane structure of the plasma fractionation membrane FractioPES (Membrana GmbH).
3.5 Membrane Production
Plasma separation membranes are mainly produced by three different processes (see also Section 2.5) (Figure 3.17–3.19): Solvent-induced phase separation (SIPS) process Temperature-induced phase separation (TIPS) process Melt spin stretch (MESS) process. The schematic course of an SIPS process, also called the wet spinning process, is shown in Figure 3.17. From a suitable polymer and a suitable solvent or solvent mixture, a solution is prepared. Here the ‘‘genome’’ of the membrane is created
Fig. 3.17 Schematic depiction of the solvent/nonsolventinduced phase separation process for manufacturing of microporous membranes.
81
82
3 Membranes for Blood Fractionation/Apheresis
because the membrane structure is predetermined (prefixed) in the solution. The solution preparation, including proper filtration, is a complex and important step. After this step, the solution is pumped into a spinneret for capillary membranes or into a casting box in the case of flat membrane production. To give the capillary membranes the correct geometry and to steer the inner skin pore structure, the bore liquid can be an inert or a composition of solvent and nonsolvent. The next important step is the precipitation, the ‘‘birth’’ of the membrane. The solvent is replaced by the nonsolvent of the coagulation bath and creates the porous polymer matrix. This diffusion process is influenced by the polymer solution composition as well as by process conditions such as the temperature of the precipitation bath, the spinning speed, the climatic conditions between the spinneret and the precipitation bath, and so on. The coagulation is followed by the washing, drying, and bundle makeup steps until the bundle is ready for insertion into a module housing. In special cases, a postfinal extraction is carried out. Most membranes worldwide are produced by wet spinning processes. Plasmapheresis membranes from polyolefins (PP, PE) are mainly produced by two different processes: TIPS MESS. A special TIPS process, the so-called ‘‘ACCUREL’’ process, is described in Figure 3.18 [15,16,38,44]. A suitable polymer and a solvent or solvent mixture such as natural seed oils (e.g., soybean and castor) are heated together in an extruder to produce a homogeneously mixed polymer solution. This solution is pumped through a spinneret
Fig. 3.18 Schematic depiction of the ACCUREL process for the manufacturing of membranes by thermally induced phase separation.
3.6 Operational Modes in Plasmapheresis Procedures
Fig. 3.19 Schematic depiction of the pore building part in a melt spin stretch process for producing of microporous membranes.
together with a gas as bore medium to create the right geometry of the hollow fiber. The preformed, hollow fiber geometry is then cooled in an air gap and in cold spinning oil, initiating a phase separation of the solvent and the porous polymer matrix, the pores of which are still filled with oil. After a washing step, for example, with hot alcohol, to remove the solvent, the membrane is wound onto bobbins or into bundles. The membrane structure can be adjusted by varying the composition of the polymer solution, the cooling speed, and the different process temperatures during spinning and cooling. In the melt spin stretch process, the membrane pores are produced in a completely different way. First, a suitable crystalline or semicrystalline polymer is melted in an extruder. The molten polymer is pressed through a spinneret, and on cooling a dense compact capillary or flat sheet is created. By annealing, stretching, and cooling steps with a special temperature and tension profile in several repeated steps (see Figure 3.19), microporous membranes with completely different structures are created (see Figure 3.14(d) and Section 2.5). This process has advantages because no solvent and extraction is required but also disadvantages because of the lower porosity, limited range of pore size, and elongated pores (lower selectivity).
3.6 Operational Modes in Plasmapheresis Procedures
As mentioned in Section 3.3, suitable process conditions have to be adjusted in the clinical application of plasma separation to reach a successful treatment without negative side effects. The main design criteria are the wall shearing rate, the created pressure drop along the filter housing, and the resulting plasma filtration rate. The wall shearing rate is calculated according to Equation (2): wall shearing rate : gw ¼
4QB ; Npr 3
ð2Þ
where N is the number of capillary membranes with inner radius r and QB is the blood flow distributed to the different capillary membranes. The blood flow changes by reduction of the plasma content over the length of the membrane or the filter,
83
84
3 Membranes for Blood Fractionation/Apheresis
respectively. This has to be considered when calculating the wall shearing rate. Furthermore, the transmembrane pressure is further an important parameter for steering the process in the right direction. The transmembrane pressure is calculated according to Equation (3): TMP ¼
PBi þ PBo PF : 2
ð3Þ
The TMP is calculated by blood input pressure (PBi), blood output pressure (PBo), and filtrate pressure (PF) in the plasma compartment. In a laminar stream, the velocity profile will be distributed as shown in Figure 3.20. The erythrocytes will be forced to go into the central stream. As explained in Section 3.3, plasma separation is carried out in cross-flow filtration mode. In the low-pressure range, the filtration performance increases linearly with increasing transmembrane pressure. Later, a plateau is reached according to the wellknown concentration polarization phenomenon [7,30,36,37] in cross-flow filtration. Blood is not a Newtonian fluid, but nevertheless it is well known that, according to Hagen–Poiseuille’s law, the streaming volume is very sensitive to tube/capillary diameter. Consequently, the blood flow rate, the plasma flux, and the corresponding transmembrane pressure have to be in the right relation to each other [14,31]. As long as the streaming velocity is high enough, the cells will be forced to move into the center of the stream (see Figure 3.20). If the wall shearing rate becomes too low and the membrane pressure is too high, the risk of hemolysis increases. This means that the red blood cells (erythrocytes) are destroyed and hemoglobin is released in the body circuit. The blood plasma becomes
Fig. 3.20 Velocity profile in a capillary membrane [13].
3.6 Operational Modes in Plasmapheresis Procedures
Fig. 3.21 Schematic explanation of hemolytic behavior of different membranes in blood contact depending on transmembrane pressure and wall sheer rate.
red in color resulting in toxic behavior. This condition has to be prevented. The starting phase of the treatment is particularly critical. For this reason, some filters have to be processed at transmembrane pressures less than 50 mmHg. The user has always to follow the care of cartridge producers’ manual. In Figure 3.21, two membranes A and B are compared with respect to their hemolytic dispositions. In general, the hemolytic tendency decreases with increasing wall shear rate and decreasing pressure. Membrane B shows hemolysis related to lower transmembrane pressures than membrane A. Above the dashed line is the area where hemolysis takes place. The schematic assembling of a plasma separation capillary membrane filter is shown in Figure 3.22. The requirements according to module design for capillary membrane plasma filters are not so high as for, for example, dialyzers [7,9,11,35]. Only a convective flow via the membrane wall takes place, and because the plasma is only drained in the filtrate (plasma) compartment of the module, no defined streaming conditions have to be created inside the bundle. Therefore, no fiber makeup such as undulation is required. According to the above-explained criteria, the filter area and the length have to be adjusted to the membrane. According to Table 3.2, filter areas between 0.15 and 0.8 m2 are usual, depending on the application. A special monitor steers the flows and pressures comparable to a dialysis monitor. Plasma volumes between 2 and 4 L are filtered in one treatment session. Flat membranes are also used in special filtration devices. Regarding the membrane area they are very effective, but need special monitors (Figure 3.23). In the Autopheresis C system produced by Baxter/Fenval, IL, USA, a polyamide (PA) membrane with an area of 70 cm2 is applied to a rotating cylinder. The blood enters the top of the filter assembly and travels down the defined space between the
85
86
3 Membranes for Blood Fractionation/Apheresis
Fig. 3.22 Schematic drawing of the module construction of a capillary membrane plasma separation filter.
rotating cylindrical membrane and the outer cylindrical housing (stationary cylinder). The plasma filtered through the membrane flows out from the filters’ central tube (axis). By rotation of the membrane, Taylor vortices are created, spiraling downward. The rotation-induced Taylor vortex enhances the plasma flux [27]. In the device of Milttenyi Biotec GmbH, as described in Figure 3.24, less than 250 cm2 membrane area is required to filter several liters of blood. A polyethersulfone
Fig. 3.23 Flat membrane filter used in a rotating plasma separation device. The inner rotating cylinder is upholstered with a microfiltration membrane of polyamide (Baxter/Fenwall, USA).
3.6 Operational Modes in Plasmapheresis Procedures
Fig. 3.24 Rotating disc plasma separator. Microfiltration flat membranes of MicroPES (Membrana GmbH) with rotating disk in between.
flat membrane MicroPES is fixed on both sides of the housing where the filtered plasma is drained. A rotating disk in between and at a defined small distance from the membrane ensures the right streaming force. This device is used to produce cell-free plasma, that is, treated in regenerable specific adsorber columns.
Fig. 3.25 From sieving . . . to adsorption – from diffusion . . . to convection membrane systems in future with combined sieving and selective adsorption feature inside the pores by grafted tentacles inside the pores.
87
88
3 Membranes for Blood Fractionation/Apheresis
View to the future: Classical adsorber technology uses beads packed in a column. The beads carry the ligand and are exposed to the plasma or the blood stream. Membrane technology is an alternative way to build adsorption devices. The inherent advantage of membranes lies in the better perfusion of the plasma or whole blood. This is seen in the convective transport of the target molecules to the ligand sites without diffusive limitations. This is in contrast to the bead technology where the adsorption kinetics is limited by the long diffusion pass (Figure 3.25).
3.7 Medical Indications for Blood Plasma Treatment
In Table 3.4, medical indications for plasma fractionation treatments are listed. Nowadays, especially applications where the blood viscosity has to be reduced to improve the microcirculation of blood have been successful in an increasing number of cases [21,22,23,25]. For example, the membrane described in Figure 3.15 is well adapted to this type of application [20]. The high-molecular-weight lipoproteins and triglycerides are rejected completely, and the slight reduction in fibrinogen also improves the viscosity behavior. Other illnesses require immunomodulation of the blood by fractionation of immunoglobulins [8,11,32,38,39]. Special kinds of such treatments are the so-called cryofiltrations where plasma proteins are precipitated by cooling the plasma to 4 8C. The precipitated aggregates are then filtered by
Tab. 3.4
Medical indications for plasma fractionation by double filtration.
Indications belonging to top 10 of registry: Hypercholesterolemia Myasthenia gravis (MG) Syst. lupus erythematosus (SLE) Guillian–Barre´ syndrome (GBS) Thromb. thrombocyt. purpua (TTP) Cryoglobulinemia New indications: Age-related macular degeneration (AMD) Sudden hearing loss Diseases with rare incidence: Burger’s arthritis Cyclosporemia Diabetic retinopathy Gromerulonephritis Polymyositis/dermatomyositis Polyneuropathy Small vessel disease Vasculitis Waldenstrom’s macroglobulinemia W. granulomatosus
References
membranes. In the so-called thermofiltration special proteins are precipitated by heating the plasma to 42 8C and are then removed by filtration [11,12]. The relatively ‘‘old’’ technology of membrane plasma separation is now undergoing a renaissance because of new indications and the requirement for highly sophisticated specific adsorber technologies for cell-free plasma [40–43].
References 1 Sawada, K. (1990) Nydegger U. E.
2 3
4 5
6
7
8
9 10
11 12 13 14
15
Therapeutic Hemapheresis in the 1990s, Karger AG, Basel. Kambic, H., and Nose´, Y. (1997) Therapeutic Apheresis, 1, 83–108. Abel, J. J., Rowntree, L. G., Turner, B. B. (1914) Journal of Pharmacology and Experimental Therapeutics, 5, 625–641. Nose´, Y. and Malchesky, P. (1981) Therapeutic Plasmapheresis, 1, 3–14. Agishi, T., Kaneko, I., Hasuo, Y., et al. (1980) Transactions – American Society for Artificial Organs, 26, 406–411. Bambauer, R. (1997) Therapeutischer Plasmaaustausch und verwandte Plasmaseparationsverfahren, Pabst, Lengerich. Zeman, L. J. and Zydney, A. L. (1996) Microfiltration and Ultrafiltration: Principles and ApplicationsMarcel Dekker, New York. Ho¨rl, W. H. and Wanner, C. (2004) Dialyseverfahren in Klinik und Praxis, 6th edn , Georg Thieme Verlag, Stuttgart. Malchesky, P. S. (2001) Therapeutic Apheresis, 5, 270–282. Bo¨hler, J., Donauer, K., Ko¨ster, W., Schollmeyer, P. J., Wieland, H., Ho¨rl, W. H. (1991) American Journal of Nephrology, 11, 479–485. Sueoka, A. (1997) Therapeutic Apheresis, 2, 135–146. Siami, F. and Siami, G. A. (1997) Therapeutic Apheresis, 1, 58–62. Gerthsen, C. and Kneser, H. O. (1971) Physik, 11. Auflage, Springer, Berlin. Krause, B., Go¨hl, H., Wiese, F. (2006) Ohlrogge K. and Ebert K. Membranen, Wiley-VCH, Weinheim. Castro, A. J. (1981) US Patent 4,247,498.
16 Henne, W., Pelger, M., Gerlach, K.,
17
18 19 20
21
22
23
24 25 26 27 28
29
30
Tretzel, J. (1983) Lysagth M. J. and Gurland H. J. Plasma Separation and Plasma Fractionation, Karger AG, Basel. Nose´, Y., Jamaji, K., Sueoka, A., Yamane, s. (1997) Therapeutic Apheresis, 1, 5–12. Nose´, Y. (1988) Artificial Organs, 12, 377–378. Malchesky, P. S. (1992) Journal of Clinical Apheresis, 7, 145–146. Valbonesi, M., Carlier, P., Borberg, H. (2004) Journal of Artificial Organs, 27, 513–515. Borberg, H., Brunner, R., Widder, R. A. (1987) Japanese Journal of Apheresis, 16, 288–292. Beykirch, H., Voigt, H., Wilke, B. (1998) Nieren und Hochdruckkrankheiten, 27, 137–144. Henderson, L. W., Koch, K. M., Dinarello, C. A., Shaldon, S. (1983) Blood Purification, 1, 3–8. Rock, W. (1990) Apheresis, Wiley-Liss, New York. Brunner, R. and Borberg, H. (1995) Journal of Artificial Organs, 794–798. Siami, G. A. and Siami, F. (2002) Therapeutic Apheresis, 5, 315–320. Kaplan, A. A. and Halley, S. E. (1990) Kidney International, 38, 160–166. Andrade, J.D. (1985) Surface and Interfacial Aspects of Boimedical Polymers, Vol. 2, Plenum Press, New York. Baeyer, H., Kochinke, F., Schwertfeger, R. (1985) Journal of Membrane Science, 22, 297–315. Jaffrin, M.J., Gupta, B.B., Ding, L.H., Garreau, M. (1984) TransactionsAmerican Society for Artificial. Organs, 30, 401–405.
89
90
3 Membranes for Blood Fractionation/Apheresis 31 Sueoka, A. (1997) Therapeutic Apheresis, 32 33 34
35
36
37
1, 42–48. Nakaji, S. and Yamamoto, T. (2002) Therapeutic Apheresis, 6, 267–270. Siami, G. A. and Siami, F. S. (2001) Therapeutic Apheresis, 5, 315–320. Gupta, B. B., Ding, L. H., Jaffrin, M. Y., Baurmeister, U. (1991) International Journal of Artificial Organs, 14, 56–60. SMOLIK, G. (1989) Ph.D. thesis. Technische Universita¨t Mu¨nchen (Mu¨nchen). Mulder, M. (1996) Basic Principles of Membrane Technology, Kluwer Academic, Dordrecht. Strathmann, H. (1979) Trennung von molekularen Mischungen mit Hilfe synthetischer Membranen, Steinkopf, Darmstadt.
38 Klingel, R., Fassbender, C., Fischer, I.,
39
40 41 42 43
44
Hattenbach, L., Gu¨mbel, H., Pulido, J., Koch, F. (2002) Therapeutic Apheresis, 6, 271–281. Geiss, H. C., Parkhofer, K. G., Donner, M. G., Schwandt, P. (1999) Therapeutic Apheresis, 3, 199–202. Stegmayr, B. G. (2000) Blood Purification, 18, 149–155. Stoffel, W., Borberg, H., Greve, V. (1981) The Lancet, 2, 1005–1007. Schneider, K. M. (1998) Kidney International, 53 (Suppl. 64), 61–65. Braun, N. and Bosch, T. (2000) Expert Opinion on Investigational Drugs, 9, 2017–2038. Hiatt, W., Vitzthum, G. H., Wagner, K. B., Gerlach, K. (1985) Materials Science of Synthetic Membranes, 9 American Chemical Society.
91
4 Membranes in the Biopharmaceutical Industry Anthony Allegrezza, Todd Ireland, Willem Kools, Michael Phillips, Bala Raghunath, Randy Wilkins, Alex Xenopoulos 4.1 Introduction
Membranes for the biopharmaceutical industry operate in streams containing relatively low concentrations of exceedingly expensive products in a highly regulated industry. These considerations have determined the progress of membrane development for this industry and the manner of choosing and optimizing membrane usage. In this chapter we will describe the present state of microporous, ultrafiltration (UF) and virus removal membranes, and the developments that led to them. Membrane use will be described from the point of view of a process engineer who has to specify and optimize the various membrane separation and purification steps in a biopharmaceutical manufacturing process. From its inception, the biopharmaceutical industry has needed to concentrate and purify the protein drugs it produced. While the first membranes used were those available at the time, manufacturers have become more sophisticated and demanding in their requirements for membranes as the industry has grown and matured. In addition, competition among membrane companies has increased. These trends have led to new membrane products specifically designed for the needs of the biopharmaceutical industry. The response of membrane manufacturers to industry needs for microporous, ultrafiltration, and membranes for virus removal has gone beyond providing economical flux rate and satisfactory retention properties and has focused on other needs. These include lowered extractables from the membrane device to the permeating stream and the capability to withstand alkalies. More recently, the need for increased capacity has resulted in newer asymmetric and composite membranes and multilayered combinations of membranes and prefilters in filtration devices. All membrane filtration processes are designed to remove some species and allow the passage of solvent and other, usually smaller, species. The membrane can remove large impurities and pass the product, or retain the product and pass solvent and salts. Every manufacturing process is different, but some common themes prevail. The
Membranes for the Life Sciences. Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes Copyright ß 2008 WILEY-VCH Verlag GmbH & Co. KGaA. All rights reserved ISBN: 978-3-527-31480-5
92
4 Membranes in the Biopharmaceutical Industry
Fig. 4.1 Basic elements of a recombinant therapeutic manufacturing line.
process engineer seeking to develop and eventually optimize a process step must identify the proper membrane through a combination of experience (e.g., manufacturer and reference literature) and laboratory experimentation, and then use scaled-down testing to determine how the membrane will perform. Intermediate sized testing is then used to determine operating parameters, and cleaning and sanitizing regimes. Microfiltration, ultrafiltration and virus removal process development all follow these basics steps, with additional specific requirements for each. Figure 4.1 shows a generic biopharmaceutical manufacturing line and will be referred to throughout this chapter. The shaded boxes denote UF processes and the shaded circle, the virus removal filtration step. All other filtrations are done using microporous membranes. It is evident that microporous steps are numerous in the overall process. With the exception of crossflow microfiltration sometimes used for clarification, all microporous use is with dead-end disposable cartridges or capsules. Microporous and UF membranes can be defined by what they do, and how they do it. Microporous membranes are capable of removing particles larger than 0.1 mm and being used primarily in dead-end filtration applications with disposable cartridges or capsules. Ultrafiltration membranes are used for concentrating or diafiltering soluble macromolecules that have a size in solution of less than about 0.1 mm and operating continuously in a tangential flow mode for extended periods of time, usually more than 4 hours and for up to 24 hours. We will see, however, that in the virus removal application, specialized UF membranes are used in a dead-end mode.
4.2 Microfiltration Membranes Used in the Biotech Industry
Microporous membranes clarify the streams from the fermenter and the centrifuge output. They are used in the process train for aseptic filtration of media and other streams entering the fermenter and for buffers used in chromatography steps. Microporous membranes aseptically filter the final filling of dosage containers, perhaps the most critical filtration step in the entire process train. Ultrafiltration membranes concentrate and diafilter protein solutions. Diafiltration (DF) is used to change buffer solutions for subsequent process steps. Flat sheet membranes dominate this area, although hollow fibers are used for some applications. Polyethersulfone (PES) and regenerated cellulose are the two major types of flat sheet membranes. Hollow fibers are primarily PES. Regenerated cellulose finds particular use where low protein binding of the expensive protein therapeutic drug product to the membrane is desired. For uses where harsh cleaning conditions or where protein binding is less important, PES membranes can be used. Virus removal in the production process for biopharmaceutical drugs require several separate robust steps with additive capabilities. Membrane processes have been proven to be an important part in virus removal and are now found in virtually all biopharmaceutical manufacturing processes. These membranes operate under perhaps the most severe requirements in membrane technology. Not only must they be capable of removing ‘‘3 logs’’ (99.9 %) of virus, but also they must pass almost the entire protein product in the feed stream. As the desire to remove smaller parvoviruses has developed, the difference in size between the protein and the virus has diminished, making meeting these almost contradictory requirements more difficult. In addition, virus removal membranes must be validatable. The most prevalent virus removal membranes presently used are regenerated cellulose hollow fibers, and flat sheet composite polyvinylidene fluoride (PVDF), PES asymmetric, or PVDF symmetric membranes.
4.2 Microfiltration Membranes Used in the Biotech Industry 4.2.1 Introduction
In the early 1900s, Zigmondy [1] developed a process of making membranes that could be used to retain bacteria. A century later, similar processes are still being used to make the microfiltration membranes that are used throughout a typical biopharmaceutical process. The more efficient pleated cartridge devices introduced in the 1970s accelerated membrane development as stronger membranes were needed to withstand the pleating process. Pleated cartridges made the process and sterile microfiltration of liquids more economical. When the first biopharmaceutical products started moving from the lab to commercialization in the early 1980s, these membrane devices were available and eased process development. For decades they have served biopharmaceutical manufacturers with little change. A combination of increasing customer
93
94
4 Membranes in the Biopharmaceutical Industry
requirements has led to new microporous membranes and membrane structures. In this section, we will discuss how present-day microporous membranes evolved. This overview will attempt to rationalize why certain materials and specific morphologies are chosen for certain applications and how one might choose membranes for various applications. Although the original customer emphasis was on the performance of the membranes (flux and rejection), these attributes are now expected. Current emphasis is focused on the robustness of the membrane device, and increased capacity. Robustness refers to the control of variability of a filter device so that the device operates successfully within the window of process variability. Capacity is the ability to run longer at a reasonable rate and not become plugged. Increasing capacity has been an empirical endeavor at best. Now, newer mathematical models more accurately describe the plugging behavior of microfiltration membranes. Final filtration applications require a high retention of Mycoplasma or the removal of bacteria from process liquids. Although the guidance of Food and Drug Administration (FDA) is clear, the interpretation of retention assurance is less clear. Some early and more state-of-the-art interpretations of retention assurance will be presented. 4.2.2 Microfiltration Membranes: Development of Industrial Membranes
Ever since Zigmondy’s invention in 1914, membranes have been made by phase inversion processes. In the Zigmondy process, a thin layer of cellulose nitrate solution is evaporated and the resulting porous film used to filter bacteria while passing other constituents of the feed. Zeman and Zydney [37] give an excellent description of processes currently used to manufacture microporous membranes. In most applications, microfiltration membranes are defined as those porous membranes that have the ability to retain bacteria but allow proteins to pass through. It was only in the 1960s that through the availability of scanning electron microscopy, it became clear that these films consisted of highly interconnected pores uniformly distributed within the film. In the 1970s, the need for new membrane materials for pleated cartridges led to polyamide membranes (nylon) from Pall Corporation and AMF (now Cuno/3M), and PVDF membranes from Millipore Corporation. These materials significantly improved the mechanical properties of the membranes in part due to slightly lower porosities. However, their strong mechanical properties allowed the fabrication of robust pleated devices which more than made up for any loss in permeability. Introduced as the biotech industry started, these devices are still being used in the majority of the microfiltration applications. Early microporous structures were web supported with woven or nonwoven fabrics to make up for the inherent weakness of the membrane. Web-supported membranes have the disadvantage that the web material is not compatible with certain posttreatments. For example, polypropylene (PP) is not resistant to gamma irradiation but has a high melting point, whereas polyethylene (PE) is not resistant to high steaming
4.2 Microfiltration Membranes Used in the Biotech Industry
temperatures but is resistant to gamma. PP is therefore often the material of choice for steamable cartridges while polyethylene can be used in gamma-treated cartridges. With the development of more robust membranes in the 1970s for pleated cartridges, a transition occurred from web-supported membranes to unsupported membranes, which are presently used in the majority of the microfiltration applications. The first microporous membranes were symmetric in structure, meaning that they had a uniform pore structure through their depth or thickness dimension. In the mid-1980s, the introduction of a new class of engineering plastics, first polysulfone and then the more stable polyethersulfone resulted in asymmetric microporous membrane structures developed at Brunswick (eventually US Filter, now part of Pall Corporation) by Wrasidlo [2]. Further developments using polysulfone polymers came from Kraus [3] (assigned to Gelman, now Pall Corporation and commercialized as Supor1) and Roesink et al. [4] (assigned to X-Flow/Norit) who independently invented the use of hydrophobic– hydrophilic polymer blends to create membranes that were intrinsically hydrophilic. The Kraus patent, based on polyethersulfone, led to structures that are symmetric. AKZO AG [5] (currently Membrana) and Fuji [6] filed patents on preparing asymmetric membranes based on a single-polymer solution that had a retentive portion of the membrane located internally in the membrane, sometimes called an hourglass symmetry from the profile of pore sizes through the membrane cross-section. Despite being available for several years, asymmetric membranes were not successfully introduced into the biotech filtration marketplace until the introduction in 1997 of the Sartopore 2 from Sartorius, a polyethersulfone-based membrane with a relatively low, hourglass-shaped asymmetry. In 2003, Millipore followed with highly asymmetric composite membranes having a superior permeability. In 2005, Pall Corporation introduced its Mach V technology. These membranes resemble in microstructure the original Supor technology as described by Kraus but show an asymmetric structure. Depending on the product, low or medium asymmetries are available. Besides Millipore, Pall, and Sartorius, other companies introduced products for this industry as well, that is, Membrana (DuraPES) and Cuno/3M (BioAssure). Although most recent products are based on polyethersulfone, the major market share in 2006 is still held by symmetric membranes: Durapore (polyvinylidene fluoride) and Ultipor (Nylon 66). 4.2.3 Effect of Membrane Structure on Properties
Figure 4.2 below illustrates the different structures. These are scanning electron photomicrografts of the cross-sections of the three types of membranes. The cartoon below each is used, in some of the following figures, to help explain membrane properties. Asymmetric membranes have higher permeabilities for a given bubble point compared to symmetric membranes. Symmetric or isotropic membranes can be regarded as having a pore size that remains relatively constant throughout the thickness of the membrane. Thus, if the membrane thickness were to be divided into
95
96
4 Membranes in the Biopharmaceutical Industry
Fig. 4.2 Types of microporous membrane structures.
equal fractions, each would contribute equally to flow resistance. For asymmetric membranes, each equally thick fraction has a different pore size and different flow resistance. For asymmetric membranes, because the retention fraction is only a small part of the total thickness, higher permeabilities result. A new class of membranes, composite asymmetric membranes having two zones within the membrane with different pore size, show an increased flow performance compared to singlepore-size symmetric membranes and to its asymmetric variants. The data shown in Figure 4.3 below illustrates how membrane structure affects properties. The data are typical of commercial membranes used in the biopharmaceutical industry. For each type, as the water bubble point (BP) increases, indicating smaller average pore size, permeability decreases. Bubble point is described in Section 3.1.2.2. Asymmetric membranes with what is considered ‘‘low’’ asymmetry,
Fig. 4.3 Water permeability relationships for three types of microporous membrane structures.
4.2 Microfiltration Membranes Used in the Biotech Industry Tab. 4.1
Commercial microporous membranes by structure and polymer.
Brand name
Vendor
Membrane material
Membrane structure
Ultipor Sartobran Durapore Supor Fluorodyne IIP Millipore Express Sartopore 2 Supor Mach V BioAssure
Pall Corp. Sartorius Corp. Millipore Corp. Pall Corp. Pall Corp. Millipore Corp. Sartorius Corp. Pall Corp. Cuno/3M
Nylon Cellulose acetate PVDF PES PVDF PES PES PES PES
Symmetric, web supported Symmetric, web supported Symmetric Symmetric Symmetric Composite asymmetric Low asymmetry, hour glass Low asymmetry Hour glass
where the ratio of pore size from one surface to the other is approximately 10, have higher permeability than symmetric membranes for equivalent BP. The asymmetric composites have the highest permeabilities. Higher permeabilities are desirable for reducing the footprint of installed membrane devices (less membrane area needed ¼ less capital cost) for applications where membrane pores are not plugged during filtration. For applications where the feed stream plugs the membrane, capacity, that is, amount of liquid that can be filtered, is more important, and permeability is less critical. Asymmetric membranes have significantly higher capacity in plugging streams when used with the more open pores at the feed side. This is more pronounced for streams that do not have any prefiltration. Given this advantage, it is therefore also not surprising that all major vendors of microfiltration normal flow filtration (NFF) devices are currently introducing devices that have asymmetric membranes. Membranes from suppliers to the biopharmaceutical industry classified by membrane material and structure are given in the Table 4.1. 4.2.4 Aspects of Cartridge Design
For some steps in the manufacturing train, many commercial devices have a combination of membranes layered in the cartridge, that is, a microporous guarding layer and a sterilizing grade microporous layer (see Table 4.2). Especially in cases where the loading on the guarding layer is not extremely high, using a guarding layer instead of a separate prefiltration step is highly desirable due to process compression and its associated reduction in footprint and hardware requirements. Pleated cartridges have one or more layers of nonwoven support layers in addition to the membrane. In pleated cartridges, cartridge output is the product of membrane flux and membrane area. Membrane suppliers can make up for lower inherent membrane flux by increasing membrane area in a cartridge, sometimes with very imaginative pleat designs. See, for example, US Patents 5,543,047 and 6,315,130. Pleated cartridge area (nominal 10 in. long by 3 in. diameter) ranges from 1 to 3 m2. How effectively the membrane is used in such designs depends on the packing
97
98
4 Membranes in the Biopharmaceutical Industry Tab. 4.2
Guarded microporous devices.
Brand name
Vendor
Pore size rating combination
Sartobran Multimedia Durapore Multilayer Durapore Supor EKV Fluorodyne EX Millipore Express SHC Sartopore 2
Sartorius Corp. Millipore Corp. Millipore Corp. Pall Corp. Pall Corp. Millipore Corp. Sartorius Corp.
0.45/0.22 0.2/0.22 0.45/0.22 0.65/0.22 0.2/0.22 0.5/0.22 0.45/0.22
density and the type of support materials used, and the nature of the feed being filtered. Scaling studies in filtration process development for a particular stream will quantitate device efficiency. The engineering scaling process (described later in Section 3) starts with membrane disks, moving to small area devices and finally large area manufacturing scale devices. The purpose is to determine inherent membrane properties at small scale and then to determine any loss in effectiveness for the conditions seen in the process being studied, due to cartridge packing or design. 4.2.5 Membrane Surface Modification
In addition to the basic material and structure of the membrane, surface modification approaches and chemistries differentiate membranes. The engineering plastics used to make membranes are hydrophobic and exhibit high protein binding (adsorption). Membrane manufacturers have devised many surface modification chemistries to produce hydrophilic, low binding membranes. The patent literature contains a wide variety of chemistries that go beyond the production of hydrophilic surfaces to improved caustic stability, low binding capabilities for specific components and increased temperature resistance. A review [7] by Ulbricht covers much recent research. Caustic stability refers to the desire of biotech producers to clean their system with up to 1N alkali and not have filter properties changed by such cleaning. In final fill operations, low binding is required for the product being filtered. For protein filtration, an ultra low binding surface modification is needed. For other active pharmaceutical ingredients (APIs), a low binding characteristic for those components is similarly useful. The surface-modified membrane must be stable toward different sterilization methods. Typical requirements for steam sterilization require temperatures significantly higher than 121 8C. Many sterile filters have product claims specifying steaming temperatures of up to 136 8C. Stability toward steaming can be judged
4.2 Microfiltration Membranes Used in the Biotech Industry
by an integrity test (see Section 3.1.2.2) of these membrane devices. Such tests give biotech manufacturers proof that the sterility assurance is maintained after steaming and filtration. Typically, this integrity test is performed through either diffusion testing or bubble point testing. Another method that is sometimes used is to steam sterilize the membrane devices, and then determine the ability to obtain a sterile filtrate when challenged with a high bioburden load. Furthermore, steaming may change the surface chemistry resulting in a change in the measured bubble point. Bubble point is directly proportional to the surface energy of the test liquid, inversely proportional to the largest pore size in the most retentive zone in the membrane and proportional to the cosine of the contact angle of the liquid with the membrane surface. If steaming changes membrane contact angle sufficiently, interpretation of calculated pore size will be in error. During membrane development, the likelihood of steaming having a deleterious effect on wetting can be probed by measuring the critical surface energy of the membrane surface before and after one or multiple steaming cycles. The critical surface energy can be characterized by identifying the highest surface tension liquid that instantly wets the membrane. Having a membrane with a critical surface energy that is significantly higher than 72 dyn/cm is desirable to guarantee that proper wetting occurs. Ideally, the critical surface energy is not changed by steaming or autoclaving. 4.2.6 Sterilizing Filters
Sterilization by use of 0.2 rated filters in pharmaceutical and biotech processes is more than just using a 0.2 rated membrane. A filter is qualified as sterilizing grade based on its ability to completely retain microorganisms under the specific conditions and with a particular process feed stream composition. Test methods are described in ASTM F-838-05 and HIMA tests. The FDA provides guidance in the Guideline on sterile drug products produced by aseptic processing [8]. Although the overall test conditions are clear, differences in some details still vary between different manufacturers. 4.2.6.1 Retention In the past, retention of sterilizing grade filters was expressed as the ability to retain more than 107 microorganisms of a certain size. Since retention occurs through size exclusion, good correlations were found between bubble point, a measure of the largest pore size of the membranes, and retention. Results were expressed in log reduction value (LRV) units. LRV ¼ log10
colony forming units found in the filtrate : colony forming units challenged to the filter
Although the LRV gives a good indication what constitutes retention, it fails to describe of what sterility means.
99
100
4 Membranes in the Biopharmaceutical Industry
The authors expect that with the implementation of the FDA’s new initiative [9]: ‘‘Pharmaceutical cGMP’s for the twenty-first century: a risk based approach,’’ membrane science in the near future will require a high level of understanding of where certain risks originate. For sterilizing grade membranes, manufacturers will need to better define how sterility assurance can be defined in a scientifically sound way. Recently, a paper [10] was presented by researchers at Millipore Corporation in which a statistical-based model was described by which sterility assurance can be calculated. The researchers based the model using fundamental principles and assumptions based on experimental studies of the retention of bacteria with microporous membranes. Rather than focusing on achieving a particular log reduction value, this approach relied on calculating the assurance to obtain complete retention downstream of a membrane filter as a function of bubble point. The method chosen as most appropriate for the data was regression of logarithm of filtrate colony forming units (CFU) versus bubble point, using retentive outcomes as censored (i.e., partial) information. A linear model of isopropyl alcohol (IPA) bubble point versus retention was fitted. From it, the probability of sterile filtrate was obtained by solving Probability (retention) ¼ exp (10(LC)), where LC is the expected log count at a given bubble point. This assumes that the probability of zero counts (i.e., retention) at a fixed bubble point follows a Poisson distribution with parameter 10^(LC) when testing is done under uniform conditions. Retention confidence was obtained from the regression relationship between bubble point and LRV (Figure 4.4). From this relationship, the minimum bubble
Fig. 4.4 Logarithm of colony forming units found on the downstream side of the membrane as a function of alcohol bubble point for a symmetric and asymmetric membrane. The lowest bubble points with complete retention are indicated with an upward arrow. The calculated minimum specifications for bubble point with a 99.9 % assurance level that sterile effluent is obtained is indicated with a downward arrow.
4.2 Microfiltration Membranes Used in the Biotech Industry
point of the membrane device is calculated for a confidence level of greater than 99.9 % that a sterile effluent is obtained when challenged with B. revundimonas diminuta at >107 organisms per cm2.
4.2.6.2 Permeability Membrane manufacturers are constantly trying to attain higher flux and capacity while maintaining required sterility assurance. One illustration of how membrane structure affects the balance between properties is shown in Figure 4.5. In this figure, the bubble point corresponding to a sterile filtrate in B. diminuta testing is given for the three types of membranes. To get the same retention assurance for an asymmetric membrane, a minimum bubble point is defined, which is significantly higher than that for the symmetric membrane such as are those currently being used commercially. Despite the higher bubble point, which generally reflects a smaller pore size, a significantly higher flux is achieved for the asymmetric membranes as shown in Figure 4.5. Besides relying on the minimum bubble point for the sterilizing grade membranes established by the membrane manufacturer, users of these membranes who sterile filter liquids have to demonstrate that acceptable sterility is obtained in their process fluid. This is described in detail in Section 3. It is known that certain organisms could potentially penetrate through 0.2 sterilizing grade membranes, that is, Mycoplasma. For those cases, a smaller pore size membrane filtration is recommended. Due to the smaller pore size, lower permeabilities and capacities are typically obtained and a larger installed footprint is needed to filter the same volume of process liquid.
Fig. 4.5 Bubble point corresponding to obtaining sterile filtrate with B. diminuta for different membrane structures.
101
102
4 Membranes in the Biopharmaceutical Industry
4.2.6.3 Capacity In many steps throughout the process, the membrane retains particulate matter and other species. How these particles are retained whether on or within the membrane structure will define the ‘‘dirt holding capacity.’’ Common practice is to use a standard pore-blockage model or a caking model to predict, based on smallscale testing, what the total capacity is for candidate membranes. This will be described in Section Membrane System Sizing – Capacity. Currently, academic and industrial researchers are studying capacity with more sophisticated models. Ho and Zydney [11] published a paper describing a transition between a standard pore-blockage model and a caking regime. Bolton et al. [12] combined a cake model with a complete pore-blockage model in a single equation to capture this transition. Knowledge of what fraction of the volume filtered is governed by complete blockage versus caking can be used to optimize membranes for its capacity. Further research is underway in an attempt to describe capacity as a function of asymmetry and as a function of prefilter layering.
4.3 Practical Membrane Considerations for Sterile Filtration by Microporous Membranes
Biopharmaceutical manufacturing is a membrane intensive industry and in particular is a heavy user of microporous membrane devices. As illustrated in Figure 4.1 and as discussed in this section, microporous devices are primarily used for sterile filtration for input streams and for aseptic vial or other container filling at the end of the manufacturing process. In the following brief tour, we will start at the fermenter and show where microporous membrane devices are placed in the various manufacturing steps. The fermenter requires multiple filtration devices. Media and associated buffers, which comprise the nutrients for the cells being grown, are sterile filtered and fed into a bioreactor. Hydrophobic sterilization membranes filter any gas streams entering the fermenter, and are on any vents during processing. Since they will not wet from liquid splashing during the process, there is no opportunity for bacteria to grow through. Except for microfiltration used for crossflow or tangential flow filtration (TFF) clarification of the cell culture, all microfiltration unit operations focus on minimizing the risk for bacterial or Mycoplasma contamination of the product. Biopharmaceutical manufacturers select media to maximize the expression levels in the cells. In recent years, there has been a shift from animal derived, serum-based media to plant derived media (i.e., soy digests) due to regulatory concerns with Kreuzfeld–Jacob syndrome and other potential contaminants. A shift to chemically defined media would be even more desirable but expression levels using these media have not been optimized. As this trend continues, membrane filtration of media will become easier and more economical. To maintain sterility in the bioreactor, a pharmaceutical grade 0.2 or 0.1mm rated membrane is used. For media where a high reduction in Mycoplasma is desirable, different 0.1 mm rated devices are recommended. Many media, especially serumbased media, have a plugging character, and in order to obtain process economies, microporous prefilter devices are commonly used prior to sterile filter devices.
4.3 Practical Membrane Considerations for Sterile Filtration by Microporous Membranes
Depending on the choice of expression system, proteins are expressed internally or externally to the cell. For internally expressed proteins, the cell culture is harvested when a predefined yield is achieved. The cells are usually concentrated by a centrifugation step, although crossflow microporous membrane devices are being used successfully as well. Once the cells are concentrated, the cells are lysed, most typically in a high-pressure homogenizer. The cell lysate containing the product of interest is then clarified to remove cell debris using depth filters and finally sterile filtered into a holding tank. Cell cultures which express protein internally, such as E. coli, are optimized to yield high titer levels of expressed protein, which is typically associated with a low viability of cells. Such cells are more easily ruptured during harvest. As a consequence, there is a high loading of cell debris that needs to be clarified. A second clarification after the centrifugation or microporous TFF step is performed through depth filtration. These are usually lenticular pad filters of bound cellulose fibers and filter aids, such as diatomaceous earth. The number and size of colloids and other particles exiting the depth filter depends on the attributes of the particular depth filter being used and the feed stream. If this permeate stream is not clean enough, the downstream sterile filter will become quickly plugged. An intermediate filter may be needed. A series of chromatography columns, that is, ion exchange, protein A, or other affinity media, purifies the clarified product. Buffers used in chromatography are usually sterile filtered to remove bioburden and other contaminants in order to increase column life and economies. For protein that is expressed external to the cells (i.e., Chinese Hamster Ovary cell lines, NS0 cell lines), the cells are removed by centrifugation, TFF or depth filtration. The separated product is then processed as above. Figure 4.1 shows that large volumes of buffers are used throughout the process, constituting a considerable usage of membrane filters. Since these buffers are clean, membrane devices used to prolong column life are chosen primarily for high permeability, to reduce the number of cartridges needed. It is expected that any commercial sterilizing (0.2mm rated) membrane will have the retention needed. Filtration of protein pools with high levels of protein can lead to undesirable protein aggregation. In such cases, microfiltration membranes are used to remove aggregates before the expensive virus removal filtration. This is described in more detail in Section 6. Once the proteins are concentrated to their final level, a final sterile filtration step can be used to sterilize the liquids for vial or container filling. In order not to affect the dosage level, a low protein binding characteristic of the membrane is required. In most filtrations at this stage, permeability and capacity are less important than the confidence that the membrane device can be validated. 4.3.1 Sterile Filtration Process Considerations
Properly done sterile filtration removes all living organisms from a fluid. It is a critical application of membranes to the biopharmaceutical manufacturing process. To
103
104
4 Membranes in the Biopharmaceutical Industry
implement a sterile filtration process, the manufacturer must take great care in material selection, system design, and scale-up to assure that the filtered product is suitable for use. In this section, we will present a standardized methodology to assist in this process. We will cover membrane filter selection criteria including materials, retention requirements and testing, flow and capacity performance testing, installation, sterilization, integrity testing, and process validation. 4.3.1.1 Filter Selection Generally, filter selection has four main considerations: compatibility; retention;
and two considerations which determine system sizing flow rate; capacity. A logical approach to filter selection will consider these four criteria in the order listed. For instance, there is no point in determining if a given filter has sufficient flow for a given application if the filter materials are not compatible with the feed stream. Compatibility Compatibility covers how membranes and membrane devices withstand the conditions under which they are operated. Chemical compatibility refers to solvation, swelling, or weakening of the membrane due to contact with the process fluids. Typical modern membranes used for sterilizing filtration include PVDF, PES, polytetrafluoroethylene (PTFE used for venting), and cellulosics. PTFE has the broadest chemical compatibility and cellulose acetate is the most limited. Whatever the material, chemical compatibility guides can be used to make an initial assessment of suitability. Guides can be found in manufacturers’ literature or chemical engineering manuals. Chemical compatibility can also be determined experimentally. Using membrane coupons, key membrane properties such as water flux, weight, thickness, and integrity can be measured before and after exposure to the product stream or individual components of the feedstream. Changes in any of these key properties indicate chemical incompatibility that could impact membrane performance. Chemical compatibility also includes other feed-stream membrane interactions such as adsorption of critical feed-stream components. Examples are proteins, preservatives, and APIs. Here again, initial determination can be done by soak tests with membrane disks and quantization done by spectroscopic or other analytical methods. Pitt [13] provides some guidance and test methodologies for protein adsorption. Hem [14] provides some guidance for preservative adsorption. In most cases, however, the only true measure is with the actual formulation processed with actual process parameters. One important reason for this is to be able to understand the effect of nonmembrane components of the filtration device on adsorption and filtration performance.
4.3 Practical Membrane Considerations for Sterile Filtration by Microporous Membranes
Heat resistance of sterilizing grade membranes is another key compatibility question. Live steam is the most common method for sterilizing membranes prior to sterile filtration. Most typical sterilizing membranes have very good thermal compatibility. Typically, the limiting factor is the support materials used in cartridge and capsule devices. Manufacturers’ recommendations should be followed. Gamma irradiation is also typical for filters that are supplied sterile. PVDF and PES are compatible with the levels of gamma irradiation required for sterilization, typically 25 kGray. PTFE and cellulosics are not gamma compatible. AAMI provides guidelines for qualifying and requalifying gamma sterilization processes [15]. A final consideration for materials compatibility is whether the membrane is hydrophobic or hydrophilic. Hydrophilic membranes wet spontaneously with water, and hydrophobic membranes repel water. Generally, hydrophilic membranes are used for aqueous streams, hydrophobic membranes for vent applications or gas filtration. Hydrophobic membranes can also be used to filter low surface tension fluids such as alcohols, but hydrophilic membranes are suitable and often used to minimize the number of different filters that must be stocked by an end user. Retention Retention requirements for sterilizing membranes are quite simple – complete retention of microorganisms in the feed stream and complete passage of the product components. Because this separation is primarily based on size, and there is a generally a large difference in size between microorganisms and most proteins or other APIs, membranes with pore size ratings of 0.2 mm or 0.1 mm will provide the necessary bacterial retention and product/passage requirements. When selecting a 0.2 or 0.1mm membrane, it is important to assure there is a certified sterilizing grade claim. The general definition of a sterilizing grade filter is a filter that when challenged with at least 107 cm2B. diminuta (ATCC19146) will produce a sterile effluent. Standard methods are available (ASTM F-838-05) that detail methods for B. diminuta retention testing. The ASTM method or close derivatives are used by filter manufacturers for product development and quality control tests. Some manufacturers use the test for membranes and some for membranes and devices. The ASTM test is designed to challenge each pore of the membrane with a single bacterial particle. B. diminuta has long been accepted as a suitable ‘‘worst case’’ organism for this test [8,16]. It is suitable due to the small size, ability to grow monodispersed and at high concentration. It is also desirable for its relative safety. Although the ASTM test is considered a suitable QC release test for membrane manufacturers, it is not sufficient for demonstrating the filter will provide suitable retention in a specific drug manufacturing process. To qualify a filter’s retention in actual production, a modification of the ASTM test must be used. The modified test must take into account process operating parameters, which could impact bacterial retention such as process time, differential pressure, and volume/area. In addition, the modified test must take into account actual process bioburden and any impact the process fluid may have on organism size. The result is a ‘‘custom’’ retention test performed as a component of the validation process.
105
106
4 Membranes in the Biopharmaceutical Industry
The components of the custom retention test are as follows: Identify native bioburden and compare it to B. diminuta to determine worst case challenge organism. (Over 99 % of existing custom retention validations have been performed with B. diminuta.) Determine if actual drug solution will inhibit microbial growth. This would be the case with antibiotics or preservative containing solutions. A noninhibitory modified product must then be used. Spiked product or noninhibitory modified product with test organism. Challenge membrane under process scale down conditions, keeping volume/area, time, and pressure consistent with fullscale process. Acceptance criteria for the test are a challenge level of at least 107 organisms per cm2 membrane area and 0 cfu downstream. The results of this test are included with the process validation documentation submitted to regulatory agencies. Results from the custom retention test, along with documentation that membrane manufacturing processes are validated, and integrity test processes are correlated to retention, are used to demonstrate that a specific filtration process is sterilizing grade. Membrane System Sizing – Flow Rate Requirements Compatibility and retention define the type of filter to be used for a given application. The next step is determining the necessary amount of filter area. Filter area requirements are driven by two process parameters – flow rate and volume capacity. Examples of process constraints that define flow rate requirements are as follows: The need to filter a specific volume in a specific period of time (e.g., one shift) or other processing time constraints. Tankto-tank transfers, such as buffer filtration processes, are typically time based. Minimum flow constraints, where the flow through the filter must be maintained at a certain level in order to maintain adequate process fluid to the next step. Filling operations are an example where low flow means low fill volume and likely process shutdown.
The driving force for flow is a critical component of flow rate determination. Driving pressure can come from either positive pressure applied with gas pressure or a pump. Or driving pressure can come from vacuum as is common in tank vent applications. When the flow requirements and driving force are defined, the first estimate of filter size can be determined using the flow/DP (DP is the pressure drop across the filter system) information provided by membrane manufacturers for the various
4.3 Practical Membrane Considerations for Sterile Filtration by Microporous Membranes
devices. These curves are given for standard fluids, usually water for hydrophilic filters and air for hydrophobic. Information for water flow is usually given for 25 8C and 1 cps. Correction tables are available for water at temperature other than 25 8C. A flow/DP curve, adjusted for feed stream viscosity, will provide a reasonable estimate of membrane behavior at the start of the filtration. However, as the membrane plugs or fouls, the flow/DP properties will change. The amount of change varies with feedstream. In some cases, such as gases or purified water, the flow/DP properties change very little and therefore the manufacturers’ flow/DP curve will not only give an estimate of how the membrane performs at the start of the filtration but also at the end. Sizing filters for these applications is simply a matter of understanding the flow/DP curve. Membrane System Sizing – Capacity However, there are many feedstreams that have enough retained contaminants to significantly change the flow/DP properties of the membrane. Examples include proteins, cell culture media, cell harvest, and so on. In these cases, trials are generally required to determine how the flow/DP conditions will change through the course of the filtration. Capacity trials can be operated in one of two modes. Abbreviated trials run at constant pressure, Vmax trials, can be used when gradual pore plugging is the operative mode. A major advantage of Vmax trials is the ability to screen multiple membrane samples in a short time with minimum volume of feedstock. Constant flow trials can be used when gradual pore plugging is not operative or for simulating processes run at constant flow.
Vmax is a method for predicting the throughput of filters based on a gradual pore plugging model [17]. Gradual pore plugging occurs when colloids or suspended matter collect on the sides of filter pores to gradually block them off, until a state of total occlusion is eventually reached. This gradual blocking of the pores results in a distinct filtration pattern. In a Vmax test, the time and volume collected up to that time are recorded at regular intervals. Test apparatus is shown in Figure 4.6. A plot of time/volume versus time is made on linear/linear axes. If the results plot as a straight line, the filter is considered to plug by the gradual pore plugging model and the formulas of Vmax can be applied to predict filter life. If the results do not plot as a straight line, it indicates the filter is plugging by some other model, such as cake formation. In these cases, Vmax should not be used. A traditional flow decay method, in which the filter is actually run with the feed stream or close surrogate until completely plugged, should be used. In the gradual pore plugging model, flow decay follows the equation Q ¼ Qi ð1 kV=2Þ2 ;
ð1Þ
107
108
4 Membranes in the Biopharmaceutical Industry
Fig. 4.6 Vmax test apparatus.
where Q is the flow rate (L/min), Qi is the initial flow rate (L/min), k is the constant, and V is the volume filtered (L). At infinite time, Q ¼ 0, and Equation (2) results Maximum volume filtered ¼ Vmax ¼ ðk=2Þ 1:
ð2Þ
When time/volume versus time is plotted and a straight line results, it follows the equation t=v ¼ At þ B;
where t is the time, v is the volume filtered up to that time, A is the slope, and B is the y-intercept. Solving for V gives the following equation: V ¼ t=At þ B ¼ 1=ðA þ ðB=tÞÞ:
Letting time go to infinity, B/t becomes zero and V ¼ Vmax ¼ 1=A:
Therefore, the inverse of the slope of the plot of t/v versus t equals the maximum volume that can be filtered by the test filter. B is the y-intercept, or the value of t/v when time is zero. 1/B has the dimensions volume per time, a flow rate. Therefore, the inverse of the y-intercept is the flow rate through the test filter at zero time or the initial flow rate. Rearranging Equation (1) with Vmax = 2/k gives Q=Q i ¼ ð1 V=Vmax Þ2 :
This equation can be used to determine the percentage of Vmax that has been used when the flow rate has dropped to a percentage of the initial flow rate. The process development engineer will use Vmax to test and compare multiple membrane options in a short time with small volumes of feed solution. Vmax results
4.3 Practical Membrane Considerations for Sterile Filtration by Microporous Membranes
can be used to make initial choices with a small investment in time and product solution. Since the trial does not simulate all the process parameters, such as process flux, time, differential pressure, and volume/area, it is limited as to scaling accuracy. For scaling purposes, it is highly recommended that process simulation trials be run before finalizing the system size. The trial should simulate as closely as possible the actual process mode (constant pressure or constant flow), actual process time, volume per area, and membrane flux. Process simulation trials can be performed with membrane coupons or small-scale capsules when sufficient quantities of feed stock are available. An alternative to Vmax testing is the constant flow Pmax test. Pmax is conducted with a positive displacement pump feeding the test filter at constant flow. The differential pressure is recorded and trended as a function of the volume filtered. The advantage of Pmax tests is that they often more closely simulate the actual process. This is especially true when process flux and maximum process operating pressure is adhered to. In addition, unlike Vmax, the test is run until the filter is plugged. The plugging volume is not predicted by extrapolation. Another advantage of Pmax test is it is not dependent on any specific plugging mechanism. The disadvantage of Pmax tests is it could potentially take a long time and large volume to run, as in cases where filter fouling is very low. Pmax test apparatus is shown in Figure 4.7.
Fig. 4.7 Pmax test apparatus.
109
110
4 Membranes in the Biopharmaceutical Industry
Fig. 4.8 A typical pleated cartridge filter showing the pleat components. Cartridges are inserted into permanently installed housings.
4.3.1.2 Device Selection There are two major categories of devices used in NFF – cartridges (Fig. 4.8) and capsules (Fig. 4.9). Cartridges supplied by membrane manufacturers are inserted into housings with an o-ring seal at the process site. Capsule filters include a plastic housing with the membrane permanently bonded inside. Cartridges generally will have lower cost per membrane area. Capsules can provide lower operating costs by minimizing labor requirements. Sterilization Considerations When deciding between cartridges or capsules, the first key consideration is sterilization method. If live steam is to be used, a cartridge in stainless steel housing will provide the highest degree of safety. Steam in place (SIP) for capsules is not recommended for the vast majority of typical capsules. Capsules with SIP claims require extensive safety precautions and must be operated with great care. On the other hand, autoclave sterilization is very common and suitable for both cartridge and capsule type devices. Typically temperatures from 121 to 126 8C are used. Gamma irradiation is the sterilization method of choice for ‘‘pre-sterilized’’ devices because it is highly lethal to all organisms. There is also the advantage of being able to sterilize large numbers of devices in their final packaging, eliminating issues of package exposure to steam or moisture.
4.3 Practical Membrane Considerations for Sterile Filtration by Microporous Membranes
Fig. 4.9 An all in one capsule filter. The pleated membrane/ support is sealed into the capsule and the entire device is disposed of after use.
All sterilization methods must be qualified for effectiveness and membrane compatibility. AAMI [11] provides guidelines for gamma irradiation dose qualification and requalification intervals. Implementation Successful implementation of the chosen membrane, device and sterilization method includes installation, sterilization, integrity testing, and running the actual filtration. An initial consideration for installation is to assure that there is sufficient space above and around the filter installation to raise the housing dome, attach and detach tubing and piping to inlet and outlet. Before finalizing system installation, the process development engineer must assure that the process scale system will perform as predicted from small-scale testing. Typical mistakes include sizing based on membrane pressure drop, then encountering flow limiting piping restrictions at full scale. For example, a common mistake is to size a process based on pressure at source, with the membrane device
111
112
4 Membranes in the Biopharmaceutical Industry
being operated at a significant distance or head difference from the source, resulting in less driving force than design. The choice of sterilization method will have a significant impact on implementation. Easiest to use are disposable filter assemblies supplied pre-sterilized. These can be obtained complete with whatever tubing, valves, containers, and so on, are required for the application. All that is required is attachment to other processing equipment. Next easiest to implement are autoclaved assemblies of the membrane device and associated tubing, and so on. These are assembled by the user on-site, wrapped in protective material, and autoclave sterilized. Ideally, the assembly will be as complete as possible prior to autoclaving in order minimize the number of aseptic connections required post-sterilization. Most difficult to operate are steam-in-place operations. First, there are safety considerations as operators must handle live steam lines. Second, the steam inlet pressure and membrane differential pressure must be carefully controlled to avoid damaging the membrane or device. Finally, as discussed in the microporous membrane section, the membrane must be able to withstand steaming without a change of properties. Integrity testing is performed to prove the membrane is free of oversized pores that would compromise retention. Most common are nondestructive tests based on capillary theory. The theory and practice of integrity testing have been covered previously many times [18]. Nondestructive integrity tests are based on capillary forces as defined in the bubble point equation BP ¼ 4 kgcosu=d;
where BP is the bubble point, k is the shape correction factor, g is the surface tension, u is the contact angle, and d is the pore diameter. This shows the relationship between pore size and the pressure required to force liquid out of membrane pores to initiate bulk gas flow. This is the fundamental basis for all nondestructive membrane integrity tests. ‘‘Bubble Point’’ tests measure the pressure required to initiate bulk gas flow. ‘‘Diffusion’’ tests measure the gas flow as a pressure below the expected bubble point pressure. Excessive gas flow at a pressure below the expected bubble point indicates the presence of oversized pores or defects. Successful integrity testing is dependent on completely wetting the membrane pores with test fluid. The most common test fluid for hydrophilic filters is water. But because water has a relatively high surface tension, it can be difficult to get water to fully penetrate all the pores. False integrity test failures due to poor wetting are common and time consuming. As discussed above, a common problem with hydrophilic modifications is they can be removed or reversed by process exposure. Live steam will reduce the surface energy of many modified polymers. In some cases, hydrophilic membranes are rendered hydrophobic by steam sterilization. The result is limited flow or, more commonly, false integrity test failure. Manufacturers’ recommendations for steam sterilization should be followed to minimize this problem. Before final membrane is
4.4 Ultrafiltration and Virus Filtration Membranes for Biopharmaceutical Applications
specified into the process, trials should be run that simulate all process conditions, including integrity testing and sterilization. The information presented in this section is common to all sterile filtration applications in the biotech industry. A process engineer who is designing a specified one or more sterile filtration steps will find that following the considerations given here and cartridge manufacturers’ recommendations will result in a well functioning process.
4.4 Ultrafiltration and Virus Filtration Membranes for Biopharmaceutical Applications
Filtration membranes are generally classified based on their size exclusion properties. At the largest pore size, we have microfiltration membranes (typical pore sizes in the range of 0.05–10mm). Ultrafiltration and virus filtration membranes, the subject of this section, have pore sizes approximately in the range of 1–100 nm, corresponding to solute molecular weights in the 1000–1 000 000 Da. Although there is overlap in the pore size range of ultrafiltration and virus filtration membrane groups, their application uses are very different. As a result, different membrane types have emerged to dominate each application. For ultrafiltration, regenerated cellulose and PES membranes are the two main types. Flat sheet membranes dominate the market, but PES hollow fiber devices are also available. For virus filtration, PVDF membranes are used, in addition to PES and regenerated cellulose. Both hollow fiber (regenerated cellulose) and flat sheet devices are available. We will cover ultrafiltration and virus filtration membranes separately. 4.4.1 Ultrafiltration Membranes
UF is widely employed in biopharmaceutical manufacturing to concentrate and diafilter biological molecules, generally proteins [19]. Biopharmaceutical manufacturers use these process steps to attain a specified product concentration range and buffer composition that is optimal for subsequent processing such as chromatography or formulation. 4.4.1.1 Membrane Suppliers The principal suppliers of UF membranes for biopharmaceutical applications today are GE Healthcare [20], Millipore [21], Pall [22], and Sartorius [23]. The first UF membranes (nonwoven supported regenerated cellulose – YM series) were introduced commercially by Amicon – now part of Millipore Corporation – in the 1970s. Millipore introduced nonwoven based PES membranes soon thereafter. Filtron – now part of Pall Corporation – followed in the 1980s with Omega membranes (also nonwoven based PES). Alpha PES membranes are also available from Pall for applications where antifoam agents are a problem. The 1990s saw the introduction of several new membranes. Millipore started offering cellulose (PL-series) and Biomax (PES) membranes, a response to YM and Omega membranes, respectively.
113
114
4 Membranes in the Biopharmaceutical Industry Manufacturers and brand names of ultrafiltration membranes for biopharmaceutical manufacturing.
Tab. 4.3
Supplier GE Healthcare GE Healthcare Millipore Millipore Pall Pall Sartorius Sartorius
Cellulose
Ultracel PLC (5–1000 kDa) Ultracel PL and YM (1–300 kDa) Regen (10–50 kDa) Hydrosart (10–100 kDa) Cellulose triacetate (5–20 kDa)
PES A/G HF (1–750 kDa) Kvick (5–100 kDa) Biomax (5–1000 kDa) PT (10–300 kDa) Omega (1–1000 kDa) Alpha (10–30 kDa) PESU (5–700 kDa) PESU (5–700 kDa)
The novelty of Biomax membranes was that they were the first macrovoid-free membrane structures. Sartorius introduced cellulose Sartocon Hydrosart as a response to YM and PL, with the additional claim of sodium hydroxide cleanability. Sartorius also offers PES and cellulose triacetate membranes. Millipore also introduced cellulose composite membranes, replacing the traditional nonwoven support with a microporous membrane. The first hollow fiber devices were offered by A/G Technology – now part of GE Healthcare – are made of PES and also claimed a macrovoid-free structure. The most recent offering is Kvick PES flat-sheet membranes by GE Healthcare Biosciences AB. Table 4.3 summarizes the key suppliers and membranes, along with the NMWCO offered. 4.4.1.2 Membrane Selection As is obvious from the above survey, PES and regenerated cellulose are the two dominant types of ultrafiltration membranes. Regenerated cellulose is often selected as a result of its low protein binding properties. This is especially important for expensive protein therapeutic drugs. Low protein binding reduces fouling and benefits a process with improved consistency, easier cleaning, and improved yield. PES membranes are used in applications where harsher cleaning chemicals are used or where low protein binding is less important. UF membranes are typically reused several times, and for that reason cleanability and solvent compatibility is a key consideration in membrane selection. Separate, but related, considerations apply for membrane storage, as the devices need to be stored in appropriate preservative solutions, in many cases, alkali, between uses.
Membrane selection for a given application is based on the following factors: retention of the product protein; retention consistency; process flux and overall process economics; scalability; mechanical robustness; chemical compatibility for cleaning/storage.
4.4 Ultrafiltration and Virus Filtration Membranes for Biopharmaceutical Applications
Selection of a particular pore size is usually done empirically and should always be confirmed in the user’s particular application. A rule of thumb for selecting membrane nominal molecular weight cut-off is to select one third to one fifth of the product MW. For example, membranes rated at 30–50kDa should be used for retention of a monoclonal antibody that has an MW around 150kDa. Even tighter membranes should be used if anything above 0.01 % passage of the product is unacceptable. 4.4.1.3 Membrane Structures Flat sheet ultrafiltration membranes are typically used, cleaned, and sanitized, sometimes stored, through many cycles. To obtain the required mechanical stability and robustness for multiple uses, most UF membranes are made with a nonwoven fabric support. Nonwoven polyoloefin supports have been used for a long time, as they offer robustness and simplicity, as well as an open, permeable substructure. Composite membranes (e.g., Millipore Ultracel PLC) are instead cast on microporous polyethylene membrane supports. The advantages are reduced microdefects that could be caused by the rough surface of nonwovens and more uniformity and flatness of the UF layer, resulting in high retention consistency. In addition, there is improved adhesion of the UF layer to the substrate, resulting in a more mechanically robust membrane. The original UF membranes had large macrovoids. More recent membranes claim a macrovoid-free structure. Although macrovoid-containing membranes have been successfully used for many years, macrovoid-free structures provide higher assurance of retention and improved consistency. They have become the norm in most current applications. Figure 4.10 shows examples of typical membrane structures. 4.4.1.4 Characterization Ultrafiltration membranes are characterized in terms of a nominal molecular weight cut-off rating, NMWCO. The rating corresponds to the retention to a certain level
Fig. 4.10 SEM images of typical ultrafiltration membranes: macrovoids on nonwoven substrate (left), macrovoid-free on nonwoven substrate (middle), composite, that is, macrovoid-free on microporous substrate (right).
115
116
4 Membranes in the Biopharmaceutical Industry
(typically 90 %) of a marker molecule. Each membrane manufacturer has their own characterization methods, and they should not be directly compared without knowledge of the methodologies used. Originally, manufacturers characterized all UF membranes with a protein retention test. Each membrane was challenged with one or more protein molecules, and specifications were set at a minimum required retention. Given the variability in purity of commercially available proteins, the lack of relevance to specific protein formulations used in the industry and the low robustness of a ‘‘minimum specification’’ approach, alternative methods were introduced. A mixed dextran solution with molecules covering a broad MW range from 1 to 1 000 000 kDa was proposed and has been adopted by the UF community [24]. Normal Molecular Weight Cutoff (NMWCO) is typically defined as the dextran MW where 90 % of dextran molecules are retained, a value known as R90. The advantage of such tests is that they provide a common platform for testing a whole family of UF membranes, which would otherwise require testing with different proteins. In addition to retention properties, water permeability, back pressure (to test integrity of the membrane–support interface) and air diffusion (to test for the presence of large defects) are also usually measured and reported for UF membranes. 4.4.1.5 Devices Essentially all ultrafiltration membranes for bioprocessing are used in TFF devices, with the exception of some virus removal devices. In TFF, also referred to as ‘‘crossflow’’ filtration, fluid flows across (tangentially) the filter membrane surface, with a small fraction of the flow permeating the membrane (perpendicular to the surface). The sweeping action of the tangential flow clears the surface of deposits thereby minimizing membrane fouling and maximizing process flux and product yield. The common device (module) formats used for biopharmaceutical applications are flat sheet membranes used in plate and frame-type cassettes or spiral wound module formats, and hollow fiber modules (Figure 4.11). Cassettes can have an open channel or a turbulence promoting screen. Screened cassettes have become the dominant module format in the biopharmaceutical
Fig. 4.11 Commercial ultrafiltration modules: hollow fibers (left), spiral-wound (middle), cassettes (right).
4.4 Ultrafiltration and Virus Filtration Membranes for Biopharmaceutical Applications
industry, as they offer high mass transfer efficiency due to their controlled flow channels, resulting in high fluxes at low tangential flows. Open-channel cassettes are used for high solids or high viscosity feeds. A very important attribute of cassettes is their ability to offer linear scale-up for reliability and speed of implementation. Spiral wound modules are still being used in high-volume pharmaceutical or industrial biotech applications. When cost is the main concern, the high membrane packing density of spiral modules is an important benefit. Hollow fiber devices are preferred when viscous fluids are being processed and an open-channel device is needed. 4.4.2 Virus Filtration Membranes
Membrane processes have proven to play an important part in virus removal and are now found in virtually all biopharmaceutical manufacturing processes. Virus removal for biopharmaceutical drugs requires several steps with additive capabilities. Virus membranes have severe requirements, as they must remove 99.9 % of virus particles while passing almost the entire protein product in the feed stream [25]. As smaller viruses (e.g., parvoviruses) have become important, the difference in size between the protein and the virus has diminished, making size-based separations even more difficult. The additional requirements (compared to UF) have led membrane development in a slightly different direction. This section will only focus on membranes that remove viruses by size exclusion. Membrane adsorbers also claim some virus removal capabilities through electrostatic interactions, but they will not be covered here. 4.4.2.1 Membrane Suppliers The most prevalent virus removal membranes presently used are regenerated cellulose hollow fibers and flat sheet polyvinylidene fluoride (PVDF) and PES membranes. The principal suppliers of virus membranes today are Asahi [26], Millipore [27], Pall [28], and Sartorius [29]. Filter manufacturers classify virus clearance filters into two broad categories based on the removal needs of the biotech industry – filters that are capable of removing viruses 50 nm or larger (retroviruses) and filters that can remove both small (20nm parvoviruses) and large viruses. Asahi Kasei Corporation (Japan) manufactures Planova filters, which were among the first membranes specifically designed for virus filtration. They are dead-end hollow fiber units with regenerated cellulose membrane made through the cuprammonium process (i.e., different from regenerated cellulose UF membranes). Pall Corporation uses hydrophilic PVDF for its Ultipor DV50 and DV20 membranes. Sartorius produces the Virosart CPV filter, which features a PES membrane. For TFF removal of small viruses, Millipore offers membranes with hydrophilic PVDF in two ratings, Viresolve 70 and Viresolve 180 membranes, designed to pass proteins with 70 kDa or 180 kDa molecular weight, respectively, while retaining virus particles. For NFF removal of small and large viruses, Millipore offers NFP and NFR
117
118
4 Membranes in the Biopharmaceutical Industry Tab. 4.4
Commercial virus removal membranes and brand names.
Supplier Large viruses only Asahi (TFF/NFF) Millipore (NFF) Pall (NFF) Small viruses Asahi (TFF/NFF) Millipore (TFF) Millipore (NFF) Pall (NFF) Sartorius (NFF)
Cellulose
PES
PVDF
Planova 35N, 75N NFR Ultipor VF DV50 Planova 15N, 20N V70, V180 NFP Ultipor VF DV20 Virosart CPV
filters, respectively. NFP uses membrane similar to V180, while NFR features a hydrophilic PES membrane. Table 4.4 above summarizes available virus membranes, separating them according to the polymer used, the viruses removed and the filtration mode they are used in. 4.4.2.2 Membrane Structures There are two broad families of virus membrane structures, skinned asymmetric membranes (Millipore) and symmetric membranes (Asahi, Pall, Sartorius). Early UF membranes of appropriate pore size were examined for virus removal, but it was found that the pore size distribution was too broad to provide the necessary removal [30]. Development of virus membranes, such as Viresolve V180, then focused on eliminating macrovoids in the UF layer. The pore size in the ultrafiltration layer increases gradually from the skin layer progressing towards the large-pore microfiltration layer. The UF skin provides the selectivity needed to exclude viruses, while the thicker microporous support layer provides mechanical support for the membrane. The advantage of a thin retentive membrane is significantly higher permeability. Alternative approaches used a much thicker, dense retentive layer that traps virus particles in its multilayer, interconnected pore structure [31]. Asahi Planova, for example, has a 35 mm-thick filtration layer to assure high viral retention. Pall’s Ultipor DV membranes are symmetric without a distinct skin layer. Commercial membranes have average pore sizes 10 nm and larger in size, so that viruses, in some cases, as small as 20 nm may be sterically excluded from the pores while still permitting transmission of the desired protein product. 4.4.2.3 Devices Both tangential flow (TFF) and normal flow (NFF) filtration devices are used for viral clearance. In both cases membrane units are typically disposable and designed for a single use, in order to avoid the strict validation requirements that would be linked to cleaning a potentially infectious particle. Historically, TFF systems were more
4.4 Ultrafiltration and Virus Filtration Membranes for Biopharmaceutical Applications
Fig. 4.12 Commercial virus membrane modules. (Courtesy Pall Corporation, Millipore Corporation, Asahi Kasei Medical, and Sartorius AG)
common, following UF experience. Recent improvements in NFF filters along with their reduced complexity of operation and easier validation have led to a predominance of NFF filters. All NFF flat-sheet filters contain two to three layers of membrane in order to increase virus removal assurance. TFF has been covered in the UF section. In NFF, also referred to as ‘‘dead-end’’ filtration, fluid flows perpendicular to the filter membrane surface, with the flow driven either with a pump (constant flow) or by pressure (constant pressure). NFF virus filters are available in a variety of formats and filter areas to satisfy strict requirements for scalability. In virus filtration, scalability affects not just process economics but also validation of virus spiking studies. Small-area filters are available for process development and virus validation studies, while for pilot and production scale operations, filters with membrane area up to 6 m2 are available. Additionally, multiple filter cartridges or module assemblies can be configured to achieve even larger filtration areas. Figure 4.12 shows various commercial devices in use. 4.4.2.4 Membrane Selection Criteria for selecting a virus filter tend to be product- and process-specific [32]. A typical biotech process might contain more than one virus filtration steps. To effectively evaluate the impact of these variables, in-house testing is typically performed. Performance related criteria for selecting a virus filter include the following: virus retention capabilities; protein product transmission;
119
120
4 Membranes in the Biopharmaceutical Industry
product throughput requirements; overall process economics; process compatibility; thermal and hydraulic stress resistances; extractables.
Compatibility with cleaning solutions is not an issue for virus filters, as they are typically disposable. Detailed validation packages, including spiking studies, are typically required by users of these filters. 4.4.2.5 Characterization The key parameter needed to characterize a virus filter is its ability to retain viruses of a certain size. This parameter is normally expressed in terms of a log reduction value, LRV, defined as follows: LRV ¼ logðCfeed =Cpermeate Þ;
where Cfeed and Cpermeate are the virus concentrations in the feed and permeate streams, respectively. For smaller viruses (such as parvovirus) membrane filters provide LRVs above 3–4. LRVs above 6 are normally seen for larger viruses (such as retrovirus). These parameters are typically determined during viral spiking studies, where appropriate virus preps are used to challenge the membranes. Membrane manufacturers have specific virus removal claims on their filters, but users generally perform a separate spiking study, using their own product formulations. Regulatory agencies currently require validation of virus removal steps using actual viruses. For assurance of filter integrity, membrane manufacturers practice particle challenge tests, using bacteriophage [33] or gold nanoparticles [34]. Compared to viruses, the advantages of bacteriophages are increased prep purity, faster more sensitive assays and safer operation. Gold particles offer much better control of size and uniformity, and simpler detection. Particle challenge tests can be performed in conditions that simulate more or less actual process conditions. The presence of fouling streams, for example, might affect retention. Proper selection of the stream is important to generate meaningful data. To completely validate virus removal within a specific process run, novel liquid porosimetric integrity tests have been developed that rapidly and nondestructively predict the intrinsic viral retention capabilities of virus-retentive membranes. The CorrTest method [35] is essentially a ratio of two membrane permeabilities measured at preselected operating conditions using a pair of mutually immiscible fluids, one of which is employed as a membrane wetting agent and the other used as an intrusion fluid. The CorrTest method can be used to verify pre- and post-use membrane integrity and has been shown to correlate well with bacteriophage fX-174 retention. Standard air diffusion tests are also performed on devices to assure against the presence of gross leaks. In contrast to particle tests – that give information on the pore
4.5 Applications of Ultrafiltration Membranes in Biopharmaceutical Manufacturing
size distribution of the membrane – air diffusion tests identify large defects on the membrane surface. In addition to integrity, adequate passage of the product of interest – or an appropriately sized marker molecule – can be verified in a separate test. The optimization of virus retention and product passage properties can yield a membrane that is best suited for this application.
4.5 Applications of Ultrafiltration Membranes in Biopharmaceutical Manufacturing
Biopharmaceutical manufacturers use ultrafiltration to concentrate and condition biological molecules, generally proteins [35–39]. Ultrafiltration membrane processes are used to provide optimum concentration ranges and/or buffer compositions for subsequent processing steps. An ultrafiltration process operates in a tangential flow (also known as crossflow) mode to retain a biological molecule while letting small molecular components such as buffer and water to freely pass through the membrane. In biopharmaceutical processing, ultrafiltration is primarily operated in a batch or a fed-batch mode. Process operation times are typically between 3 and 8 hours. Manufacturing scale system sizes range from being as low as 5 m2 of membrane filter area for specialty therapeutics to as high as 300 m2 for high-dose monoclonal antibody applications. Figure 4.1 (see page 92) shows the typical location of ultrafiltration steps in the downstream purification of a monoclonal antibody. There are broadly three different areas where manufacturers use ultrafiltration in downstream biopharmaceutical applications: 1. Post-harvest concentration: The ultrafiltration step is used to reduce volume and adjust the buffer conditions prior to loading of the product on the first chromatography step. Low feed concentrations (0.2–2 g/L), high process volumes (1000– 20 000 L), and higher level of impurities (DNA, lipids, host cell protein, etc.) characterize this area. Bioburden and fouling play an important role in process design in this process step. A typical process will concentrate the feed stream 5–10-fold with two- to threefold diafiltration. 2. Intermediate buffer exchange: This step is very similar to step 1 above except that the feed is more concentrated (5–30 g/L) and process volumes (200–1000 L) and impurity levels are lower. Typically, the feed is concentrated between 5 and 10 fold with three- to fivefold diafiltration. 3. Formulation: The emphasis on the formulation UF step is to carefully achieve a predetermined product concentration and formulation buffer conditions. The product is very pure at this step and may be concentrated up to 180–200 g/L. Diafiltration
121
122
4 Membranes in the Biopharmaceutical Industry
volumes are also relatively high, ranging between 8 and 12 depending on the extent of buffer exchange required. The engineer faced with developing and operating an ultrafiltration process operation will want to optimize the key elements of process consistency and robustness, the ability of the process to operate under normal operating condition variations, product yield, product purity, ease of use, scalability, validation, and process economics. The manufacturing process may impose constraints in the form of fitting a process to an existing equipment, limitations on buffer or cleaning chemical usage, meeting floor space requirements and product quality considerations at operating conditions (pumping, process duration, etc.). 4.5.1 Ultrafiltration Theory
There are several excellent treatments of ultrafiltration theory in the literature [36,37,41–43]. In this section, we examine the relationships among critical parameters that derive from the commonly employed theories to explain ultrafiltration behavior. In the polarization theory, the product concentrations may be related to the permeate flux and tangential flow parameters as follows: Cw Cp J ¼ exp ; Cb Cp k
where Cw, Cb and Cp are the concentrations of the product at the membrane surface, bulk feed, and permeate, respectively, J is the flux or permeate flow per unit area, and k is the mass transfer coefficient, which is affected by tangential flow rate. An empirical gel model is obtained from Equation (1) by taking Cp ¼ 0 and setting Cg (or gel concentration) ¼ Cw to get J ¼ k lnðCg =Cb Þ:
Equation (1) indicates that the ultrafiltration performance parameters, k and Cg, may be obtained from a plot of J versus ln Cb, k is obtained from the slope, and Cg from the x-intercept. Finally, there is also an osmotic pressure model that relates process flux to transmembrane pressure and osmotic pressure, P, resulting from concentration of protein at the membrane wall. The osmotic model is expressed as J ¼ L pðTMP DPÞ:
The method for determining the ultrafiltration performance parameters, k and Cw, are detailed in [19].
4.5 Applications of Ultrafiltration Membranes in Biopharmaceutical Manufacturing
Fig. 4.13 Characteristic flux versus TMP curve in an ultrafiltration process.
Figure 4.13 shows a typical flux versus transmembrane pressure (TMP) curve. The region at low flux/low TMP is called the linear region, where the flux is linearly dependent on TMP. The region at high flux/high TMP is called the polarized region and in this section, the flux is independent of TMP. In between these two regions lies what is termed the ‘‘knee’’ of the flux curve. Increasing pressure beyond the knee gives diminishing return in improving flux. The flux versus TMP curve is also dependent on crossflow and protein concentration – a higher flux is generally realized at higher crossflow rates or lower protein concentrations for a given TMP. The intrinsic membrane sieving, also called passage, is defined as si ¼ (Cperm/ Cwall), while intrinsic membrane retention or rejection is defined as ri ¼ 1 si. The intrinsic sieving is inherent to the membrane and solute, while an observed sieving as so ¼ (Cperm/Cbulk) varies with polarization. 4.5.2 Typical Ultrafiltration Process
A typical schematic of an ultrafiltration process is shown in Figure 4.14. The process starts with filling the protein product solution in the feed tank, recirculating this feed using the feed pump, and removing virtually product-free permeate as a waste stream. As the process proceeds, the tank volume drops and the concentration of retained product in the tank increases. This concentration step proceeds until the product concentration meets a certain target concentration. The buffer condition is then modified using what is called the diafiltration step where a different buffer, or diafiltrate, is added at the same rate as permeate is withdrawn (also known as constant volume diafiltration). During diafiltration, the tank volume and retained protein
123
124
4 Membranes in the Biopharmaceutical Industry
Fig. 4.14 Ultrafiltration process schematic.
concentration remains constant (for r ¼ 1). Diafiltration is complete when the buffer is changed to the desired composition. The solution then proceeds to the next step. The relationship between product concentration and volumetric reduction factor X ¼ (initial volume)/(final volume), the number of diafiltration volumes, N ¼ buffer volume added)/(fixed retentate volume) and membrane rejection, r is CRN ¼ C0 e½½ð1rÞNþrlnX :
Note that for freely passing solutes (r ¼ 0), >4 diavolumes are needed to achieve a specification of <1% of the original buffer components. The corresponding equation for retentate product yield may be written as YieldRetentate ¼ eð1rÞðNþlnXÞ :
Permeate loss is expressed as 1 YieldRetentate. Note that a membrane with 1 % sieving (99 % retention) can have process yield losses much higher than 1 % because the protein is repeatedly cycled past the membrane during the entire process with losses at every pass, that is, the higher the N, the more is the yield loss. A high yielding process (<1 % total product loss) typically requires sieving of <0.1 % (retention of >99.9 %). 4.5.2.1 Process Development and Optimization [38] The process parameters that govern successful development, design and operation of an ultrafiltration process are as follows: 1. membrane type and module characteristics; 2. operating parameter optimization; 3. processing plan; 4. system design implementation. Membrane Type and Module (Device) Format Membrane selection for a given application is based on factors such as chemical compatibility, mechanical robustness, and retention consistency for the product protein, as well as process flux and
4.5 Applications of Ultrafiltration Membranes in Biopharmaceutical Manufacturing
overall economics (cost). Experience with vendors as well as their record of quality manufacturing practices (ISO, cGMP) is also a consideration that influences membrane selection. Operating Parameter Selection and Optimization A systematic process development methodology is required to achieve a robust, consistent and optimized TFF step. Candidate membranes are often screened using low membrane area (50–100 cm2) linearly scaleable cassette devices – volume requirements for these devices are between 50 and 500 cc. For more detailed optimization investigation, a 0.1 m2 device is often used with process volumes ranging from 1 to 15 L. Pilot-scale processing, which is often carried out to generate material for product stability and characterization studies, is used to confirm operation scalability and robustness. Volumes at pilot-scale range from 20 to 2000 L depending on the application. A typical process development sequence is described below: 1. Module installation and conditioning: Flush and measure normalized water permeability (NWP). Verify integrity using air diffusion. Precondition membrane devices by flushing with buffer.
2. Initial fouling characterization: Add product solution and measure flux and passage versus time in permeate recycle mode (permeate and retentate recycled to feed tank). This is done to evaluate membrane fouling behavior and allow for membrane conditioning in product solution. (Note: The initial conditioning verifies that the module is integral and also establishes as baseline permeability for the device. The fouling characterization study should show asymptotic approach to steady-state flux and retention. Continued decline in performance indicates a membrane compatibility issue.) 3. Flux and crossflow excursion in initial feed: In a total recycle mode (permeate and retentate returned to feed tank), measure flux, protein passage, and turbidity versus TMP (10–60 psi) and crossflow (or DP of 10–30 psi). (Note: Vary the TMP (10–60psi) at constant crossflow (say P ¼ 10 psi); repeat the procedure at different crossflows (or P ¼ 20 psi, 30 psi, etc.).) 4. Concentration mode: Measure flux, passage, turbidity, retentate concentration, temperature, and permeate volume versus time while removing permeate to achieve concentration. 5. Flux and crossflow excursion in final retentate: Measure flux, passage, and turbidity versus TMP (10–50 psi) and crossflow (P of 10–30psi) in total recycle mode.
125
126
4 Membranes in the Biopharmaceutical Industry
6. Diafiltration mode: Repeat step 5 while withdrawing permeate and adding diafiltrate at the same rate to the feed tank to achieve target impurity concentration – this mode of diafiltration is referred to as constant volume diafiltration. 7. Product recovery: Recover retentate product by depolarizing and using a plug-flow flush. 8. Measure yield. 9. Membrane CIP: Flush with buffer, then WFI, add 0.1N NaOH solution, recirculate for 45 min at 20 8C in permeate recycle mode, and measure NWP. NWP should be the same as the initial value. If not, recleaning is required. Additional development will include repeatability evaluation, cleaning optimization, and further exploration of particular conditions. Selection of Optimum TMP and Crossflow A typical flux excursion behavior is shown in Figure 4.15. The optimum TMP is located at the ‘‘knee’’ of the flux curve to obtain reasonable flux and avoid formation of aggregates. If there is a difference in the flux curves between the starting solution and the diafiltered solution, a conservative approach for polarization would be to select the lower of the two TMP values.
Fig. 4.15 General flux trends in ultrafiltration.
4.5 Applications of Ultrafiltration Membranes in Biopharmaceutical Manufacturing
Fig. 4.16 Process data for example scale-up calculations.
Choice of crossflow rate needs further consideration. Higher crossflow rates tend to result in higher flux and reduced polarization, but this also leads to larger pump size with a concomitant increase in holdup volume and pump passes (potential for product degradation). For linearly scalable modules, the following approach may be used for guidance in crossflow selection. Figure 4.16 provides data for an example calculation. In this example, a device with 0.1 m2 membrane area is operated at two crossflow rates and the permeate flux plotted versus TMP. The optimum point for each rate is chosen, and the permeate flux recorded. For this example, the crossflow feed rates are Q1 ¼ 0.65 L/min Q2 ¼ 0.39 L/min Crossflow feed rates normalized for membrane area are termed feed flux JFQ1 ¼ 6.5 L/min/m2 JFQ2 ¼ 3.9 L/min/m2 The permeate flux at the optimum point for each case is JfQ1 ¼ 150 L/m2/h JfQ2 ¼ 86 L/m2/h We assume V/T, permeate volume/process time is equal. Then, since A ¼ Membrane area ¼ V/T permeate flux, A1/A2 ¼ (1/150)/(1/86) ¼ 0.57 The area at the higher crossflow rate is 57 % of the lower crossflow rate. Now we calculate the ratio of feed rates required at each feed crossflow. Pump rate ¼ feed flow flux area ¼ JFQ A; and the ratio is 6:5=3:9 0:57 ¼ 0:95:
In this example, the difference between pumping rates is not significant, so one would chose the higher crossflow rate, because less membrane area would result in
127
128
4 Membranes in the Biopharmaceutical Industry
lower capital costs and smaller system size. In other cases, the shapes of the permeate flux versus TMP curves may dictate otherwise. It is also important to note that this method applies to systems that scale linearly (i.e., crossflow per unit area is the same for all system sizes). For nonlinear system scaling, for example, some hollow fiber or spiral wound systems, the procedure for selecting crossflow rates is based more on experience than any analytical method. Flux typically drops as protein concentration increases, so choose an average flux for the above calculation. For a robust scale-up, always incorporate a safety margin into the membrane area requirements to account for lot-to-lot variability effects on membrane permeability, feedstock fouling characteristics, and batch volumes. Typically, a safety margin of at least 20–50 % extra membrane area is used, but this could increase or decrease depending on the expected variability in the process. 4.5.3 Processing Plan Optimization
In the development of a processing plan, the engineer has to consider choice of the mode of operation, diafiltration strategy, process time, temperature, and an assessment of process robustness vis-a`-vis lot-to-lot variability associated with feed and membrane. 4.5.3.1 Mode of Operation Most UF processes in the biopharmaceutical industry are operated in a batch mode (as opposed to continuous mode). In a batch mode, the entire product feed is recirculated within the system (no new feed is added to the system); permeate is continuously removed from the system during this time resulting in an increase in product concentration. The retentate, at its desired concentration, is available at the end of the processing time. When large concentration factors (>15–20) need to be achieved, a variation of batch process called fed batch is often used (Figure 4.17). The configuration provides some flexibility in processing a variety of batch volumes in a single skid. For a
Fig. 4.17 Fed-batch configuration.
4.5 Applications of Ultrafiltration Membranes in Biopharmaceutical Manufacturing
Fig. 4.18 Fed-batch process concentrations.
fed-batch operation, the retentate is returned to a smaller tank, not the large feed tank. Feed is added to the small retentate tank as permeate is withdrawn. The smaller retentate tank can allow a smaller working volume without foaming. Figure 4.18 shows the retentate concentration over the course of the process as a function of the tank ratio ¼ VFeed tank/VRetentate tank. Notice that the fedbatch process operates at a higher overall concentration compared to the batch process and consequently at a lower average flux. Typical fed-batch tank ratios are chosen to be <4–5 to allow for process flexibility, while minimizing loss of operating flux. 4.5.3.2 Diafiltration Mode/Strategy Constant-volume diafiltration is commonly used control mode for adding diafiltration buffer. To perform a constant-volume DF, buffer is added to the recycle tank at the same rate that filtrate is removed. The total volume of retentate remains constant throughout the process. Another important aspect of the diafiltration process is its placement (strategy) in the overall process. The optimum point for placement of diafiltration may be derived from the gel polarization model [44] as (Figure 4.19). Copt ¼ Cg =e;
where Cg is the concentration at which the flux drops to zero and e ¼ 2.718, which is the base of the Naperian logarithm. For monoclonal antibody processing, Cg values of 200–300 g/L have been reported, yielding an optimum diafiltration concentration of 70–110 g/L. Until recently, final antibody concentrations have generally been in the 5–20 g/L range,
129
130
4 Membranes in the Biopharmaceutical Industry
Fig. 4.19 Optimum diafiltration point – polarization model.
where it is convenient to diafilter to the final formulation concentration. That is, it is simpler to concentrate to 20 g/L and diafilter at this concentration (i.e., you would not take the concentrate to the optimum range of 70–110 g/L in order to diafilter followed by dilution to come back to 20 g/L). However, with a recent push towards high formulation concentrations, in the range of 150–200 g/L, diafiltration at the optimum diafiltration concentration in process applications is increasingly becoming a reality. Since, for example, if the final desired concentration is 150 g/L, one can pause during the concentration step at 70–110 g/L (which is the optimum diafiltration concentration) in order to carry out the diafiltration, and once diafiltration is complete, further concentrate to the desired final concentration of 150 g/L. A more general approach for selecting the optimum diafiltration point is to use the DF optimization parameter approach. In this approach, one calculates the diafiltration optimization parameter, DF ¼ C J, at each protein concentration (from the plot of the flux vs. protein concentration curve). A plot of the DF optimization parameter versus protein concentration is constructed to find the optimum protein concentration where the value of the DF optimization parameter is maximized (Figure 4.20). It is important to plot these data with the protein in both the initial and final buffers, since flux can often change significantly with different buffers. If the optimum is very different for the two buffers, it is most conservative to choose the optimum based on the buffer curve which results in the lower value for the product concentration. Finally, the goal of a diafiltration step is to reduce buffer or contaminant species from a product in the retentate. Since increasing the number of diavolumes that are performed adversely impacts yield, it is best to minimize diavolumes consistent with obtaining correct final composition. Figure 4.21 illustrates the relationship between contaminant removal and number of diavolumes. The maximum effective diavolume is about 14 before the limits of the system or the chemistry are reached (system deadlegs, mixing effects, etc.).
4.5 Applications of Ultrafiltration Membranes in Biopharmaceutical Manufacturing
Fig. 4.20 Optimum diafiltration point – diafiltration optimization parameter approach.
4.5.4 Scale-up Considerations
Once a process has been developed at lab bench scale, it must be translated to industrial scale and validated, and this can present unanticipated surprises and challenges. Often, there is little opportunity to perform intermediate-scale runs due to time and material constraints. In addition, material from the initial industrial-scale runs is usually required for time-sensitive clinical or market supply. Therefore, accurate and dependable scale-up is critical for the success of a process. The simplest way to ensure accurate and predictable translation of product yield and purity from bench to industrial scale is to use linear-scale techniques.
Fig. 4.21 An example of contaminant removal by diafiltration.
131
132
4 Membranes in the Biopharmaceutical Industry
To linearly scale a TFF process [45], all fluid dynamic and membrane module parameters must be kept constant between scales of operation. Fluid dynamic parameters, which are set by the user, include the ratio of feed volume to membrane area, feed rate per membrane area, filtrate flux, and retentate and filtrate pressures. Membrane module parameters are inherent in the specific filters that are chosen, and include membrane material and pore size, turbulence promoter, channel height, channel length, and feed and filtrate flow geometries. Therefore, true linear scaling can only be done with modules from the same supplier. 4.5.4.1 Process Implementation Considerations Once a protein processing procedure has been developed, it must be integrated into a complete process. The typical sequence of steps in an ultrafiltration/diafiltration process are set-up and pre-use cleaning, integrity and permeability testing, pre-use equilibration, protein processing, product recovery, post-use cleaning and testing and storage (Figure 4.22). The integrity test helps to ensure that the installed membranes have not sustained any damage during storage and handling. An integrity testing is normally carried out prior to startup and after each post-use cleaning. The typical integrity test for an ultrafiltration system involves measuring air diffusion across the wetted membranes at a specified pressure. The diffusive flow is compared against the specification provided by the membrane manufacturer. The air flow integrity test allows for identification of problems such as macroscopic holes in the membrane, cracks in the seals, or improperly seated modules.
Fig. 4.22 Typical operational sequence for an ultrafiltration process.
4.5 Applications of Ultrafiltration Membranes in Biopharmaceutical Manufacturing
It is also common practice to measure and compare the permeability (also referred to as normal water permeability or NWP) of the membrane system to assess its cleanliness from run-to-run. The normal water permeability is calculated as NWP ¼ ðflux temperature correction factorÞ=TMP:
The units of NWP are [L/m2/h psi/g]. Product recovery strategy is a key component of the process operating sequence. Product recovery is the process of removing the product from the TFF system into a vessel appropriate for storage or further processing. The bulk of the product, which is typically in the recycle tank, is pumped out using the feed pump. However, some liquid remains held up in the piping and the modules. A welldesigned system has minimal deadlegs in the piping and is sloped to a collection port at the lowest point in the piping to improve draining. Beyond simply draining the system, however, one of the following methods can be used to increase product recovery: low-pressure air blowdown; buffer displacement; buffer flush; buffer recirculation. Overall product recovery in the final retentate should be >95 % and yields of >99 % are common. After each membrane use and product recovery, the system assembly is cleaned using standard cleaning protocols [46,47]. Cleaning/sanitizing chemicals that are commonly used in ultrafiltration processes include 0.1–0.5 N NaOH, 200–400 ppm sodium hypochlorite, 0.1–0.3 N phosphoric acid, peroxiacetic acid, and so on. If another protein processing run does not immediately follow the cleaning, recirculate an appropriate storage solution through the TFF assembly to prevent organism growth. The membrane modules must remain filled with storage solution until the next run to prevent drying of the membranes. 4.5.4.2 Process Robustness A process implemented at large scale must be robust if it is to be successful. A robust TFF process will perform well within the lot-to-lot feedstock and membrane variations that it encounters. While developing a process, it can be very useful to test performance at the extremes of these variations, as far as possible. These performance parameters characterize a well-designed, robust ultrafiltration process:
Yield (overall) Process flux consistency Product retention (membrane) NWP recovery (run-to-run)
95–98 % 10 % run-to-run 99.9 % 20 % cellulose membranes 20–35 % for PES membranes
133
134
4 Membranes in the Biopharmaceutical Industry
Typical flux
Typical sizing
Product and process specific; for example, 30–120 LMH for 30 kDa membrane with MAb Product and process specific; for example, 5–10 m2/KL for MAb
4.5.5 System Considerations To implement a complete TFF process, the piping and equipment associated with the membrane modules must be selected and a method for controlling the process parameters at their set-points must be chosen.
4.5.5.1 Equipment Options In addition to the membrane modules and holder, at minimum a working TFF operation requires a recycle vessel, a feed pump, a retentate control valve, and pressure sensors for the feed and retentate lines. Many systems also include feed and filtrate flow meters, a filtrate pressure sensor, and sensors for temperature, pH, conductivity, or UV absorbance. Most TFF systems used for protein processing are operated in a sanitary manner, requiring sanitary fitting.
4.5.5.2 Process Control Options Throughout a TFF process, as protein is concentrated or exchanged into different buffers, the process parameters need to be adjusted so that they remain at their set points. Several methods of process control are used to accomplish this. The tangential flow can be controlled to maintain either constant pressure drop; constant crossflow rate.
Controlling to constant pressure drop is a simple and easy option in the sense that it requires the use of only feed and retentate pressure gauges. The exact feed flow is not known. Since pressure drop is uniquely related to crossflow (P ¼ AQn), a constant pressure drop is assumed to connote a constant flow rate. However, in many cases a constant pressure drop may not always ensure that the flow rate is maintained constant. Differences in the internal membrane module resistance, pump slip, fluid viscosity changes, and so on. during a process may contribute to changes in the fluid crossflow without impacting pressure drop. Controlling to constant crossflow rate is a more robust way of controlling the process. A flow meter is required in the feed or retentate flow line for this control option. The applied pressure can be controlled (by modulating the retentate valve) to maintain a constant Retentate pressure; TMP;
4.6 Practical Aspects of Virus Filtration Process Design and Implementation
flux; Cwall (protein concentration at the membrane surface); mixed mode control.
Our process development engineer, having reached this point, will find that by following the systematic methodology presented here will have an excellent understanding of the biopharmaceutical manufacturing process that results. Our engineer will be able to produce the necessary SOP’s, validation documents and operating instructions from detailed experience. In operation, the variance in day-to-day running can be expected to be controlled based on the knowledge gained during scale-up and implementation.
4.6 Practical Aspects of Virus Filtration Process Design and Implementation
Recombinant products such as monoclonal antibodies are expressed by mammalian, bacteria or yeast cells in fermenters, and within ascites fluid, or fluids from transgenic mammals. Mammalian cell lines may contain endogenous viruses that are generated in the bioreactor. Endogenous retroviruses are expressed because the retroviral genome is integrated into the cell line and cannot be screened out during the creation of the Master Cell Bank. This causes retrovirus like particles, or RVLPs, to be produced within the bioreactor. Products can also become contaminated by adventitious viruses, which enter the process streams. Although regulatory agencies do not mandate the inclusion of specific viral clearance technologies, they do mandate the safety standard for final doses, and require full validation of viral clearance steps by the manufacturer. Regulations and good manufacturing practice (GMP) require two orthogonal and robust steps for endogenous viral clearance [48]. Orthogonal steps rely upon different mechanisms to achieve virus clearance. For adventitious viruses, these requirements typically result in the use of multiple viral clearance steps [49]. Filtration removes viruses based on size exclusion, since the pores of the filter are smaller than the virus. Virus filtration is considered a robust operation because the removal efficiency is insensitive to normal variations in process conditions. Consequently, most well-designed downstream processes include a virus filtration step. 4.6.1 Membrane Selection
There are many commercially available virus filters, each with their own strengths and weaknesses. Filter selection should be based upon the nature of the application (product and process) and the performance of the filter as demonstrated in both qualification and validation studies. A systematic methodology for developing a robust virus removal step includes the following:
135
136
4 Membranes in the Biopharmaceutical Industry
virus filter selection; process design and optimization; process sizing and simulation; virus validation studies; manufacturing implementation.
Virus clearance filters are classified into two broad categories to meet the removal needs of the biotech industry – filters that are capable of removing viruses 50nm or larger (retroviruses) and filters that can remove both small (20nm Parvoviruses) and large viruses. NFF virus filters are available in a variety of formats and filter areas. Small-area filters are generally available for process development and optimization studies as well as virus validation studies. For pilot and production scale operations, commercial vendors offer individual virus filters ranging in size from 0.07 to 6m2. Additionally, multiple filter cartridges or module assemblies can be configured to achieve even larger filtration areas. Commercial filters that are currently available for virus removal applications in the normal flow filtration mode are summarized in Table 4.5.
Tab. 4.5
Vendors and brand names of commercially available virus filtration products.
Company type
Product name
Virus
Sizes
Millipore FF
NFP
>4 log X-174 bacteriophage
Scale-down 3.5 cm2; process modules 0.08–1.5 m2
Millipore TFF
NFR Viresolve 70
>6 log retrovirus >4 log polio; >7 log retrovirus
Sartorius NFF
Viresolve 180 Virosart CPV
>3 log polio; >6 log retrovirus >4 log PP7 bacteriophage; >6 log retrovirus
Pall NFF
DV20
>3 log PP7 bacteriophage; >6 log PR772 bacteriophage
Asahi TFF/NFF
DV50 Planova 15N
>6 log PR772 bacteriophage >6.2 log parvovirus; >6.7 log poliovirus
Planova 20N
>4.3 log parvovirus; >5.4 log Encephalomyocarditis >5.9 log Bovine viral diarrhea virus; >7.3 HIV
Planova 35N
Scale-down 150 and 1000 cm2;process modules 0.75–1.4 m2 Scale-down module 5 and 20 cm2; process module through 0.7–2.1 m2 Scale-down 14 and 140 cm2; process modules 0.07–6 m2 Scale-down modules 10 and 100 cm2; process modules 0.12–4.0 m2
4.6 Practical Aspects of Virus Filtration Process Design and Implementation
Performance-related criteria for selecting a virus filter include virus retention capabilities, protein product transmission/product recovery from the filtration step, product throughput (rate) requirements, and overall process economics. These criteria tend to be product specific, and to effectively evaluate the impact of these variables, in-house testing is typically performed. Less obvious considerations for selecting a virus filter revolve around process compatibility and system integration issues. All materials of construction must be chemically compatible both with the protein product as well as all relevant processing conditions. Additionally, thermal and hydraulic stress resistances, extractibles, and the effects of cleaning/sterilization/sanitization on the membrane devices should be evaluated to determine if they are consistent with the proposed implementation scheme. Additional information on these topics can be found in the PDA Technical Report No 41 on Virus filtration [49] or from the various vendors listed in Table 4.4. To properly optimize a virus filtration process and establish process robustness, one must consider all processing variables that impact virus retention (LRV), product recovery, and product throughput. Additionally, from an economic point of view, process optimization is extremely important. For large volume processes, such as monoclonal antibodies, virus filtration can be one of the most expensive unit operations. Virus filtration is more expensive than sterile filtration due to both higher filter costs and lower product throughputs. Table 4.6 provides a typical range for cost and performance parameters for virus and sterile filters. Virus filtration can either be run in a NFF mode or a TFF mode [50]. Historically, TFF systems were more common, but recent improvements in NFF filters have lead to their predominance. Because of this predominance of NFF approaches, TFF systems will not be discussed further here. In NFF, also referred to a ‘‘dead-end’’ filtration, fluid flows perpendicular to the filter membrane surface. NFF processes can be run either under constant flow operation or constant pressure operation. Constant flow is more common in manufacturing settings as most people would use pumps to drive the filtration and it is simpler to run at a constant pump setting.
Tab. 4.6 Comparison of virus filter costs, process fluxes, and capacities compared to sterilizing grade filters.
Filter type Virus Parameter
Sterile
NFF 20 nm virus filter
NFF 50 nm virus filter
TFF virus filter (>20 nm)
Unit filter cost ($/m2) Typical process flux (L/m2/h/psi) Typical design capacity (L/m2)
200–300 200–500 >2000–4000
>2000–4000 0.5–6 60–500
>1000 20–30 800–1500
>2000–4000 5–15 250–500
NFF, normal flow filtration and TFF, tangential flow filtration.
137
138
4 Membranes in the Biopharmaceutical Industry
During operation, protein products or other components can accumulate at the membrane surface or adsorb to internal surfaces. These two fouling mechanisms will reduce the hydraulic permeability of the membrane and may impact virus retention. Fouling results in a decrease in filtrate flow rate with time for constant pressure operations or an increase in upstream pressure with time for constant flow operations. 4.6.2 Process Development and Optimization
A schematic representation of the experimental set-up to conduct normal flow filtration experiments at constant pressure is shown in Figure 4.23. The scale-down test may be carried out in either a constant pressure or a constant flow mode. The constant pressure set-up is often simpler, and the testing is easier to execute in that the set-up does not require a pump to drive the filtration process. The typical steps employed in a scale-down NFFprocess evaluation are described in the following general test protocol. System set-up. Water flush. Installation check: Flush the filter with water and carry out a pressure hold test to confirm installation integrity of the devices. (This step is optional for process development and is typically carried out in virus validation studies.)
Fig. 4.23 Experimental set-up for virus removal testing.
4.6 Practical Aspects of Virus Filtration Process Design and Implementation
Buffer conditioning. Product filtration: During filtration, filtrate volume (V) collected is measured and recorded at various filtration times (t). Filtration time may vary between 45 and 120 minutes. Assay filtrate sample for product concentration. Recovery: Assay buffer flush sample for product concentration and calculate product recovery. Installation check. Calculate filter capacity and initial flux: The filter capacity and the initial flux are generally obtained by fitting the experimental data (V vs. t) to the gradual pore plugging model. (Vmax – see Section 3.1.1.4.) Calculate minimum required filter area: Once the filter capacity and initial flux values are calculated, the minimum required filter area can be calculated from the Vmax model. This value should only be used as a comparative tool for different devices during process optimization studies. The final design filter area will be determined during process simulation and virus validation studies.
Optimization of a virus filtration process involves evaluating the effect of a variety of process parameters to arrive at optimum conditions that would ensure robust, consistent, and scalable operation. Figure 4.24 represents a generic approach to optimization schematically. Some of the key process development parameters that impact process performance are described in more detail below. There are typically three locations within the downstream process train where a normal flow virus filtration step is implemented within a given downstream process. These locations are as follows: following the low-pH inactivation step; following the intermediate chromatographic operation; or after the final chromatography step. Since protein concentration, impurity concentration, and process volumes vary dramatically throughout the downstream process train, it should come as no surprise that the actual filtration requirements are highly dependent upon where in the process the virus filtration step is located. The benefit of increasing filter capacity and flow at lower product concentrations is offset by an increase in process volume. The interplay of these two competing effects can often result in a feed concentration that minimizes required filtration area [51]. An optimum feed concentration may exist that maximizes filtration performance (minimizes filtration area (m2) and maximizes productivity (g/m2/h)). For high concentrations (>10–15 g/L), it may be advantageous to dilute the product to improve filterability. The effect of filtration pressure is often best determined by conducting an excursion study to evaluate filter capacity and flow as a function of pressure. It is customary to evaluate pressure effects in the 10–50 psi range. In general, higher
139
140
4 Membranes in the Biopharmaceutical Industry
Fig. 4.24 General approach to optimization of virus filtration.
operating pressures increase the average process flux and decrease the required filter area [40]. The magnitude of this impact is dependent upon several factors, including feed solution condition, feed concentration, impurity profile, and virus filter. 4.6.3 Capacity
Prefiltration of the feed solution can have a dramatic impact on filter performance. Prefiltration removes various impurities or contaminants such as protein aggregates, DNA and other trace materials. While larger size impurities can be removed by prefiltering with a 0.2mm or 0.1mm rated microporous membrane, smaller
4.6 Practical Aspects of Virus Filtration Process Design and Implementation
impurities such as protein aggregates that may only be marginally larger in size compared to the protein product, are not easily amenable to size-based removal methods. Prefiltration through adsorptive depth filtration has been observed to provide significant protection for certain virus removal filters [52]. The impact of prefiltration can be quite dramatic; with up to 10-fold reductions in required filter area sometimes achievable. As these filters work by nonspecific multimode adsorption, product recovery should be confirmed to ensure good yield. For some protein solutions, the freeze–thaw of a material can have a significant impact on filtration performance. In fact, in some instances, it has been observed that the required filter area is five- to sixfold higher when measured using material that has been previous frozen compared to fresh feed [51]. While the actual purification process may not have a freeze–thaw step, feed samples required for virus validation testing are often conveniently submitted in a frozen form due to material stability/ availability considerations. In such situations, if freeze–thaw is observed to produce an adverse impact of filtration performance, a prefilter is often used to restore performance similar to the unfrozen material. As discussed in Section 3.1.1.4, a gradual pore-plugging model is described by the Vmax model. Filter sizing is impacted by the filter capacity, Vmax, the initial flow rate, Qi, and the batch time, tb. For typical processing times less than 4 hours, a higher flux membrane with a corresponding lower capacity often results in lower filtration area compared to a high-capacity/low-flux filter. For processing times greater than 18 hours, the high-capacity/low-flux filter would result in a process with lower filter area. It should be noted, however, that shorter processing times have the added benefit of allowing for the possibility of in-line processing with other purification steps as well as mitigating potential product stability issues. 4.6.4 Small-Scale Simulation
Once the optimum filtration conditions have been determined, it is recommended that a simulation study be performed. This would initially be performed at the small scale (3.5–14 cm2), then repeated at a larger scale as the process is scaled-up. This would involve running the filtration to the desired end point, which may be a specific filtration time, volume/area ratio, or percent flux decline. One of the outcomes of successful process development is a process that is robust and easy to implement when scaled-up to manufacturing. In order to demonstrate scalability of the process, it is recommended that pilot-scale studies be conducted using devices containing 100–1000 cm2 of filter area. This scale represents a 10–300fold scale-up from the initial simulation studies. 4.6.5 Pilot-Scale Studies
The objectives of the pilot-scale studies are twofold. A first objective is to obtain confirmation that the process parameters (process loading, time, flux or pressure,
141
142
4 Membranes in the Biopharmaceutical Industry
and yield) are with predicted ranges and estimated bounds. Second, the pilot-scale studies are used to obtain information on the entire operation (installation, flushing, sterilization/sanitization, integrity testing, process, product recovery, etc.) so as to enable drafting of SOPs and batch records for cGMP manufacturing. Information obtained during the pilot-scale studies can also be used to establish appropriate performance limits for water permeability (NWP), integrity testing, and other secondary operations related to the virus filtration. 4.6.6 Virus Validation Studies
The purposes of the virus validation studies are to confirm the LRV claims for the filtration step and to verify the filter sizing established in the scale-up phase. These tests are run at a small scale, maintaining critical parameters such as pressure, flux, and loading capacity at their commercial operation values while mimicking other operating procedures such as pre-processing WFI flush-outs and buffer equilibration. The tests are typically run concurrent with the manufacturing-scale consistency/validation batches. Due to the handling and assay requirements for virus studies, the tests are typically conducted at specialized labs. The filter is challenged with representative feedstock containing a virus spike. The concentration of the virus in the feed and the pooled permeate is measured to calculate the LRV. Parallel control assays are run to correct for virus losses due to artifacts such as dilution, concentration, filtration, and storage of samples before titration. Typically, manufacturers will place a lower limit of LRV 3 on the (log) reduction factors that will be combined to yield the overall reduction factor for the manufacturing process. To accurately represent manufacturing settings, the test feedstock must be identical to the commercial-scale feedstock. Shipping or storage constraints may require freezing feedstock, which can result in protein aggregates. Aggregates can cause premature filter plugging that may alter scaling parameters such as loading capacity. The problem can be obviated by either removing aggregates with microfiltration or generating fresh feedstock at the site of the virus spiking study. The viruses used in the spiking studies depend on the specifics of the process and virus contaminants. The regulations recognize ‘‘relevant’’ model viruses that represent endogenous viruses, and nonspecific model viruses to validate ‘‘general viral clearance’’ for adventitious contamination. Murine Leukemia Virus (MuLV) is the generally accepted RVLP model for endogenous virus tests. If use of a relevant virus is not possible, the manufacturer chooses the best specific model virus to serve as a model for the relevant virus. To satisfy the ‘‘general viral clearance’’ objective, the study sponsor will generally evaluate two or three additional viruses. The nonenveloped parvoviruses (20 nm) are often accepted as a worst case for filtration. The test thus comprises a four- or five-virus panel that represents viruses of different genomes (DNA and RNA), sizes and surface properties (enveloped and nonenveloped).
4.6 Practical Aspects of Virus Filtration Process Design and Implementation
Regulatory guidance states that ‘‘the amount of virus added to the starting material for the production step that is to be studied should be as high as possible’’ [52]. However, so as not to unacceptably alter the product composition, the volume of spike should be kept below 10 % and typically below 5 %. The guidance also voices concerns over virus aggregation that could be induced by deliberately concentrating the virus. The use of aggregated virus could lead to underestimation of inactivation effectiveness and overestimation of size-exclusion effectiveness [54]. The common practice is to use size-based prefiltration, such as a 0.22 or 0.45 microporous membrane to remove virus aggregates from a spiked feed stream prior to performing the clearance study. Asahi uses a Planova 35 or 70 as pre-filter. Impurities contained within the virus spike may also foul the membrane, preventing the tests from reaching important scaling parameters such as loading capacity. Methods of generating highly pure virus preparations are increasingly being used to prevent fouling due to spike impurities [55,56]. Minimizing the amount of virus spike used while still being able to reach the desired LRV target is another approach. Virus retention has been observed to decline with fouling for a variety of filters [25,51,55,57,58]. If the virus spike required to achieve the target LRV causes excessive fouling, alternative validation methods may be used to determine LRV at higher throughput values [55]. These alternative methods may be used for validation after consulting with the appropriate regulatory agencies. 4.6.7 Implementation
Once the virus clearance step has been optimized and virus validation studies completed, an implementation strategy is required for robust process operation. After determining the filter capacity (L/m2) required for a process during process simulation/scale-up and virus validation studies, the filter area required for processing a given batch volume can be calculated. Various filter configurations are made available by manufacturers to facilitate large-scale implementation. Normal flow virus filters are operated either in constant pressure mode or in constant flow mode. Typical factors to be considered during large-scale virus filtration system design include the following: Minimum and maximum batch volume. Minimum and maximum flow rate; it is important to consider flow rates during pre- and post-use water flush and for post-use system cleaning/sanitization. Maximum operating pressure and differential pressures across the prefilter and the virus filter. If in-line dilution is needed to maintain constant feed concentration, appropriate dilution and mixing hardware. Minimum and maximum concentration and appropriate instrumentation to span the range.
143
144
4 Membranes in the Biopharmaceutical Industry
Appropriate hardware and connections to enable the filters and the system to be steamed, autoclaved or chemically sanitized. Filter housing configuration – individual filters in parallel or a multifilter housing. System hold-up volume versus validated post-process buffer rinse. Pre- and post-use integrity tests.
In the case of normal flow virus clearance filters, pressure vessels are typically employed for constant pressure operation. However, when very large process volumes are involved, it may be easier to use a pump with a pressure feedback loop to carry out constant pressure filtration. A typical sequence of operations in a virus filtration process includes the following steps, very similar to the protocol used for ultrafiltration process scale-down testing. Filter installation and flushing – typically used to reduce extractables. Follow manufacturer’s directions and validation package. Measurement of NWP – Confirm filter is within established ranges. Sterilization/sanitization – This step must integrate to the downstream processing philosophy of the user. Some virus filters are available pre-sterilized. Consider the Manufacturer’s guidelines for autoclaving/SIP treatment of the virus filter. Pre-use integrity testing. Buffer pre-conditioning. Processing and product recovery. Post-production integrity testing. To ensure that virus clearance is consistent with manufacturer’s claims and results obtained during virus validation studies, filter integrity should be checked both preand post-use. To facilitate this, filter manufacturers have developed a variety of destructive and nondestructive physical integrity tests that are related to virus retention, which were discussed in Section 4.2.5. Ultimately, the objectives of properly designed physical integrity testing are threefold: to confirm that the virus removal filter is properly installed; assurance that the filter is free from gross defects and damage; confirmation that the filter removes viruses consistent with both manufacturers’ specifications and end-user virus validation studies. Filter manufacturers should be able to provide evidence that integrity test methods and acceptance criteria correlate to retention of viruses in the targeted size range under standard conditions. The complexity of integrity testing virus filters should not be overlooked when selecting the virus removal filter for manufacturing. Key integrity test considerations include performance, safety, logistics, validation, and regulatory support [32].
4.7 Membrane Adsorbers
Currently available integrity tests for virus removal filters can generally be classified into three categories [50,59]. The first category is a particle challenge test, the second type is a gas–liquid porosimetry test and the third type is a liquid–liquid porosimetry test. A more detailed summary of the various tests along with troubleshooting techniques can be found in the PDA TR41 [32]. While only nondestructive tests can be used pre-use, either type of test can be used for post-use testing. Nondestructive tests are either gas–liquid or liquid–liquid porosimetry tests. In general, a gas–liquid porosimetry test such as diffusion test or pressure hold test is recommended to complement liquid–liquid porosimetry test or particle challenge test to check for gross defects in the system. Pre-use integrity testing can be performed either before or after sterilization/ sanitization. Post-sterilization integrity tests are particularly useful since they ensure that the filters are not damaged during the sterilization process. However, in an aseptic process, one must maintain system sterility during filter wetting and integrity testing steps. Prior to protein processing, a buffer flush is generally recommended in order to displace WFI with the appropriate buffer. The buffer flush can be carried out using the conditions that are employed during protein filtration (same DP, TMP or filtrate flux). About 10 L of buffer per m2 of filter area is a reasonable volume of buffer. After the buffer flush, the system is ready for protein processing. The protein product should be processed using the process conditions and operating window established during the scale-down optimization studies and virus validation studies. In the case of normal flow filters, protein recovery may be enhanced with a buffer rinse. The buffer rinse can be carried out using the conditions that are employed during protein filtration (same DP or TMP or filtrate flux). Flush volume depends on the upstream volume of the system and desired protein yield. About 10 L/m2 is a reasonable flush volume for a well-engineered system.
4.7 Membrane Adsorbers
Historically, membrane devices have purified products in fluid streams by size-based filtration. More recently, the use of membranes functionalized with specific ligands has started to gain widespread use for the adsorptive purification of biotherapeutics. While bead-based chromatography is widely employed and effective, membrane chromatography has been heralded as a technology potentially suited for large-scale applications due to its ability to integrate capture and purification steps for processing large amounts of product in relatively short times [60]. In bead-based chromatography, most of the available surface area for adsorption is internal to the bead. Consequently, the separation process is inherently slow since the rate of mass transport is controlled by pore diffusion. To minimize this diffusional resistance and concomitantly maximize dynamic binding capacity, small diameter beads can be employed. However, the use of small diameter beads comes at the price of increased column pressure drop. Consequently, the optimization of preparative
145
146
4 Membranes in the Biopharmaceutical Industry
chromatographic separations often involves a compromise between efficiency/ dynamic capacity (small beads favored) and column pressure drop (large beads favored). In contrast, membrane-based chromatographic systems (also called membrane adsorbers), have the ligands attached directly to the convective membrane pores, thereby eliminating the effects of internal pore diffusion on mass transport. Additionally, the use of microporous membrane substrates with a tight membrane pore size distribution coupled with effective flow distributors can minimize axial dispersion and provide uniform utilization of all active sites [61,62]. Consequently, mass transfer rates of membrane adsorber media may be an order of magnitude greater than that of standard bead-based chromatography media [62], allowing for both high efficiency and high-flux separations. Since single or even-stacked membranes are very thin compared to columns packed with bead-based media, reduced pressure drops are found along the chromatographic bed, thus allowing increased flow rates and productivities. The necessary binding capacity is reached by using membranes of sufficient internal surface area, yielding device configurations of very large diameter to height ratios (d/h) [60]. Properly designed membrane adsorbers have chromatographic efficiencies that are 10–100 better than standard preparative bead-based resins. Consequently, to achieve the same level of separation on a membrane adsorber, a bed height 10-fold less can be utilized. Bed lengths of 1–5 mm are standard for membrane adsorbers, compared to bed heights of 10–30 cm for bead-based systems. Due to the extreme column aspect ratios required for large-volume membrane adsorbers, device design is critical. To maintain the inherent performance advantages associated with membrane adsorbers, proper inlet and outlet distributors are required to efficiently and effectively utilize the available membrane volume. 4.7.1 Membrane Chemistries
Membrane adsorbers are commercially available in a variety of chemistries ranging from standard ion-exchange chemistries (strong and weak anion and cation exchangers) to hydrophobic interaction chemistries, reversed phase chemistries, and affinity chemistries [61]. Membrane adsorber devices are traditionally available as single sheets, stacked disks, radial flow systems, pleated devices, or hollow fibers [62]. Device sizes range from small-volume devices containing <1 mL for scouting experiments and method development to devices containing several liters of media for large-scale preparative separations. Table 4.7 summarizes the currently commercially available membrane adsorber products. Sartorius’s Sartobind family of single-use disposable membrane adsorbers comprises 15 layers of a nominal 3mm cellulosic membrane [23]. Small-scale devices designed for method development employ a syringe filter format with a bed volume of approximately 2.1 mL. Larger manufacturing scale devices employ a radial flow cartridge with membrane volumes ranging from 7 mL up to 540 mL. Sartorius also has a family of multiple-use membrane chromatography radial flow
4.7 Membrane Adsorbers Tab. 4.7
Commercially available membrane adsorbers.
Company
Membrane
Available chemistries
Small-scale device
Large-scale device
Sartorius AG Nominal 3 mm (www.sartorius.com) cellulosic Pall Corporation (www.pall.com)
Ion-exchange 15-layer stack 15-layer affinity activated (2.1 mL) radial flow specialized (7–2100 mL) Nominal 0.8 nm Ion-exchange 16-layer stack 16-layer pleated polyethersulfone (0.35 mL) capsule (5–5000 mL)
units with device volumes ranging from several milliliter to 2100 mL. These devices can also be run in series or parallel to achieve the necessary performance. Pall’s Mustang family of disposable membrane adsorbers comprises 16 layers of a nominal 0.8mm polyethersulfone membrane [22]. For method development, small 16-layer coins (0.35 mL bed volume) contained in a stainless-steel housing are available. Manufacturing scale devices comprise a 16-layer pleated capsule with membrane volumes ranging from 5 mL to 5000 mL. To process even larger volumes of fluid, these devices can also be configured in series. Although Sartorius AG and Pall Corporation are currently the only two companies with commercially available membrane adsorbers, due to the relative infancy of membrane adsorber technology, we can expect new competitors and new technologies to continuously emerge. 4.7.2 Current Applications
Early work in the area of membrane chromatography was primarily focused on the bind–elute purification of various proteins [62–66]. However, recent advances in the theoretical and experimental understanding of the performance of membrane chromatography has helped to focus the current applications of membrane adsorbers to primarily two areas – flow-through applications aimed at removing trace impurities and bind–elute purification of extremely large molecules essentially excluded from the internal pore structure of commercially available beadbased resins. Examples of flow-through applications include polishing applications aimed at removing low levels of nucleic acid, host cell protein, endotoxin, virus, and product aggregates and pre-capture applications aimed at removing impurities that either foul the Protein A column or create product stability issues upon product elution. Examples of large-molecule bind–elute purification include gene therapy vectors such as viral vectors and plasmids, as well as extremely large protein molecules. 4.7.2.1 Flow-Through Polishing Due to the lower binding capacity of membrane adsorbers compared to bead-based resins, universal adoption of membrane adsorber technology has been slow, even
147
148
4 Membranes in the Biopharmaceutical Industry
though the high flux advantages provided by membrane adsorbers would lead to higher productivity [67]. For trace-impurity removal applications, adsorptive capacity is not a significant limitation. Rather, the adsorptive binding capacity of bead-based columns used in this application are typically three to four orders of magnitude larger than required since the columns are normally sized to achieve a desired flow rate (i.e., the process is throughput limited). Since membrane-based systems have a distinct flow rate advantage and sufficient capacity for binding trace levels of impurities and contaminants, membrane adsorbers are ideally suited for this application. Flow-through anion-exchange membrane adsorbers have proven to be an extremely powerful polishing step designed to remove trace impurities from monoclonal antibodies solutions. Under neutral pH conditions, many viruses, nucleic acids, endotoxins, and host cell proteins are negatively charged and will bind strongly to an anion-exchange membrane. In contrast, many monoclonal antibodies are typically basic in nature (pI value >7), and, as such, will not interact with an anion-exchange membrane adsorber. This difference in charge has been successfully exploited to effect the separation of various trace impurities from monoclonal antibodies [68–70]. Reported LRVs for endotoxin (4 LRV), nucleic acids (6 LRV), and several mammalian viruses (2–6 LRV) are consistent with those obtained with standard bead-based resins. To highlight the performance advantages of membrane adsorbers, Phillips et al. has shown that for efficiently designed membrane adsorbers, 6 LRV clearance of virus can be achieved at residence times less than 0.4 seconds [69]. Residence times on the order of several minutes are typically required to achieve this degree of separation with bead-based chromatographic systems. Zhou et al. [70] have conducted an economic analysis and concluded that singleuse disposable membrane adsorbers can be an economically viable alternative to standard bead-based separations. Although the cost of single-use membrane adsorber media is typically higher than bead-based media that is reused for hundreds of cycles, the use of membrane adsorbers often result in lower hardware costs, significantly lower buffer usage, and savings in validation studies (column packing, column reuse). Primarily due to savings in buffer, Zhou et al. conclude that membrane adsorber technology is economically preferred. 4.7.2.2 Flow-Through Precapture Protein A column chromatography is routinely used for the capture and purification of monoclonal antibodies from cell culture harvest streams. Product elution from Protein A columns is generally done at low-pH conditions where the possibility of coeluted impurities precipitating is real. The consequences of this precipitation may include clogging of downstream sterilizing-grade filters and fouling of the Protein A column, both of which are detrimental to the robustness and process economics of the downstream purification. Adsorptive-based removal of these impurities prior to Protein A column chromatography has been shown to minimize the possibility of precipitation during product elution. Shukla et al. [71] have exploited the adsorptive properties of depth filters and
4.7 Membrane Adsorbers
anion-exchange resins prior to Protein A capture chromatography to minimize the extent of precipitation. Lepore et al. [72] have shown that the use of anion-exchange membrane adsorbers also work well for this application, with significantly higher loadings compared to standard bead-based resins. Lepore et al. also conducted an economic analysis indicating that the use of membrane adsorbers is economically advantageous. 4.7.2.3 Large Molecule Bind–Elute Purification For very large molecules, bead-based chromatography resins have been shown to display very low dynamic capacities that decrease significantly with increasing linear velocity [73]. The low dynamic binding capacities are mostly attributable to the inaccessibility of the resin pores to the larger molecules. The dynamic capacity for membrane adsorbers has been shown to be both significantly larger than highly porous bead-based resins and essentially independent of flow velocity. These qualities make membrane adsorbers ideally suited for the purification of very large molecules. The purification of plasmids and viral vectors for gene therapy applications are uniquely suited to take advantage of the properties of membrane adsorbers. Pora [74] describes the use of a Q membrane adsorber for the capture and purification of plasmids. Using a 260 mL membrane adsorber, approximately 71 L of clarified lysate containing 1.5 g pDNA was processed. The step yield was approximately 95 % and the total cycle time was 24 minutes. The use of bead-based resins most likely would have required significantly higher bed volumes and much higher cycle times to effect this separation. Han et al. have successfully used various ion-exchange membranes for the adsorption of Aedes aegypti densonucleosis virus (a mosquito specific parvovirus with pI around 5.6) [75]). They conclude that membrane adsorbers may be ideally suited for virus capture since nearly all of the ligands are available for interaction. 4.7.3 Future Trends
Membrane adsorbers will continue to find niche markets that are capable of exploiting the inherent advantages of membrane chromatography compared to bead chromatography – namely high efficiency due to minimal mass transfer effects (fast separations), large external surface areas (high-binding capacities for very large molecules currently excluded from the porous structure of bead-based resins), and pre-packed disposable devices (ease-of-use considerations). Anion-exchange membrane adsorbers have been successfully employed for the efficient removal of several impurities from monoclonal antibody streams. Other applications that require the removal of trace level of impurities from a product stream can obviously exploit the advantages of membrane chromatography. To effect these separations, however, may require the development of novel membrane chemistries capable of achieving the desired selectivity between the impurity and product molecule. It is quite likely that new membrane adsorber chemistries will be developed as these new polishing applications are identified.
149
150
4 Membranes in the Biopharmaceutical Industry
Currently, one of the most visible trends in biotechnology manufacturing is disposability. As entire downstream purification trains begin to migrate toward complete disposability, membrane chromatography begins to play a more important role. Although complete disposability may never be a reality on the manufacturing scale, the flexibility and rapid change-out capabilities associated with disposable manufacturing may be ideally suited for early phase manufacturing of clinical product and contract manufacturing organizations. Additionally, disposable manufacturing may be a requirement in the area of personalized medicines where minuscule batches are manufactured for the treatment of a single patient. In these instances, membrane chromatography would play a critical role in the purification of these products. Finally, a focus on membrane adsorber device configuration could have an important effect on the future of membrane chromatography. Historically, membrane adsorbers were incorporated into traditional filter configurations. Although this was fine for polishing applications, the flow distribution and hold-up volumes were not properly designed to make membrane adsorbers competitive in the bind– elute purification markets. Improvements in these areas could significantly increase the potential markets available for membrane chromatography.
References 1 Zsigmondy, R. and Bachman, R.
2 3
4
5
6
7
8
Filter and method of producing same. US Patent 1,421,341. Wrasidlo, W. J. Asymmetric membranes. US Patent 4,629,563. Kraus, M. et al. Filtration membranes and method of making same. US Patent 4,900,449. Roesink, H. D. W. et al. Process for the preparation of hydrophilic membranes and such membranes. US Patent 4,798,847. Walch, A. et al. Microporous asymmetrical hydrophilic membrane made of a synthetic polymer. US Patent 4,720,343. Sasaki, J. et al. Asymmetric microporous membrane containing a layer of minimum pores below the surface thereof. US Patent 4,933,081. Ulbricht, M. (2006) Advanced functional polymer membranes. Polymer, 47, 2217–2262. Guidance for Industry Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, U.S.
9
10
11
12
13
Department of Health and Human Services, Food and Drug Administration September 2004. FDA report. Pharmaceutical cGMPs for the 21st Century – a risk based approach, final report, September 2004 (www.fda.goc/cder/gmp/ gmp2004/GMP_final report2004.htm). Blanchard, M. (2007) Quantifying sterile membrane retention performance. BioProcess International 5 (5) 44–51. Ho, C. and Zydney, A. L. (2000) A combined pore blockage and cake filtration model for protein fouling during microfiltration. Journal of Colloid and Interface Science, 232 (2), 389–399. Bolton, G.,La Casse, D., Kuriyel, R. (2006) Combined models of membrane fouling: development and application to microporous and ultrafiltration membranes. Journal of Membrane Science, 277 (1-2), 75–84. Pitt, A. M. (March 1987) The Nonspecific Protein binding of
References
14
15
16
17
18
19
20
21 22
23 24
25
Polymeric Microporous Membranes. Journal of Parenteral Science and Technology. Bin, T., McCrosky, L., Kulshreshtha, A. K., Hem, S. L. (2000) Adsorption of esters of p-hydroxybenzoic acid by filter membranes: mechanism and effect of formulation and processing parameters. Pharmaceutical Development and Technology, 5 (1), 95–104. ANSI/AAMI/ISO 11137–1994/5, Sterilization of health care products – Requirements for validation and routine control – Radiation sterilization. PDA Technical Report No. 26 – Sterilizing Filtration of Liquids, 1998. Scott, F. E. (1989) Principles of integrity testing hydrophilic microporous membrane filters, parts 1 and 2. Pharm. Tech. Badmington, F., Wilkins, R., Payne, M., Honig, E. S. (1995) Vmax testing for practical microfiltration train scale-up in biopharmaceutical processing. BioPharm, 8 (7). Ghosh, R. (2003) Protein Bioseparation Using Ultrafiltration: Theory, Applications and New Developments, Imperial College Press, London. http://www1.amershambiosciences. com/APTRIX/upp00919.nsf/content/ ProteinConc_HomePage. http://www.millipore.com/ eHandbook.nsf/docs/ufhome. http://www.pall.com/ datasheet_biopharm_ 33901.asp. http://www.sartorius.com/ index.php?id=845. Tkacik, G. and Michaels, S. (1991) A rejection profile test for ultrafiltration membranes and devices. Bio/ Technology, 9, 941. Carter, J. and Lutz, H. (2002) An overview of viral filtration in biopharmaceutical manufacturing. European Journal of Parenteral Science, 7 (3), 72–78.
26 http://www.asahi-kasei.co.jp/planova/
en/product/filters.html. 27 http://www.millipore.com/markets/
28
29 30 31
32
33
34
35
36
37
bioprocess.nsf/docs/ viresolveselector. http://www.pall.com/datasheet_ biopharm_28637.asp?sectionid= description. http://www.sartorius.com/ index.php?id=2284. DiLeo, A. J. et al. (1992) Biotechnology, 10, 182–188. Hongo-Hirasaki, T., Yamaguchi, K., Yanagida, K., Okuyama, K. (2006) Removal of small viruses (parvovirus) from IgG solution by virus removal filter Planova 20N’. Journal of Membrane Science, 278, 3. PDA Technical Report 41. (March 2005) Virus Filtration, 59(2), Parenteral Drug Association. Aranha-Creado, H. and Brandwein, H. (1999) Application of bacteriophages as surrogates for mammalian viruses: a case for use in filter validation based on precedents and current practices in medical and environmental virology. PDA Journal of Pharamaceutical Science and Technology, 53 (2), 75–82. Tsurumi, T., Osawa, N., Hirasaki, T., Yamaguchi, K., Manabe, S., Yamashiki, T. (1990) Mechanism of removing monodisperse gold particles from a suspension using cuprammonium regenerated cellulose hollow fiber (BMM hollow fiber). Polymer Journal, 22, 303–311. Gadam, S., Phillips, M., Orlando, S., Kuriyel, R., Pearl, S., Zydney, A. (1997) A liquid porosimetry technique for correlating intrinsic protein sieving: Applications in ultrafiltration processes. Journal of Membrane Science, 133, 111–125. Cheryan, M. (1986) Ultrafiltration Handbook, Technomic PublishingCompany Inc, Pennsylvania. Zeman, L. J. and Zydney, A. L. (1996) Microfiltration and Ultrafiltration: Principles and Applications, Marcel Dekker, New York.
151
152
4 Membranes in the Biopharmaceutical Industry 38 Millipore Corporation (1999) Protein
39
40
41
42
43
44
45
46
47
48
Concentration and Diafiltration by Tangential Flow Filtration. Lit No TB032 Rev. B. Ho, W. S. W. and Sirkar, K. K. (1992) Membrane Handbook, Van Nostrand Reinhold, New York. Eykamp, W. (1997) Section 22 membrane separation processes, In: Perry, R. H. and Green, D. W. (Eds), Perry’s Chemical Engineers’ Handbook, 7th edn , McGraw-Hill, New York. van Reis, R., Goodrich, E. M., Yson, C. L., Frautschy, L. N., Whiteley, R., Zydney, A. L. (1997) Constant Cwall Ultrafiltration Process Control. Journal of Membrane Science, 130, 123–140. Vilker, V. L. C., Colton, C. K., Smith, K. A., Green, D. L. (1984) The osmotic pressure of concentrated protein and lipoprotein solutions and its significance to ultrafiltration. Journal of Membrane Science, 20, 63– 77. Vilker, V. L., Colton, C. K., Smith, K. A. (1984) Concentration polarization in protein ultrafiltration. Part I: An optical shadowgraph technique for measuring concentration profiles near a membrane–solution interface. AIChE Journal, 27, 632–637. Ng, P., Lundblad, L., Mitra, G. (1976) Optimization of solute separation by diafiltration. Separation Science, 2, 499–502. van Reis, R., Goodrich, E. M., Yson, C. L., Frautschy, L. N., Dzengeleski, S., Lutz, H. (1997) Linear scale ultrafiltration. Biotechnology and Bioengineering, 55, 737–746. Millipore Corporation. (2000) Techniques for Demonstrating Cleaning Effectiveness of Ultrafiltration Membranes. Lit No TB1502EN00. Petrone, J., Erdenberger, T., Esenther, C. (2003) Process Validation for Monitoring the Performance of Reusable Tangential Flow Filtration Membrane Devices. ACS Annual Meeting New Orleans, LA. FDA (1994) Draft points to consider (PTC) in the manufacture and
49 50
51
52
53
54
55
56
57
testing of monoclonal antibody products for human use. CBER. PDA. PDA Technical Report No. 41 Virus Filtration 2005. Levy, R. V., Phillips, M. W., Lutz, H. (1998) Filtration and the removal of viruses from biopharmaceuticals, In: Meltzer, T. H.Jornitz, M. W. (Ed.), Filtration in the Biopharmaceutical Industry, Marcel Dekker, 619–646. Ireland, T., Lutz, H., Siwak, M., Bolton, G. (2004) Viral filtration of plasma-derived human IgG. Biopharm International, 17 (11), 38– 44. Siwak, M. (2003) Process for prefiltration of a protein solution. US Patent US20,030,201,229 A1. Lutz, H. (1997) Membrane filtration with optimized addition of second liquid to maximize flux. US Patent 5,597,486. Brorson, K., Krejci, S., Lee, K., Hamilton, E., Stein, K., Xu, Y. (2003) Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnology and Bioengineering, 82 (3), 321–329. Bolton, G., Cabatingan, M., Rubino, M.,Lute, S., Brorson, K., Bailey, M. (2005) Normal flow virus filtration: detection and assessment of endpoint in bioprocessing. Biotechnology and Applied Biochemistry, 42, 133–142. Previsani, N., Fontana, S., Hirt, B., Beard, P. (1997) Growth of the parvovirus Minute Virus of Mice MVMp3 in EL4 lymphocytes is restricted after cell entry and before viral DNA amplification: cell-specific differences in virus uncoating in vitro. Journal of Virology, 71 (10), 7769–7780. Hirasaki, T., Noda, T., Nakano, H., Ishizaki, T., Manabe, S., Yamamoto, N. (1994) Mechanisms of removing Japanese Encephalitis Virus (JEV) and gold particles using cuprammonium regenerated cellulose hollow fiber (i-BMM or BMM) from aqueous solution
References
58
59
60
61
62
63
64
65
66
containing protein. Polymer Journal, 26 (11), 1244–1256. Omar, A. and Kempf, C. (2002) Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion, 42 (8), 1005–1010. Phillips, M. W. (1996) Integrity testing virus-retentive membranes, Proceedings from the PDA Fourth International Congress, Vienna, Austria. Thommes, J. and Kula, M. R. (1995) Membrane chromatography – an integrative concept in the downstream processing of proteins. Biotechnology Progress, 11, 357–367. Deshmukh, R. R., Warner, T. N., Hutchison, F., Murphy, M., Leitch, W. E., De Leon, P., Srivatsa, G. S., Cole, D. L., Sanghvi, Y. S., (2000) Large-scale purification of antisense oligonucleotides by highperformance membrane adsorber chromatography, J. Chromatogr. A, 890, 179–192. Ghosh, R. (2002) Protein separation using membrane chromatography: opportunities and challenges. Journal of Chromatography A, 952, 13–27. Frey, D. D., Water, R. V., Zhang, B. (1992) Dispersion in stackedmembrane chromatography. Journal of Chromatography A, 603, 43–47. Finger, U. B., Thommes, J., Kinzelt, D., Kula, M. R. (1995) Application of thiophilic membranes for the purification of monoclonal antibodies from cell culture media. Journal of Chromatography B, 664, 69–78. Roper, D. K. and Lightfoot, E. N. (1995) Separation of biomolecules using adsorptive membranes. Journal of Chromatography A, 702, 3–26. Charcosset, C. (1999) Purification of proteins by membrane chromatography. Journal of Chemical Technology and Biotechnology, 71, 95–110.
67 Tennikova, T. B., Belenkii, B. G.,
68
69
70
71
72
73
74
75
Svec, F. (1990) High performance membrane chromatography. A novel method of protein separation. Journal of Liquid Chromatography, 13, 63–70. Knudsen, H. L., Fahrner, R. L., Xu, Y., Norling, L. A., Blank, G. S. (2001) Membrane ion-exchange chromatography for process-scale antibody purification. Journal of Chromatography A, 907, 145–154. Phillips, M., Cormier, J., Ferrence, J., Dowd, C., Kiss, R., Lutz, H., Carter, J., (2005) Performance of a membrane adsorber for trace impurity removal in biotechnology manufacturing. Journal of Chromatography A, 1078 74–82. Zhou, J. X. and Tressel, T. (2006) Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnology Progress, 22, 341–349. Yigzaw, Y., Piper, R., Tran, M., Shukla, A. (2006) Exploitation of the adsorptive properties of depth filters for host cell protein removal during monoclonal antibody purification. Biotechnology Progress, 22, 288–296. Lepore, J., Polilli, B., Gill, D., Liu, C. L. Capaldi, M., Magill, A., Wang, J., Miao, F. (2006) Clarification of cell culture harvest utilizing membrane chromatography, Recovery of Biological Products XII. Litchfield, Arizona. Yang, H., Viera, C., Fischer, J., Etzel, M. R. (2002) Purification of a large protein using ion-exchange membranes. Industrial and Engineering Chemistry Research, 41, 1597–1602. Pora, H. (2005) Efficient plasmid purification strategies. Genetic Engineering News, 25, 48–50. Han, B., Specht, R., Ranil Wickramasinghe, S., Carlson, J. O. (2005) Binding Aedes aegypti densonucleosis virus to ion exchange membranes. Journal of Chromatography A, 1092, 114–124.
153
155
5 Membrane Applications in Red and White Biotechnology Stephan Lu¨tz, Nagaraj Rao 5.1 Introduction
In living systems, membranes and membrane processes play a crucial role in the survival, growth, metabolism, defense, and reproduction processes. As our understanding of the role played by membranes gradually increases, the development of new application areas becomes a logical consequence. Several of these newer areas have been covered in other chapters of this book. In this chapter, we will focus on the application of membranes in red and white biotechnology. ‘‘Red’’ biotechnology refers to medical applications of biotechnology, starting from diagnostics and ending with therapy. It also covers the biotechnological production of pharmaceuticals and diagnostics. ‘‘White’’ biotechnology, by definition, is the application of nature’s toolset to industrial production. Membranes are made up of natural materials (such as tissues) or synthetic materials (such as certain polymers). They are permeable to certain substrates in solution. The movement of molecules across a membrane is regulated in both directions, giving the membrane its unique properties and wide applicability. In Figure 5.1, commonly used filtration processes in biotechnology and the retention properties of membranes are shown. In reverse osmosis, particles, macromolecules, and low molecular mass compounds such as salts and sugars are separated from a solvent, usually water. The feed solution often has high osmotic pressure, and this must be overcome by the hydrostatic pressure applied as the driving force. Thus, microfiltration, ultrafiltration, nanofiltration, and reverse osmosis differ from each other in the size of the particles being separated. Interestingly, membrane processes are finding application in biotechnology at practically every stage of production [1–3]. This includes sterile dosage of substrates into the bioreactor, bubble-free aeration, and retention of biocatalysts using a variety of techniques, as well as product concentration and recovery based on different unit operations. These membrane processes are shown schematically in Figure 5.2.
Membranes for the Life Sciences. Edited by Klaus-Viktor Peinemann and Suzana Pereira Nunes Copyright ß 2008 WILEY-VCH Verlag GmbH & Co. KGaA. All rights reserved ISBN: 978-3-527-31480-5
156
5 Membrane Applications in Red and White Biotechnology
Fig. 5.1 Types of filtration and retention properties of membranes.
5.2 Types of Membrane Processes in Red and White Biotechnology 5.2.1 Bubble-Free Aeration
In the case of biotransformations where aeration is required for the supply of oxygen, gas sparging is the preferred method because of the large mass-transfer rates and operational simplicity. However, gas sparging can damage cultured animal cells, since they are more sensitive to shear stress caused by vigorous mixing and gas sparging. In such cases, bubble-free aeration is achieved by the use of silicon membrane tubing, which allows the gas to diffuse into the medium without the
Fig. 5.2 Schematic representation of membrane processes used in biotechnology.
5.2 Types of Membrane Processes in Red and White Biotechnology
formation of bubbles. Another advantage of such tubing is the fact that its permeability for carbon dioxide is greater than that for oxygen, because of which there is no accumulation of carbon dioxide in the medium. 5.2.2 Filtration Processes
In the case of membrane processes using filtration techniques, the pore size of the membranes plays a deciding factor in contributing to the efficiency of the process. With the advent of membranes with fairly well-defined pore sizes, it is now possible to carry out separation processes for the retention of biocatalysts, cofactors, salts, and solvents. The importance of biocatalyst retention on the economics of a biotransformation can be judged from Figure 5.3. When the retention factor R is only 95 %, there is a rapid decrease in the relative concentration of the biocatalyst over a certain number of residence times. When the retention factor is greater than 99.99 %, there is no significant loss in the biocatalyst concentration in the reactor, and a very large number of residence times can be achieved in the continuous biotransformation process. 5.2.3 Dialysis and Electrodialysis
In the case of dialysis, one or more solutes are transferred from one solution, called the ‘‘feed,’’ to another solution, called the ‘‘dialysate,’’ through a membrane down their concentration gradient. When pressure is employed besides the concentration gradient for separation, the process is called pervaporation.
Fig. 5.3 Importance of high retention of biocatalyst on membranes.
157
158
5 Membrane Applications in Red and White Biotechnology
In electrodialysis, the separation of components of an ionic solution occurs in a cell consisting of a series of anion- and cation-exchange membranes. These are arranged in an alternate manner between an anode and a cathode to form individual electrodialysis cells. During the process of electrodialysis, there is an increase in the ion concentration of one type in one type of compartment and is accompanied by a simultaneous decrease in the concentration in the other type of compartment. 5.2.4 Adsorption of Microorganisms
In adsorption, material accumulates on the surface of a solid adsorbent having a multiplicity of pores of different sizes. Adsorption is a common operation employed for the purification of biological products. Various physical, chemical, or physicochemical forces may be involved in the adsorption phenomenon. Activated carbon and ion-exchange resins may be used, depending on the nature of the material to be adsorbed. In ion-exchange adsorption, the adsorbents have ionic groups with easily dissociable counter-ions. In affinity adsorption, proteins may be absorbed biospecifically on the basis of their interaction with a complimentary tertiary structure. Microorganisms and enzymes are also adsorbed onto inert surfaces in order to carry out biotransformations.
5.3 Examples of Membrane Processes in Biotechnology 5.3.1 Bubble-Free Gassing 5.3.1.1 Hydrogen Several naturally occurring enzymes use hydrogen as a substrate. For example, the hydrogenase I obtained from the hyperthermophilic archaeon Pyrococcus furiosus (PfH2ase), a microorganism found in the Volcano regions of Italy, can split hydrogen heterolytically and catalyze regio- and enantioselective hydrogenation. The limiting factors for this process are the solubility of hydrogen and the hydrogen transfer rate. In nature, the solubility of a gas is increased by an enormous increase in the membrane surface, as exemplified by the bronchi, bronchioles, and alveoli of the lungs. Based on these principles, polymeric membranes are employed to introduce a gas into a bioreactor. The polymeric membrane functions as a gas distributor and is able to control the gas–liquid interface area and the mass-transfer coefficient independently of each other [4]. The pressure can also be divided into two partial pressures, one for the gas phase and one for the liquid phase. For the regeneration of cofactors, sources of hydrogen that have been studied in biotransformations include alcohols such as isopropanol, sugars such as glucose6-sulfate, formate, and molecular hydrogen. Continuous cofactor reduction using biotransformations with molecular hydrogen as the source of the reducing agent is
5.3 Examples of Membrane Processes in Biotechnology
Fig. 5.4 Bubble-free H2-aeration in an enzyme membrane reactor for continuous reduction of cofactor NADPþ.
possible when the biocatalyst accepts hydrogen as a substrate. The enzyme PfH2ase has been used in batch and continuous experiments in order to reduce the cofactor NADP+ to NADPH (Figure 5.4) [5,6]. Mertens et al. have described the potential applications of PfH2ase and similar hydrogen-activating hydrogenases for the production of NADPH, biosensors, and biofuel cells [7]. 5.3.1.2 Oxygen The bubble-free introduction of oxygen into a bioreactor is usually done with the help of silicone tubings that pass through the bioreactor. Mammalian cells have been immobilized on macroporous carriers made from small glass beads of up to 0.7 mm diameter. These are then suspended and cultivated in a continuously operated fluidized bed reactor. The introduction of oxygen occurs via a silicone tube that passes through the reactor (Figure 5.5). As a result, the entire length of the fluidized bed reactor is provided with oxygen, irrespective of the axial position of the reactor. Depending on the oxygen transfer rate and the oxygen consumption rate, the length of the tube is calculated. Efficient mixing of the gas in the liquid helps in reducing the radial oxygen gradient. Maximum cell densities of up to 3.3–50 107 cells/mL have been achieved using this principle. Pharmaceutically important proteins, including antibodies and immunoglobulins, can be manufactured using this method [8,9]. The cultivation of CHO-2DS cell lines in a protein-free medium with bubble-free aeration, accompanied by improved cell growth and better production of human prothrombin, has been reported. [10]. Bubble-free aeration was found to be advantageous. BHK-21 cells have been fermented on a technical scale in protein-free culture media in a membrane-airlift bioreactor [11]. The production of recombinant human interleukin 2 was studied both with and without bubble-free aeration. By modifying the SM1F7 culture medium by addition of the surfactant Pluronic F-68 (BASF), the tolerance of the cells toward hydrodynamic stress was increased. The defoamer did
159
160
5 Membrane Applications in Red and White Biotechnology
Fig. 5.5 Bubble-free introduction of oxygen through a silicone tube for cell culture.
not adversely affect the cultivation. The cultivation of the BHK-21 cells could be carried out on a 1000-L scale without bubble-free aeration. This implies that a decision has to be taken on a case-to-case basis if bubble-free aeration is a must or not. The human tumor antigen and type I transmembrane protein Mucin MUC1 plays an important role in the diagnosis of cancer cells. A continuous perfusion culture process by the fermentation of CHO-K1 cells, using bubble-free oxygenation, has been developed [12] . The optimum pO2 value was found to be at 40 % air saturation. The cell activity could be maintained at a level above 85 %. A space–time yield (STY) of 100 mg/L/day could be achieved for MUC1-IgG2a. The CHO-K1 cells could be transferred into the serumfree suspension culture with the help of the ProCHO4-CDM medium. Studies on the control of bubble size, which has a direct bearing on the performance of mammalian cells, have been carried out by Nehring et al. [13]. Keeping the bubble size small releases lesser energy when the bubbles are burst. Microbubbles with 100–500 mm diameter can be generated in an aqueous media by using specially designed hydrophilic materials such as porous ceramics. The ceramic gas bubbling system consisted of a porous ceramic pipe filled with titanium dioxide and fixed on to a steel structure. An early bubble-free reactor for the cultivation of mammalian cells has been described by Schulze and Stahl [14]. This has been modified for use in the cultivation of the phototropic microalgae Scenedesmus communis by Gorenflo et al. Light energy was provided to the microorganisms by fitting the bioreactor with a new system of irradiation of light. A cylinder made of stainless steel mesh was designed. The pore size was twice the size of the cells (10 mm in diameter). As a result, the cells were retained outside the cylinder and internal aeration was found to be optimal [15]. Bubble-free aeration often helps in stabilizing the biocatalyst. The extracellular laccase of the white-rot fungus Pyconporus cinnabarinus (DSM 15225) was immobilized on DEAE-Sephadex after cultivation. The bubbling of oxygen through a silicone
5.3 Examples of Membrane Processes in Biotechnology
tube in the enzyme membrane reactor used to carry out the biotransformation stabilized the enzyme in continuously run experiments [16]. 5.3.2 Membranes for Cell Retention 5.3.2.1 Higher Cells/Red Biotechnology The fermentation of higher cells, such as hematopoietic stem cells, poses more challenges than the cultivation of fungi and bacteria. This is because of the unique requirements of the higher cells, including sensitivity to shear stress and the nature of cell division. In an interesting study exploiting the physical characteristics of cells and imitating the naturally occurring hematopoietic microenvironment, Meissner et al. have shown that it is possible to replicate bone marrow stromal cells by a three-dimensional cocultivation in porous microcarriers in a fixed-bed reactor [17]. A membraneseparated cocultivation method for the separation of hematopoietic and stromal cells was employed, instead of a conventional coculture in microcarriers. During the cocultivation, the two types of cells were separated with the help of a porous membrane. The membrane pore size allowed the diffusion of the secreting stromal growth factors as well as an intercellular contact through the membrane (Figure 5.6). As a result, various degrees of expansion were observed for different colonyforming and burst-forming cells. For very early progenitor cells (CFU-GEMM) and later progenitor cells (CFU-GM and BFU-E), expansion degrees of 4.2-fold, 7-fold, and 1.8-fold were observed. Using similar principles, cultivation of progenitor cells (colony-forming cells, CFC, and cobblestone area forming cells, CAFC) was found to be more efficient. The population of the CAFCs, for example, could be increased 39 times in the membrane method described above, while only a sevenfold increase was observed in the suspension cultures [18]. The production of IgG2a monoclonal antibodies by hybridoma cells has been carried out using a perfusion culture system along with a ceramic membrane module. In this so-called stirred ceramic membrane reactor system, consisting of 10 vertical, cylindrical tubes with an active surface area of 400 cm2, the volumetric productivity increased sevenfold [19].
Fig. 5.6 Membrane-separated cocultivation of hematopoietic and stromal cells.
161
162
5 Membrane Applications in Red and White Biotechnology
5.3.2.2 Whole-Cell Biotransformation With the advent of simpler genetic engineering techniques, ‘‘tailor-made’’ microorganisms (so-called ‘‘designer bugs’’) are now being increasingly developed for specific biotransformations. Ernst et al. have expressed a regio- and enantioselective (R)-alcohol dehydrogenase from Lactobacillus brevis and a formate dehydrogenase from Mycobacterium vaccae N10 into Escherichia coli. This functional overexpression enabled the reduction of keto compounds into hydroxy compounds, for example, the reduction of methyl acetoacetate to (R)-3-hydroxybutanoate [20]. The specific cell productivity could be significantly improved by the introduction of a recombinant cofactor regeneration system in the whole-cell biocatalyst. No byproduct formation was observed, in addition. Current trends indicate that such ‘‘designer bugs’’ will be increasingly used in biotransformations. The retention of microorganisms on membranes during biotransformation has been utilized to manufacture chiral diol, (2R,5R)-hexanediol. In this process, resting cells of Lactobacillus kefiri DSM 20587 were retained over an ultrafiltration membrane with a molecular weight cut-off (MWCO) of 400 kDa. The reduction of the diol was carried out at 30 8C under anaerobic conditions (Figure 5.7). The selectivity for the diol was 78 % and the enantio- and diastereoselectivity were found to be 99 %. A space–time yield of 64 g/L/day was achieved. Due to the high selectivity of the process, downstream processing and product purification became much simpler [21]. By using genetically modified E. coli coexpressing genes of LbDH and FDH from M. vaccae, (R)-methyl-3-hydroxybutanoate with an enantiomeric excess of >99 % was obtained, starting from methyl acetoacetate in this whole-cell biotransformation. Reaction engineering enabled the lowest biocatalyst consumption in a continuous reactor (0.9 gWCW/g). In comparative studies with enzyme-coupled systems, it was concluded that reaction engineering techniques allow lower biocatalyst consumption in whole-cell bioreductions. Whole-cell immobilization further reduced the biocatalyst consumption [22]. In an unusual application, whole cells of Pseudomonas putida type A1 were retained in a hollow-fiber membrane reactor in order to degrade gas-phase toluene biocatalytically with a high oxygen availability. A porous, hydrophobic polyethylene membrane functioned as a carrier for the active biofilm. Toluene and other components diffused through the lumen of the membrane into the aqueous phase and were biocatalytically oxidized in this phase containing nutrient and microorganism. Incoming toluene concentration between 86 and 97 % could be degraded when the incoming air had a toluene concentration between 0.85 and 4.3 kg/m3/day [23]. 5.3.3 Membranes for Enzyme Retention
The use of membranes for retention of enzymes in bioreactors forms a significant part of red and white biotechnology. Since enzymes usually are large molecular
5.3 Examples of Membrane Processes in Biotechnology
Fig. 5.7 Manufacture of (2R,5R)-hexanediol with cell retention.
weight compounds, with molecular weights ranging from 10 to 150 kDa or more, membranes with defined pore sizes (or MWCO) find a wide range of applications for enzyme retention during the biotechnological production of fine chemicals. A typical example is the industrial production of amino acids by the acylase process using enzyme membrane reactors by the German firm of Degussa. This process is in use for over two decades now. In addition to proteinogenic amino acids such as alanine, methionine (Figure 5.8), valine, and tryptophan, nonproteinogenic amino acids such as O-benzylserine, norleucine, and nor-valine are manufactured on an industrial scale. Starting from the racemic acetate mixture, only one enantiomer is hydrolyzed by the catalyst [24,25]. By establishing a direct phase contact in the pores of a hydrophobic, microporous membrane, a hydrophobic product can be extracted from the stream coming out of a bioreactor. Thus, an extraction step can be directly coupled to a biotransformation step, thereby enabling the removal of poorly soluble products and unreacted educts (Figure 5.9). Kruse et al. have used this method to couple an extraction step to an enzyme membrane reactor with continuous cofactor regeneration [26]. A commercially available hydrophobic membrane (Celgard membrane in a LiquiCel lab module) functions as the extractor and extracts the hydrophobic product into
163
164
5 Membrane Applications in Red and White Biotechnology
Fig. 5.8 Racemic resolution of N-acetyl-methionine using acylase.
the organic phase. The regeneration of the hydrophilic cofactor takes place in the aqueous phase unhindered. The residence time of the cofactor is decoupled from that of the substrate. Several ketones have been reduced enzymatically, based on these principles, to the corresponding, hydrophobic chiral alcohols. An NADþ-alcohol dehydrogenase from Rhodococcus erythropolis was employed. There was an increase in the total turnover number by a factor of 20–25. In the above example, an extraction step has been used after a biotransformation step to remove a hydrophobic product from the loop. In the case of substrates that are poorly soluble in aqueous media, attempts have been made to introduce the so-called
Fig. 5.9 Coupling of a membrane-based extraction step to a biotransformation process.
5.3 Examples of Membrane Processes in Biotechnology
emulsion membrane reactors prior to the biotransformation step. By using a hydrophilic ultrafiltration membrane, it has been shown that an emulsion of 2-octanone can be separated into its phases and the aqueous phase is saturated with the organic substrate. This aqueous phase is fed into the enzyme membrane reactor where the actual biotransformation takes place. The enantioselective reduction of 2-octanone to (S)-2-octanol is shown in Figure 5.10. The biotransformation is catalyzed by a carbonyl reductase obtained from Candida parapsilosis (CPCR) and is accompanied by continuous reduction of the cofactor NADþ. By bringing the product stream in contact with the emulsion reactor, the product is extracted. Production of (S)-octanol to the extent of 21.2 g/L/day and with an enantiomeric excess of >99.5 % could be achieved over a period of four months in a continuous experiment [27]. A variety of methods are now available to modify the carrier surfaces for immobilization of biocatalysts. Similarly, the surface of membranes can be chemically modified in order to change its properties. Plasma-induced graft polymerization of poly(a-allyl glycoside) has been used by Deng et al. to increase the biocompatibility and hydrophilicity of a polypropylene hollow-fiber microfiltration membrane. A two-phase membrane reactor using the lipase from Candida rugosa as the biocatalyst, immobilized on the membrane, was used for the hydrolysis of olive oil. Under optimized reaction conditions, a volumetric reaction rate of 0.074 mm/L/h could be attained [28]. The importance of chiral amines as the building blocks to manufacture pharmaceuticals and agrochemicals is growing. Transaminases are being considered as
Fig. 5.10 Coupling of an emulsion membrane reactor with an enzyme membrane reactor for biotransformation of poorly soluble substrates.
165
166
5 Membrane Applications in Red and White Biotechnology
potential biocatalysts for their synthesis. In one type of biotransformation, however, the reaction is accompanied by the oxidation of one of the enantiomers to the corresponding ketone, which causes strong product inhibition. To overcome this problem, the enzyme membrane reactor has been coupled with a hollow-fiber membrane contactor. The racemic substrates a-methyl benzylamine and 1-amino tetraline yielded the products with enantiomeric purities of 98 and 95.5 %, respectively, when the (S)-specific v-transaminase from Vibria flusialis JS17 or Bacillus thuringensis JS64 was used [29]. Similarly, hollow-fiber contactors have been used for the production of enantiomerically pure monoesters from meso diesters. A pig liver esterase was used, and the polysulfone ultrafiltration hollow-fiber module had a MWCO value of 30 kDa. The asymmetrical pores of the fibers served to immobilize the enzyme. The reaction and the separation steps occur simultaneously in this module. The loss of enzyme activity was found to be low [30]. Baccatin III is a precursor in the synthesis of the antitumor compound paclitaxel. It has been continuously produced in an enzyme membrane reactor, starting from 10-deacetyl baccatin III by using an acyl transferase of plant origin, overexpressed in E. coli. The substrate is obtained by methanolic extraction of the European yew needles or cuts. The product was selectively separated from the biocatalyst in the bioreactor and extracted in the solvent phase, made up of diisopropyl ether present in an integrated module. The equilibrium of the reaction is shifted favorably by using this method. A polysulfone membrane with a MWCO of 10 kDa was used. It was observed that a reduction in the biotransformation temperature from 15 to 10 8C improved the biocatalytic stability [31]. This example demonstrates once again the importance of membrane processes in red biotechnology applications. Miniaturization of the enzyme membrane reactor has led to the development of micro enzyme membrane reactors with volumes of <200 mL. Such reactors function as practical tools for education, research, and product development. The quantities of biocatalyst and chemicals required for the experiments are significantly reduced [32]. 5.3.4 Membranes for Cofactor Retention
In many cases, the catalytic activity of an enzyme comes into force only in the presence of a cofactor, often called a coenzyme. While metallic cofactors are cheap to obtain, cofactors such as NADþ and NADPþ are extremely expensive. For this reason, cofactor regeneration plays a crucial role in the economics of a biotransformation. Wichmann and Vasic-Racki have reviewed the advantages and disadvantages of the different strategies of cofactor regeneration [33]. Closely related to cofactor regeneration is the retention of the cofactor in the biocatalytic reactor, so that it is not subjected to the unit operations that the product stream has to undergo subsequently. Cofactor retention by the use of membranes has been studied. Thus, for example, in the continuous reduction of trimethyl pyruvate to L-tert-leucine, catalyzed by the enzyme leucine dehydrogenase, the total turnover number (ttn) of the cofactor NADH is dependent on the type of membrane employed.
5.3 Examples of Membrane Processes in Biotechnology
Fig. 5.11 Dependence of total turnover number of cofactor NADH on type of retention membrane.
When an ultrafiltration membrane was used in an enzyme membrane reactor, the ttn was found to be 2325 (Figure 5.11). However, when a nanofiltration membrane was used, the ttn increased to 7920. Rosmarinicacid,anesterbetweencaffeicacidandachiraldihydroxyphenyllactic acid (‘‘hydroxy-DOPA’’), has been investigated intensively for its anti-inflammatory properties. Rosmarinicacid has been producedby planttissue culture in significant quantities. Biotransformation reactions also allow the synthesis of the naturally occurring product. Thus, 3,4-dihydroxyphenyl pyruvic acid has been reduced to (S)-3,4-(dihydroxyphenyl) lactic acid using a lactate dehydrogenase and a formate dehydrogenase, the latter for continuous cofactor regeneration in a manner similar to the one described above. The (S)-3,4-(dihydroxyphenyl) lactic acid has been converted to rosmarinic acid in a second biotransformation using caffeoyl coenzyme A transferase [34,35]. The continuous regeneration of the cofactor NADPH during the Baeyer–Villiger oxidation of 4-methyl cyclohexanone to 5-methyloxepan-2-one has been described by Rissom et al. [36,37]. The product could also be synthesized in a repetitive batch mode (Figure 5.12). The chiral lactone had an enantiomeric purity of >99 % [38]. 5.3.5 Application of Dialysis and Electrodialysis in Biotransformations
White biotechnology offers an interesting alternative to the synthesis of pyruvates. Pyruvates are chemically synthesized at high reaction temperatures by oxidation reactions using heavy metal catalysts, starting from tartaric acid, propylene glycol, or lactic acid. In the case of biotransformations, a high extracellular pyruvate concentration greater than 500 mmol/L causes an inhibition of the microbial pyruvate synthesis. Therefore, the product has to be separated, as soon as it is formed, in an integrated process. This has been achieved by the integration of an electrodialysis step by Zelic et al. [39]. The fermentation using the designer bug E. coli YYC2O2
167
168
5 Membrane Applications in Red and White Biotechnology
Fig. 5.12 Monooxygenase catalyzed Baeyer–Villiger oxidation.
Idh2A:Kan yields pyruvate in a concentration of more than 900 mmol/L under optimized conditions. Amino acids and peptides are interesting product groups for investigations using electrodialysis, because of their charged nature at different pH values except the isoelectric point. By combining electrodialysis with ultrafiltration, acid and base bioactive peptides have been separated simultaneously by Poulin et al. [40]. Peptides from a b-lactoglobulin (b-lg) hydrolysate obtained from whey were separated by using an ultrafiltration membrane stacked in an electrodialysis cell. The process, called electrodialysis with ultrafiltration (EDUF), showed a high selectivity. Starting from 40 peptides present in the raw hydrolysate, only 13 were recovered in the separated adjacent solutions. In addition, among these 13 migrating peptides, three acidic– anionic peptides migrated only into one compartment, while three basic–cationic peptides migrated only into the other compartment, independent of the pH of the hydrolysate. The ACE-inhibitory peptide b-Ig 142–148 showed the highest migration value of 10.75 %. In addition to cationic and anionic membranes, a cellulose ester UF membrane with a MWCO of 20 kDa was used in the above experiments. 5.3.6 Application of Pervaporation and Stripping in Biotransformations
Substrate-coupled cofactor regeneration (e.g., the oxidation of 2-propanol to acetone) is interesting for NADPH-dependent enzymes as no efficient enzyme-coupled
5.3 Examples of Membrane Processes in Biotechnology
system is yet available. Although higher conversions can be achieved by increasing the 2-propanol concentration, this also leads to the formation of more coproduct acetone. In such situations, it is essential to remove the coproduct as much as possible, preferably in situ, in order to achieve higher conversions. During the bioconversion of 5-oxo-hexanoic acid ethyl ester to the (S)-hydroxy ester, 2-propanol was reduced to acetone and was removed by employing stripping or pervaporation. The biotransformation was catalyzed by the NADPH-dependent enzyme carbonyl reductase from C. parapsilosis (Figure 5.13). Although both methods gave similar results with regard to product formation, pervaporation offers several advantages over stripping on a technical scale with regard to foaming and emission values [41]. The alcohol dehydrogenase from L. brevis (LbADH) is dependent on the cofactor NADPH for its catalytic activity. A two-phase bioreactor has been used to carry out the reduction of tert-butyl-6-chloro-3,5-dioxo-hexanoate (CDHE) to tert-butyl-(S)-4chloro-5-hydroxy-3-oxo-hexanoate (CHOE). During the biotransformation, a byproduct, tert-butyl-(4-oxo-4,5-dihydrofuran-2-yl)-acetate is formed due to the elimination of HCl in aqueous media. In order to avoid this, the CDHE is dissolved in methyl-tertbutyl ether (MTBE) and the enzyme and 2-propanol are dissolved in the buffer. The biphase emulsion reactor used gave the best results for the LbADH catalyzed reduction of CDHE with respect to selectivity, substrate concentration, ttn, and enzyme consumption, as well as downstream processing. Efficient separation of acetone also improved the space–time yield [42].
Fig. 5.13 Pervaporation for acetone removal in a biotransformation process.
169
170
5 Membrane Applications in Red and White Biotechnology
5.3.7 Nanofiltration and Ultrafiltration in Biotechnology
Several of the examples described in the previous sections employ either nanofiltration or ultrafiltration either during the biotransformation step or for subsequent downstream processing. The protective action of neuraminic acid-containing glycoconjugates in human milk has been well documented. This has led to the synthesis of various molecules based on neuraminic acid for possible therapeutic applications. The performance of a diafiltration membrane process for desalting of the permeate stream during the enzymatic synthesis of CMP-Neu5Ac and GDP-Man has been studied. The nucleotide sugars could be retained by a nanofiltration membrane in a cross-flow module. Only salts were allowed to pass through. The purification steps yielded CMP-Neu5Ac in >95 % purity and >90 % yield. GDP-Man gave values of 95 and 88 %, respectively [43,44]. In another well-established application of red biotechnology, the industrial production of recombinant tissue-type plasminogen activator (rt-PA) and other proteins, starting from mammalian cells, employs tangential flow filtration using UF membranes for product isolation. Up to 5000 L/h of the medium can be processed with protein yields generally >99 %. Cell vitality and cell density were maintained during the process. Since the UF membrane had a pore size of only 0.2 mm, the filtrate could be collected directly into containers after passing through a sterile filter. The latter could also be steamed in place. Scaling-up of the process followed a linear pattern [45]. Recombinant HIV-1 transcription–transactivator protein (Tat-protein) from a bacterial lysate could be separated easily by using a nylon membrane, modified chemically with an acyl anhydride and subsequent covalent coupling of avidin and biotin. In this affinity microfiltration technique, the product mTat primarily contained monomeric forms of the oligopeptidase sequence. While the membrane process led to a fourfold improvement in protein recovery, nonspecific protein adsorption was also observed [46]. 5.3.8 Bioelectrochemical Applications
Electrochemical oxidation, ultrafiltration, extraction, and distillation have been combined in a process to carry out the oxidative separation of racemic 1-phenyl1,2-ethane diol. The cofactor NAD+ was regenerated by anodic oxidation of NADH using the mediator 2,20 -azinobis(3-ethyl-benzothiazolin-6-sulfonate (ABTS). An electrochemical, extractive enzyme membrane reactor was developed for this purpose [47]. In further studies, the cofactors NADþ and NADPþ have been electrochemically reduced by an indirect method, using (pentamethylcyclopentadienyl-2,20 -bipyriddine aqua)-rhodium(III) as the mediator. It was observed that for the reduction reaction, adsorption of the mediator on the fixed-bed graphite cathode was essential. Stronger adsorption led to lower mediator consumption. Using a coated titanium mesh as the anode, values of ttn of up to 400 were achieved for the mediator. In order to hinder the reoxidation of the product, a cation exchange membrane was placed between the electrodes (Figure 5.14).
5.3 Examples of Membrane Processes in Biotechnology
Fig. 5.14 Indirect electrochemical cofactor reduction.
Selectivity and conversion values achieved were practically quantitative. The space–time yield was between 500 and 1000 g/L/day [48]. The first asymmetric electroenzymatic oxidation of thioanisole to (R)-methylphenyl sulfoxide with an enantiomeric purity greater than 98.5 % has been carried out by Luetz et al. with in situ electrochemical generation of hydrogen peroxide [49]. The hydrogen peroxide functioned as the oxidizing agent for the enzyme chloroperoxidase from Caldariomyces fumago. A dialysis tube membrane separates the counter electrode (a platinum wire) from the working electrode (a carbon felt). The divided cell (Figure 5.15) gave productivity values as high as 30 g/L/day when the experiments were carried out on a 300 mL scale.
Fig. 5.15 Divided cell for electrochemical hydrogen peroxide generation and biotransformation.
171
172
5 Membrane Applications in Red and White Biotechnology
In situ regeneration of cofactors such as NADH using electroenzymatic pathways offer attractive, low-priced alternatives to the regeneration methods described in earlier sections of this chapter. Considerable efforts are under way to achieve this. The in situ electroenzymatic regeneration of NADH, during the formation of lactate from pyruvate, has been studied in fixed-bed membrane reactors. The lipoamide dehydrogenase enzyme and the electron mediator methyl viologen were used. Porous graphite electrodes were coated with a cation exchange membrane. Substrate, product, enzyme lactate dehydrogenase, and coenzyme were present in the same solution. Yield of lactate improved considerably as a result of the electroenzymatic regeneration of NADH [50].
5.4 Summary From the wide variety of applications and principles described above, it is evident that membranes have a major role to play in industrial red and white biotechnology. This is further fuelled by the fact that properties of membranes can be modified in a better fashion now. In addition, a variety of polymeric materials are available for these applications. Mechanical and chemical stability can be improved to suit individual process requirements. The range of membrane-based applications in red and white biotechnology will continue to show an upward trend.
5.5 Acknowledgment
The authors are grateful to Prof. Dr C. Wandrey for ongoing support and discussions. References 1 Luetz, S., Rao, N., Wandrey, C. (2005)
2
3
4
5
Membranen in der Biotechnologie, Chemie Ingenieur Technik, 77, 1669. Liese, A., Seelbach, K., Wandrey, C. (2006) Industrial Biotransformations, 2nd edn , Wiley-VCH, Weinheim. Luetz, S., Rao, N., Wandrey, C. (2006) Membranes in Biotechnology, Chemical Engineering & Technology, 29, 1. Bommarius, A., Krimmer, H.-P. Reichert, D. et al. (2003) Volume gassing, German Patent DE 101 63 168 of 03.07.2003. Mertens, R., Greiner, L., van den Ban, E. C. D. et al. (2003) Practical application of hydrogenase I from Pyrococcus furiosus for NADPH generation and regeneration, Journal of Molecular Catalysis B: Enzymatic, 24/25, 39.
6 Mertens, R., Wandrey, C., Liese, A.
(2005) Reaktionstechnische Aspekte der enzymatischen Herstellung von NADPH im Enzym-Membran-Reaktor, Chemie Ingenieur Technik, 77, 609. 7 Mertens, R. and Liese, A. (2004) Biotechnological applications of hydrogenases, Current Opinion in Biotechnology, 15, 343. 8 Luellau, E., Dreisbach, E., Grogg, A. et al. (1992) Immobilization of animal cells on chemical modified siran carrier in Animal Cell Technology: Developments, Processes and Products, (eds. Spier, R. E.Griffiths, J. B. Macdonald, C.), Butterworth-Heinemann, London, 469. 9 Noll, T., Biselli, M., Wandrey, C. (1996) Wirbelschichtreaktor und BiomasseMonitor – ein leistungsfa¨higes
References
10
11
12
13
14
15
16
17
18
19
20
Fermentationssystem fu¨r Sa¨ugerzellen, BIOSpektrum, 1, 65. Chen, Z., Iding, K., Luetkemeyer, D., Lehmann, J. (2000) A low-cost chemically defined protein free medium for a recombinant CHO cell line producing prothrombin, Biotechnology Letters, 22, 837. Hesse, F., Ebel, M., Konisch, N. et al. (2003) Comparison of a production process in a membrane-aerated stirred tank and up to 1000-L airlift bioteactors using BHK-21 cells and chemically defined protein-free medium, Biotechnology Progress, 19, 833. Link, T., Ba¨ckstro¨m, M., Graham, R., et al. (2004) Bioprocess development for the production of a recombinant MUC-1 fusion protein expressed by CHO-K1 cells in protein-free medium, Journal of Biotechnology, 110, 51. Nehring, D., Czernak, P., Vorlop, J., Luebben, H. (2004) Experimental study of a ceramic microsparging aeration system in a pilot-scale animal cell culture, Biotechnology Progress, 20, 1710. Schulze, S. and Stahl, W. (1994) Ein neuartiger Bioreaktor fu¨r Zellkulturen, BioEngineering, 10, 28. Gorenflo, V., Schulze, S., Braun, A. M., Stahl, W. (1998) The tumbling reactor: a new reactor design for biotechnology, Biotechnology Techniques, 12, 55. Pilz, R., Hammer, E., Schauer, F., Kragl, U. (2001) Laccase-catalyzed synthesis of coupling products of phenolic substrates in different reactors, Applied Microbiology and Biotechnology, 60, 708. Meissner, P., Schroeder, B., Herforth, C., Biselli, M. (1999) Development of a fixed-bed bioreactor for the expansion of human hematopoietic progenitor cells, Cytotechnology, 30, 227. Noll, T. (2003) Stammzellen – Moeglichkeiten ihrer Expansion am Beispiel haematopoetischer Stammzellen aus Nabelschnurblut, Medizinische Klinik, 98 (Suppl. II), 7. Dong, H., Tang, Y. -J., Obashi, R., Hamel, J. -F. P. (2005) A perfusion culture system using a stirred ceramic membrane reactor for hyperproduction of IgG(2a) monoclonal antibody by hybridoma cells, Biotechnology Progress, 21, 140. Ernst, M., Kaup, B., Mu¨ller, M. et al. (2005) Enantioselective reduction of
21
22
23
24
25
26
27
28
29
30
carbonyl compounds by whole-cell biotransformation, combining a formate dehydrogenase and a (R)specific alcohol dehydrogenase, Applied Microbiology and Biotechnology, 66, 629. Haberland, J., Hummel, W., Daussmann, T., Liese, A. (2002) New continuous production process for enantiopure (2R, 5R)-hexanediol, Organic Process Research and Development, 6, 458. Tan, A. W. I. (2006) Applications of Whole Cell Biotransformations fort he Production of Chiral Alcohols, Dissertation, Universitaet Bonn. Kim, D. -J. and Kim, H. (2005) Degradation of toluene vapor in a hydrophobic polyethylene hollow fiber membrane bioreactor with Pseudomonas putida, Process Biochemistry, 40, 2015. Wandrey, C., Wichmann, R., Leuchtenberger, W. et al. (1983), Process for the continuous enzymatic transformation of water-soluble alpha-keto carbonic acids into the corresponding amino acids, DE 30641270. Woeltinger, J., Drauz, K., Bommarius, A. S. (2001) The membrane reactor in the fine chemicals industry, Applied Catalysis, A, 221, 171. Kruse, W., Hummel, W., Kragl, U. (1996) Alcohol-dehydrogenase-catalyzed production of chiral hydrophobic alcohols. A new approach leading to a nearly waste-free process, Recueil des Travaux Chimiques des Pays-Bas, 115, 239. Liese, A., Zelinski, T., Kula, M.-R. et al. (1998) A novel reactor concept for the enzymatic reduction of poorly soluble ketones, Journal of Molecular Catalysis B: Enzymatic, 4, 91. Deng, H. -T., Xu, Z.-K., Dai, Z.-W. et al. (2005) Immobilization of Candida rugosa lipase on polypropylene microfiltration membrane modified by glucopolymer hydrolysis of olive oil in biphasic bioreactor, Enzyme and Microbial Technology, 36, 996. Shin, J. -S., Kim, B. -G., Liese, A., Wandrey, C. (2001) Kinetic resolution of chiral amines with v-transaminase using an enzyme-membrane reactor, Biotechnology and Bioengineering, 73, 179. Souza, H. A., Afonso, C. A. M., Mota, J. P. B., Crespo, J. G. (2005) Modelling the enantioselective hydrolysis of a meso-diester using pig liver esterase in
173
174
5 Membrane Applications in Red and White Biotechnology
31
32
33
34
35
36
37
38
39
40
a two-phase hollow fibre reactor, Chemical Engineering Research and Design, 83 (A3), 285. Pflieger, C., Becker, M., Beckmann, D. et al. (2006) Membrane-supported extraction in enzymatic reactions in the presence of an organic solution medium, Chemie Ingenieur Technik, 78, 120. Mueller, D. H., Liauw, M. A., Greiner, L. (2005) Microreaction technology in education: Miniaturized enzyme membrane reactor, Chemical Engineering and Technology, 28, 1569. Wichmann, R. and Vasic-Racki, D. (2005) Cofactor regeneration at the lab scale, Advances in Biochemical Engineering/Biotechnology, 92, 225. Rao, N. N., Petersen, M., Alfermann, A. W., Wandrey, C. (1990) Enzymatisches Verfahren zur Gewinnung von Rosmarinsaeure DE 3841914 of 07.06.1990. Pabsch, K., Petersen, M., Rao, N. N. et al. (1991) Chemoenzymatic synthesis of rosmarinic acid, Recueil des Travaux chimiques des Pays-Bas, 110, 199. Tishkov, V., Galkin, A., Marchenko, G., et al. (1993) Formate dehydrogenase from methylotrophic bacterium Pseudomonas SP 101 – Gene cloning and expression in Escherichia coli, Biotechnology and Applied Biochemistry, 18, 201. Seelbach, K., Riebel, B., Hummel, W. et al. (1996) A novel, efficient regenerating method of NADPH using a new formate dehydrogenase, Tetrahedron Letters, 37, 2523. Rissom, S., Schwarz-Linek, U., Vogel, M. et al. (1997) Synthesis of chiral e-lactones in a two-enzyme system of cyclohexanone mono-oxygenase and formate dehydrogenase with integrated bubble-free aeration, Tetrahedron: Asymmetry, 8, 2523. Zelic, B., Gostovic, S., Vuorilehto, K. et al. (2004) Process strategies to enhance pyruvate production with recombinant Escherichia coli: from repetitive fed-batch to in situ product recovery with fully integrated electrodialysis, Biotechnology and Bioengineering, 85, 638. Poulin, J. -F., Arniot, J., Bazinet, L. (2006) Simultaneous separation of acid and basic bioactive peptides by electro-
41
42
43
44
45
46
47
48
49
50
dialysis with ultrafiltration membrane, Journal of Biotechnology, 123, 314. Stillger, T., Boenitz, M., Filho, M. V., Liese, A. (2002) Ueberwindung von thermodynamischen Limitierungen in substratgekoppelten Cofaktorregenerierungsverfahren, Chemie Ingenieur Technik, 74, 1035. de Oliveira Villela Filho, M. (2003) Enantioselective reduction of hydrophobic keto compounds in multiphase bioreactor, Dissertation, Universita¨t Bonn. Elling, L. (1997) Glycobiotechnology: Enzymes for the synthesis of nucleotide sugars, Advances in Biochemical Engineering/Biotechnology, 58, 89. Dudziak, G., Fey, S., Hasbach, L., Kragl, U. (1999) Nanofiltration for purification of nucleotide sugars, Journal of Carbohydrate Chemistry, 18, 41. van Reis, R., Leonard, L. C., Hsu, C. C., Builder, S. E. (1991) Industrial scale harvest of proteins from mammalian cell culture by tangential flow filtration, Biotechnology and Bioengineering, 38, 413. Hollman, A., Christian, D., Ray, P. et al. (2005) Selective isolation and purification of Tat protein via affinity membrane separation, Biotechnology Progress, 21, 451. Degenring, D., Schroeder, I., Wandrey, C. et al. (2004) Resolution of 1,2-diols by enzyme-catalyzed oxidation with anodic, mediated cofactor regeneration in the extractive membrane reactor: gaining insight by adaptive simulation, Organic Process Research and Development, 8, 213. Vuorilehto, K., Luetz, S., Wandrey, C. (2004) Indirect electrochemical reduction of nicotinamide coenzymes, Bioelectrochemistry, 65, 1. Lu¨tz, S., Steckhan, E., Liese, A. (2004) First asymmetric electroenzymatic oxidation catalyzed by a peroxidase, Electrochemistry Communications, 6, 583. Chen, X., Fenton, J. M., Fisher, R. J. and Peattie, R. A., Evaluation of in situ electroenzymatic regeration of coenzyme NADH in packed bed membrane reactors, Journal of the Electrochemical Society, 151, E56.
175
6 Membranes in Controlled Release Nicholas A. Peppas, Kristy M. Wood, J. Brock Thomas 6.1 Introduction
Membranes have become increasingly important for use in separation processes including microfiltration, ultrafiltration, gas permeation, pervaporation, dialysis, and reverse osmosis. In the biomedical industry, synthetic polymer membranes are used in a variety of applications including hemodialysis, blood oxygenators, and controlled release of therapeutics [1,2]. Rose and Nelson [3] were responsible for the first introduction of membranes for controlling drug release using osmotic pumps. Fol